PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12Q 1/68, C07H 21/00, 21/02, 21/04, C12P 19/34, C07K 13/00

A1

(11) International Publication Number: **WO 95/16793**

(43) International Publication Date: 22 June 1995 (22.06.95)

(21) International Application Number: PCT/US94/14746

(22) International Filing Date: 16 December 1994 (16.12.94)

(30) Priority Data:

08/168,877	17 December 1993 (17.12.93)	US
08/209,521	8 March 1994 (08.03.94)	US
08/352,902	9 December 1994 (09.12.94)	US

(71) Applicants *(for all designated States except US)*: OREGON HEALTH SCIENCES UNIVERSITY [US/US]; 3181 S.W. Sam Jackson Park Road, Portland, OR 97201 (US). DANA-FARBER CANCER INSTITUTE [US/US]; 44 Binney Street, Boston, M A 02115 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: BAKER, Sean, M. [GB/US]; 2520 S.W. Beaverton Highway, Portland, OR 97201 (US). BOLLAG, Roni, J. [US/US]; 231 Watervale Road, Martinez, GA 30907 (US). KOLODNER, Richard, D. [US/US]; 241 Perkins Street, Jamaica Plain, MA 02130 (US). BRONNER, C., Eric [US/US]; Apartment 110, 3211 S.W. Tenth, Portland, OR 97201 (US). LISKAY, Robert, M. [US/US]; 1110 Terrace Drive, Lake Oswego, OR 97034 (US).

(74) Agent: VAN RYSSELBERGHE, Pierre; Kolisch, Hartwell, Dickinson, McCormack & Heuser, Suite 200, 520 S.W. Yamhill, Portland, OR 97204 (US).

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: COMPOSITIONS AND METHODS RELATING TO DNA MISMATCH REPAIR GENES

(57) Abstract

Genomic sequences of human mismatch repair genes are described, as are methods of detecting mutations and/or polymorphisms in those genes. Also described are methods of diagnosing cancer susceptibility in a subject, and methods of identifying and classifying mismatch-repair-defective tumors. In particular, sequences and methods relating to human *mutL* homologs, *hMLH1* and *hPMS1* genes are provided.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	**GB**	United Kingdom	**MR**	Mauritania
AU	Australia	**GE**	Georgia	**MW**	Malawi
BB	Barbados	**GN**	Guinea	**NE**	Niger
BE	Belgium	**GR**	Greece	**NL**	Netherlands
BF	Burkina Faso	**HU**	Hungary	**NO**	Norway
BG	Bulgaria	**IE**	Ireland	**NZ**	New Zealand
BJ	Benin	**IT**	Italy	**PL**	Poland
BR	Brazil	**JP**	Japan	**PT**	Portugal
BY	Belarus	**KE**	Kenya	**RO**	Romania
CA	Canada	**KG**	Kyrgystan	**RU**	Russian Federation
CF	Central African Republic	**KP**	Democratic People's Republic of Korea	**SD**	Sudan
CG	Congo			**SE**	Sweden
CH	Switzerland	**KR**	Republic of Korea	**SI**	Slovenia
CI	Côte d'Ivoire	**KZ**	Kazakhstan	**SK**	Slovakia
CM	Cameroon	**LI**	Liechtenstein	**SN**	Senegal
CN	China	**LK**	Sri Lanka	**TD**	Chad
CS	Czechoslovakia	**LU**	Luxembourg	**TG**	Togo
CZ	Czech Republic	**LV**	Latvia	**TJ**	Tajikistan
DE	Germany	**MC**	Monaco	**TT**	Trinidad and Tobago
DK	Denmark	**MD**	Republic of Moldova	**UA**	Ukraine
ES	Spain	**MG**	Madagascar	**US**	United States of America
FI	Finland	**ML**	Mali	**UZ**	Uzbekistan
FR	France	**MN**	Mongolia	**VN**	Viet Nam
GA	Gabon				

COMPOSITIONS AND METHODS RELATING TO DNA MISMATCH REPAIR GENES

This invention was made with government support under Agreement No. GM 32741 and Agreement No. HG00395/GM50006 awarded by the National Institute of Health in the General Sciences Division. The government has certain rights in the invention.

This application is a continuation-in-part from U.S. Patent Application Serial No. 08/209,521, titled: MAMMALIAN DNA MISMATCH REPAIR GENES PMS1 AND MLH1, filed on March 8, 1994, which is a continuation-in-part from U.S. Patent Application Serial No. 08/168,877, filed on December 17, 1993. All of the above patent applications are incorporated by reference.

Field of the Invention

The present invention involves DNA mismatch repair genes. In particular, the invention relates to identification of mutations and polymorphisms in DNA mismatch repair genes, to identification and characterization of DNA mismatch-repair-defective tumors, and to detection of genetic susceptibility to cancer.

Background

In recent years, with the development of powerful cloning and amplification techniques such as the polymerase chain reaction (PCR), in combination with a rapidly accumulating body of information concerning the structure and location of numerous human genes and markers, it has become practical and advisable to collect and analyze samples of DNA or RNA from individuals who are members of families which are identified as exhibiting a high frequency of certain genetically transmitted disorders. For example, screening procedures are routinely used to screen for genes involved in sickle cell anemia, cystic fibrosis, fragile X chromosome syndrome and multiple sclerosis. For some types of disorders, early diagnosis can greatly improve the person's long-term prognosis by, for example, adopting an aggressive diagnostic routine, and/or by

making life style changes if appropriate to either prevent or prepare for an anticipated problem.

Once a particular human gene mutation is identified and linked to a disease, development of screening procedures to identify high-risk individuals can be relatively straight forward. For example, after the structure and abnormal phenotypic role of the mutant gene are understood, it is possible to design primers for use in PCR to obtain amplified quantities of the gene from individuals for testing. However, initial discovery of a mutant gene, i.e., its structure, location and linkage with a known inherited health problem, requires substantial experimental effort and creative research strategies.

One approach to discovering the role of a mutant gene in causing a disease begins with clinical studies on individuals who are in families which exhibit a high frequency of the disease. In these studies, the approximate location of the disease-causing locus is determined indirectly by searching for a chromosome marker which tends to segregate with the locus. A principal limitation of this approach is that, although the approximate genomic location of the gene can be determined, it does not generally allow actual isolation or sequencing of the gene. For example, Lindblom et al.[3] reported results of linkage analysis studies performed with SSLP (simple sequence length polymorphism) markers on individuals from a family known to exhibit a high incidence of hereditary non-polyposis colon cancer (HNPCC). Lindblom et al. found a "tight linkage" between a polymorphic marker on the short arm of human chromosome 3 (3p21-23) and a disease locus apparently responsible for increasing an individual's risk of developing colon cancer. Even though 3p21-23 is a fairly specific location relative to the entire genome, it represents a huge DNA region relative to the probable size of the mutant gene. The mutant gene could be separated from the markers identifying the locus by millions of bases. At best, such linkage studies have only limited utility for screening purposes because in order to predict one person's risk, genetic analysis must be performed with tightly linked genetic markers on a number of related individuals in the family. It is often impossible to obtain such information, particularly if affected family members are deceased. Also, informative markers may not exist in the family

under analysis. Without knowing the gene's structure, it is not possible to sample, amplify, sequence and determine directly whether an individual carries the mutant gene.

Another approach to discovering a disease-causing mutant gene begins with design and trial of PCR primers, based on known information about the disease, for example, theories for disease state mechanisms, related protein structures and function, possible analogous genes in humans or other species, etc. The objective is to isolate and sequence candidate normal genes which are believed to sometimes occur in mutant forms rendering an individual disease prone. This approach is highly dependent on how much is known about the disease at the molecular level, and on the investigator's ability to construct strategies and methods for finding candidate genes. Association of a mutation in a candidate gene with a disease must ultimately be demonstrated by performing tests on members of a family which exhibits a high incidence of the disease. The most direct and definitive way to confirm such linkage in family studies is to use PCR primers which are designed to amplify portions of the candidate gene in samples collected from the family members. The amplified gene products are then sequenced and compared to the normal gene structure for the purpose of finding and characterizing mutations. A given mutation is ultimately implicated by showing that affected individuals have it while unaffected individuals do not, and that the mutation causes a change in protein function which is not simply a polymorphism.

Another way to show a high probability of linkage between a candidate gene mutation and disease is by determining the chromosome location of the gene, then comparing the gene's map location to known regions of disease-linked loci such as the one identified by Lindblom et al. Coincident map location of a candidate gene in the region of a previously identified disease-linked locus may strongly implicate an association between a mutation in the candidate gene and the disease.

There are other ways to show that mutations in a gene candidate may be linked to the disease. For example, artificially produced mutant forms of the gene can be introduced into animals. Incidence of the disease in animals

carrying the mutant gene can then be compared to animals with the normal genotype. Significantly elevated incidence of disease in animals with the mutant genotype, relative to animals with the wild-type gene, may support the theory that mutations in the candidate gene are sometimes responsible for occurrence of the disease.

One type of disease which has recently received much attention because of the discovery of disease-linked gene mutations is Hereditary Nonpolyposis Colon Cancer (HNPCC).[1,2] Members of HNPCC families also display increased susceptibility to other cancers including endometrial, ovarian, gastric and breast. Approximately 10% of colorectal cancers are believed to be HNPCC. Tumors from HNPCC patients display an unusual genetic defect in which short, repeated DNA sequences, such as the dinucleotide repeat sequences found in human chromosomal DNA ("microsatellite DNA"), appear to be unstable. This genomic instability of short, repeated DNA sequences, sometimes called the "RER+" phenotype, is also observed in a significant proportion of a wide variety of sporadic tumors, suggesting that many sporadic tumors may have acquired mutations that are similar (or identical) to mutations that are inherited in HNPCC.

Genetic linkage studies have identified two HNPCC loci thought to account for as much as 90% of HNPCC. The loci map to human chromosome 2p15-16 (2p21) and 3p21-23. Subsequent studies have identified human DNA mismatch repair gene *hMSH2* as being the gene on chromosome 2p21, in which mutations account for a significant fraction of HNPCC cancers.[1, 2, 12] *hMSH2* is one of several genes whose normal function is to identify and correct DNA mispairs including those that follow each round of chromosome replication.

The best defined mismatch repair pathway is the *E.coli* MutHLS pathway that promotes a long-patch (approximately 3Kb) excision repair reaction which is dependent on the *mutH*, *mutL*, *mutS* and *mutU* (uvrD) gene products. The MutHLS pathway appears to be the most active mismatch repair pathway in *E.coli* and is known to both increase the fidelity of DNA replication and to act on recombination intermediates containing mispaired bases. The system has been reconstituted *in vitro*, and requires the *mutH, mutL, mutS* and uvrD (helicase II)

proteins along with DNA polymerase III holoenzyme, DNA ligase, single-stranded DNA binding protein (SSB) and one of the single-stranded DNA exonucleases, Exo I, Exo VII or RecJ. hMSH2 is homologous to the bacterial *mutS* gene. A similar pathway in yeast includes the yeast *MSH2* gene and two *mutL*-like genes referred to as *PMS1* and *MLH1*.

With the knowledge that mutations in a human *mutS* type gene (*hMSH2*) sometimes cause cancer, and the discovery that HNPCC tumors exhibit microsatellite DNA instability, interest in other DNA mismatch repair genes and gene products, and their possible roles in HNPCC and/or other cancers, has intensified. It is estimated that as many as 1 in 200 individuals carry a mutation in either the *hMSH2* gene or other related genes which encode for other proteins in the same DNA mismatch repair pathway.

An important objective of our work has been to identify human genes which are useful for screening and identifying individuals who are at elevated risk of developing cancer. Other objects are: to determine the sequences of exons and flanking intron structures in such genes; to use the structural information to design testing procedures for the purpose of finding and characterizing mutations which result in an absence of or defect in a gene product which confers cancer susceptibility; and to distinguish such mutations from "harmless" polymorphic variations. Another object is to use the structural information relating to exon and flanking intron sequences of a cancer-linked gene, to diagnose tumor types and prescribe appropriate therapy. Another object is to use the structural information relating to a cancer-linked gene to identify other related candidate human genes for study.

Summary of the Invention

Based on our knowledge of DNA mismatch repair mechanisms in bacteria and yeast including conservation of mismatch repair genes, we reasoned that human DNA mismatch repair homologs should exist, and that mutations in such homologs affecting protein function, would be likely to cause genetic instability, possibly leading to an increased risk of developing certain forms of human cancer.

We have isolated and sequenced two human genes, *hPMS1* and *hMLH1* each of which encodes for a protein involved in DNA mismatch repair. *hPMS1* and *hMLH1* are homologous to *mutL* genes found in *E.coli*. Our studies strongly support an association between mutations in DNA mismatch repair genes and susceptibility to HNPCC. Thus, DNA mismatch repair gene sequence information of the present invention, namely, cDNA and genomic structures relating to *hMLH1* and *hPMS1*, make possible a number of useful methods relating to cancer risk determination and diagnosis. The invention also encompasses a large number of nucleotide and protein structures which are useful in such methods.

We mapped the location of *hMLH1* to human chromosome 3p21-23. This is a region of the human genome that, based upon family studies, harbors a locus that predisposes individuals to HNPCC. Additionally, we have found a mutation in a conserved region of the *hMLH1* cDNA in HNPCC-affected individuals from a Swedish family. The mutation is not found in unaffected individuals from the same family, nor is it a simple polymorphism. We have also found that a homologous mutation in yeast results in a defective DNA mismatch repair protein. We have also found a frameshift mutation in *hMLH1* of affected individuals from an English family. Our discovery of a cancer-linked mutations in *hMLH1*, combined with the gene's map position which is coincident with a previously identified HNPCC-linked locus, plus the likely role of the *hMLH1* gene in mutation avoidance makes the *hMLH1* gene a prime candidate for underlying one form of common inherited human cancer, and a prime candidate to screen and identify individuals who have an elevated risk of developing cancer.

hMLH1 has 19 exons and 18 introns. We have determined the location of each of the 18 introns relative to *hMLH1* cDNA. We have also determined the structure of all intron/exon boundary regions of *hMLH1*. Knowledge of the intron/exon boundary structures makes possible efficient screening regimes to locate mutations which negatively affect the structure and function of gene products. Further, we have designed complete sets of oligonucleotide primer pairs which can be used in PCR to amplify individual complete exons together with surrounding intron boundary structures.

We mapped the location of hPMS1 to human chromosome 7. Subsequent studies by others[39] have confirmed our prediction that mutations in this gene are linked to HNPCC.

The most immediate use of the present invention will be in screening tests on human individuals who are members of families which exhibit an unusually high frequency of early onset cancer, for example HNPCC. Accordingly, one aspect of the invention comprises a method of diagnosing cancer susceptibility in a subject by detecting a mutation in a mismatch repair gene or gene product in a tissue from the subject, wherein the mutation is indicative of the subject's susceptibility to cancer. In a preferred embodiment of the invention, the step of detecting comprises detecting a mutation in a human *mutL* homolog gene, for example, *hMLH1* of *hPMS1*.

The method of diagnosing preferably comprises the steps of: 1) amplifying a segment of the mismatch repair gene or gene product from an isolated nucleic acid; 2) comparing the amplified segment with an analogous segment of a wild-type allele of the mismatch repair gene or gene product; and 3) detecting a difference between the amplified segment and the analogous segment, the difference being indicative of a mutation in the mismatch repair gene or gene product which confers cancer susceptibility.

Another aspect of the invention provides methods of determining whether the difference between the amplified segment and the analogous wild-type segment causes an affected phenotype, i.e., does the sequence alteration affect the individual's ability to repair DNA mispairs.

The method of diagnosing may include the steps of: 1) reverse transcribing all or a portion of an RNA copy of a DNA mismatch repair gene; and 2) amplifying a segment of the DNA produced by reverse transcription. An amplifying step in the present invention may comprise: selecting a pair of oligonucleotide primers capable of hybridizing to opposite strands of the mismatch repair gene, in an opposite orientation; and performing a polymerase chain reaction utilizing the oligonucleotide primers such that nucleic acid of the mismatch repair chain intervening between the primers is amplified to become the amplified segment.

In preferred embodiments of the methods summarized above, the DNA mismatch repair gene is *hMLH1* or *hPMS1*. The segment of DNA corresponds to a unique portion of a nucleotide sequence selected from the group consisting of SEQ ID NOS: 6-24. "First stage" oligonucleotide primers selected from the group consisting of SEQ ID NOS: 44-82 are used in PCR to amplify the DNA segment are . The invention also provides a method of using "second stage" nested primers (SEQ ID NOS: 83-122), for use with the first stage primers to allow more specific amplification and conservation of template DNA.

Another aspect of the present invention provides a method of identifying and classifying a DNA mismatch repair defective tumor comprising detecting in a tumor a mutation in a mismatch repair gene or gene product, preferably a *mutL* homolog (*hMLH1* or *hPMS1*), the mutation being indicative of a defect in a mismatch repair system of the tumor.

The present invention also provides useful nucleotide and protein compositions. One such composition is an isolated nucleotide or protein structure including a segment sequentially corresponding to a unique portion of a human *mutL* homolog gene or gene product, preferably derived from either *hMLH1* or *hPMS1*.

Other composition aspects of the invention comprise oligonucleotide primers capable of being used together in a polymerase chain reaction to amplify specifically a unique segment of a human *mutL* homolog gene, preferably *hMLH1* or *hPMS1*.

Another aspect of the present invention provides a probe including a nucleotide sequence capable of binding specifically by Watson/Crick pairing to complementary bases in a portion of a human *mutL* homolog gene; and a label-moiety attached to the sequence, wherein the label-moiety has a property selected from the group consisting of fluorescent, radioactive and chemiluminescent.

We have also isolated and sequenced mouse *MLH1* (*mMLH1*) and *PMS1* (*mPMS1*) genes. We have used our knowledge of mouse mismatch repair genes to construct animal models for studying cancer. The models will be useful to identify additional oncogenes and to study environmental effects on mutagenesis.

We have produced polyclonal antibodies directed to a portion of the protein encoded by *mPMS1* cDNA. The antibodies also react with hPMS1 protein and are useful for detecting the presence of the protein encoded by a normal *hPMS1* gene. We are also producing monoclonal antibodies directed to *hMLH1* and *hPMS1*.

In addition to diagnostic and therapeutic uses for the genes, our knowledge of *hMLH1* and *hPMS1* can be used to search for other genes of related function which are candidates for playing a role in certain forms of human cancer.

Description of the Figures

Figure 1 is a flow chart showing an overview of the sequence of experimental steps we used to isolate, characterize and use human and mouse *PMS1* and *MLH1* genes.

Figure 2 is an alignment of protein sequences for *mutL* homologs (SEQ ID NOS: 1-3) showing two highly-conserved regions (underlined) which we used to create degenerate PCR oligonucleotides for isolating additional *mutL* homologs.

Figure 3 shows the entire cDNA nucleotide sequence (SEQ ID NO: 4) for the human *MLH1* gene, and the corresponding predicted amino acid sequence (SEQ ID NO: 5) for the human MLH1 protein. The underlined DNA sequences are the regions of cDNA that correspond to the degenerate PCR primers that were originally used to amplify a portion of the *MLH1* gene (nucleotides 118-135 and 343-359).

Figure 4A shows the nucleotide sequences of the 19 exons which collectively correspond to the entire *hMLH1* cDNA structure. The exons are flanked by intron boundary structures. Primer sites are underlined. The exons with their flanking intron structures correspond to SEQ ID NOS: 6-24. The exons, shown in non-underlined small case letters, corespond to SEQ ID NOS: 25-43.

Figure 4B shows nucleotide sequences of primer pairs which have been used in PCR to amplify the individual exons. The "second stage"

amplification primers (SEQ ID NOS: 83-122) are "nested" primers which are used to amplify target exons from the amplification product obtained with corresponding "first stage" amplification primers (SEQ ID NOS: 44-82). The structures in Figure 4B correspond to the structures in Tables 2 and 3.

Figure 5 is an alignment of the predicted amino acid sequences for human and yeast (SEQ ID NOS: 5 and 123, respectively) MLH1 proteins. Amino acid identities are indicated by boxes and gaps are indicated by dashes.

Figure 6 is a phylogenetic tree of MutL-related proteins.

Figure 7 is a two-panel photograph. The first panel (A) is a metaphase spread showing hybridization of the *hMLH1* gene of chromosome 3. The second panel (B) is a composite of chromosome 3 from multiple metaphase spreads aligned with a human chromosome 3 ideogram. The region of hybridization is indicated in the ideogram by a vertical bar.

Figure 8 is a comparison of sequence chromatograms from affected and unaffected individuals showing identification of a C to T transition mutation that produces a non-conservative amino acid substitution at position 44 of the hMLH1 protein.

Figure 9 is an amino acid sequence alignment (SEQ ID NOS: 124-131) of the highly-conserved region of the MLH family of proteins surrounding the site of the predicted amino acid substitution. Bold type indicates the position of the predicted serine to phenylalanine amino acid substitution in affected individuals. Also highlighted are the serine or alanine residues conserved at this position in MutL-like proteins. Bullets indicate positions of highest amino acid conservation. For the MLH1 protein, the dots indicate that the sequence has not been obtained. Sequences were aligned as described below in reference to the phylogenetic tree of Figure 6.

Figure 10 shows the entire nucleotide sequence for *hPMS1* (SEQ ID NO: 132).

Figure 11 is an alignment of the predicted amino acid sequences for human and yeast PMS1 proteins (SEQ ID NOS: 133 and 134, respectively). Amino acid identities are indicated by boxes and gaps are indicated by dashes.

Figure 12 is a partial nucleotide sequence of mouse *MLH1* *mMLH1*) cDNA (SEQ ID NO: 135).

Figure 13 is a comparison of the predicted amino acid sequence for mMLH1 and hMLH1 proteins (SEQ ID NOS: 136 and 5, respectively).

Figure 14 shows the cDNA nucleotide sequence for mouse *PMS1* (*mPMS1*) (SEQ ID NO: 137).

Figure 15 is a comparison of the predicted amino acid sequences for mPMS1 and hPMS1 proteins (SEQ ID NOS: 138 and 133, respectively).

Definitions

gene - "Gene" means a nucleotide sequence that contains a complete coding sequence. Generally, "genes" also include nucleotide sequences found upstream (e.g. promoter sequences, enhancers, etc.) or downstream (e.g. transcription termination signals, polyadenylation sites, etc.) of the coding sequence that affect the expression of the encoded polypeptide.

gene product - A "gene product" is either a DNA or RNA (mRNA) copy of a portion of a gene, or a corresponding amino acid sequence translated from mRNA.

wild-type - The term "wild-type", when applied to nucleic acids and proteins of the present invention, means a version of a nucleic acid or protein that functions in a manner indistinguishable from a naturally-occurring, normal version of that nucleic acid or protein (i.e. a nucleic acid or protein with wild-type activity). For example, a "wild-type" allele of a mismatch repair gene is capable of functionally replacing a normal, endogenous copy of the same gene within a host cell without detectably altering mismatch repair in that cell. Different wild-type versions of the same nucleic acid or protein may or may not differ structurally from each other.

non-wild-type - The term "non-wild-type" when applied to nucleic acids and proteins of the present invention, means a version of a nucleic acid or protein that

functions in a manner distinguishable from a naturally-occurring, normal version of that nucleic acid or protein. Non-wild-type alleles of a nucleic acid of the invention may differ structurally from wild-type alleles of the same nucleic acid in any of a variety of ways including, but not limited to, differences in the amino acid sequence of an encoded polypeptide and/or differences in expression levels of an encoded nucleotide transcript of polypeptide product.

For example, the nucleotide sequence of a non-wild-type allele of a nucleic acid of the invention may differ from that of a wild-type allele by, for example, addition, deletion, substitution, and/or rearrangement of nucleotides. Similarly, the amino acid sequence of a non-wild-type mismatch repair protein may differ from that of a wild-type mismatch repair protein by, for example, addition, substitution, and/or rearrangement of amino acids.

Particular non-wild-type nucleic acids or proteins that, when introduced into a normal host cell, interfere with the endogenous mismatch repair pathway, are termed "dominant negative" nucleic acids or proteins.

homologous - The term "homologous" refers to nucleic acids or polypeptides that are highly related at the level of nucleotide or amino acid sequence. Nucleic acids or polypeptides th are homologous to each other are termed "homologues".

The term "homologous" necessarily refers to a comparison between two sequences. In accordance with the invention, two nucleotide sequences are considered to be homologous if the polypeptides they encode are at least about 50-60% identical, preferably about 70% identical, for at least one stretch of at least 20 amino acids. Preferably, homologous nucleotide sequences are also characterized by the ability to encode a stretch of at least 4-5 uniquely specified amino acids. Both the identity and the approximate spacing of these amino acids relative to one another must be considered for nucleotide sequences to be considered to be homologous. For nucleotide sequences less than 60 nucleotides in length, homology is determined by the ability to encode a stretch of at least 4-5 uniquely specified amino acids.

upstream/downstream - The terms "upstream" and "downstream" are art-understood terms referring to the position of an element of nucleotide sequence. "Upstream" signifies an element that is more 5' than the reference element. "Downstream" refers to an element that is more 3' than a reference element.

intron/exon - The terms "exon" and "intron" are art-understood terms referring to various portions of genomic gene sequences. "Exons" are those portions of a genomic gene sequence that encode protein. "Introns" are sequences of nucleotides found between exons in genomic gene sequences.

affected - The term "affected", as used herein, refers to those members of a kindred that either have developed a characteristic cancer (e.g. colon cancer in an HNPCC lineage) and/or are predicted, on the basis of, for example, genetic studies, to carry an inherited mutation that confers susceptibility to cancer.

unique - A "unique" segment, fragment or portion of a gene or protein means a portion of a gene or protein which is different sequentially from any other gene or protein segment in an individual's genome. As a practical matter, a unique segment or fragment of a gene will typically be a nucleotide of at least about 13 bases in length and will be sufficiently different from other gene segments so that oligonucleotide primers may be designed and used to selectively and specifically amplify the segment. A unique segment of a protein is typically an amino acid sequence which can be translated from a unique segment of a gene.

References

The following publications are referred to by number in the text of the application. Each of the publications is incorporated here by reference.

1. **Fishel, R., et al.** Cell 75, 1027-1038 (1993).
2. **Leach, F., et al.** Cell 75, 1215-1225 (1993).
3. **Lindblom, A., Tannergard, Pl, Werelius, B. & Nordenskjold, M.** Nature Genetics 5, 279-282 (1993).
4. **Prolla, T.A., Christie, D.M. & Liskay, R.M.** Molec. and Cell. Biol. 14, 407-415 (1994).

5. **Strand, M. Prolla, T.A., Liskay, R.M. & Petes, T.D.** Nature 365, 274-276 (1993).

6. **Aaltonen, L.A., et al.** Science 260, 812-816 (1993).

7. **Han, H.J., Yanagisawa, A., Kato, Y., Park, J.G. & Nakamura, Y.** Cancer 53, 5087-5089 (1993).

8. **Ionov, Y., Peinado, M.A. , Malkhosyan, S., Shibata, D. & Perucho, M.** Nature 363, 558-561 (1993).

9. **Risinger, J.I. et al.** Cancer 53, 5100-5103 (1993).

10. **Thibodeau, S.N., Bren, G. & Shaid, D.** Science 260, 816-819 (1993).

11. **Levinson, G. & Gutman, G.A.** Nucleic Acids Res. 15, 5323-5338 (1987).

12. **Parsons, R., et al.** Cell 75, 1227-1236 (1993).

13. **Modrich, P.** Ann. Rev. of Genet. 25, 229-53 (1991).

14. **Reenan, R.A. & Kolodner, R.D.** Genetics 132, 963-73 (1992).

15. **Bishop, D.K., Anderson, J. & Kolodner, R.D.** PNAS 86, 3713-3717 (1989).

16. **Kramer, W., Kramer, B., Williamson, M.S. & Fogel, S.** J. Bacteriol. 171, 5339-5346 (1989).

17. **Williamson, M.S., Game, J.C. & Fogel, S.,** Genetics 110, 609-646 (1985).

18. **Prudhomme, M., Martin, B., Mejean, V. & Claverys, J.** J. Bacteriol. 171, 5332-5338 (1989).

19. **Mankovich, J.A., McIntyre, C.A. & Walker, G.C.** J. Bacteriol. 171, 5325-5331 (1989).

20. **Lichter, P., et al.** Science 247, 64-69 (1990).

21. **Boyle, A., Feltquite, D.M., Dracopoli, N., Housman, D. & Ward, D.C.** Genomics 12, 106-115 (1992).

22. **Lyon, M.F. & Kirby, M.C.,** Mouse Genome 91, 40-80 (1993).

23. **Reenan, R.A. & Kolodner, R.D.** Genetics 132, 975-85 (1992).

24. **Latif, F. et al.** Cancer Research 52, 1451-1456 (1992).

25. **Naylor, S.L., Johnson, B.E., Minna, J.D. & Sakaguchi, A.Y.** Nature 329, 451-454 (1987).

26. **Ali, I.U., Lidereau, R. & Callahan, R.** Journal of the National Cancer Institute 81, 1815-1820 (1989).

27. **Higgins, D., Bleasby, A. & Fuchs, R.** Comput. Apple Biosci. 8, 189-191 (1992).

28. **Fields, S. & Song, O.K.** Nature 340, 245-246 (1989).

29. **Lynch, H.T., et al.** Gastroenterology 104, 1535-1549 (1993).

30. **Elledge, S.J., Mulligan, J.T., Ramer, S.W., Spottswood, M. & Davis, R.W.** Proc. Natl. Acad. Sci. U.S.A. 88, 1731-1735 (1991).

31. **Frohman, M.** Amplifications, a forum for PCR users 1, 11-15 (1990).

32. **Powell, S.M., et al.** New England Journal of Medicine 329, 1982-1987 (1993).

33. **Wu, D.Y., Nozari, G. Schold, M., Conner, B.J. & Wallace, R.B.** DNA 8, 135-142 (1989).

34. **Mullis, K.E.B. & Faloona, F.A.** Methods in Enzymology 155, 335-350 (1987).

35. **Bishop, T.D., Thomas, H.** Cancer Sur. 9, 585-604 (1990).

36. **Capecchi, M.R.** Scientific American 52-59 (March 1994).

37. **Erlich, H.A.** PCR Technology, Principles and Applications for DNA Amplification (1989).

38. **Papadopoulos et al.** Science 263, 1625-1629 (March 1994).

39. **Nicolaides et al.** Nature 371, 75-80 (September 1994).

40. **Tong et al.** Anal. Chem. 64, 2672-2677 (1992).

41. **Debuire et al.** Clin. Chem. 39, 1682-5 (1993).

42. **Wahlberg et al.** Electrophoresis 13, 547-551 (1992).

43. **Kaneoka et al.** Biotechniques 10, 30, 32, 34 (1991).

44. **Huhman et al.** Biotechniques 10, 84-93 (1991).

45. **Hultman et al.** Nuc. Acid. Res. 17, 4937-46 (1989).

46. **Zu et al.** Mutn. Res. 288, 232-248 (1993).

47. **Espelund et al.** Biotechniques 13, 74-81 (1992).

48. **Prolla et al.** Science 265, 1091-1093 (1994).

49. **Bishop et al.** Mol. Cell. Biol. 6, 3401-3409 (1986).

50. **Folger et al.** Mol. Cell. Biol. 5, 70-74 (1985).

51. **T.C. Brown et al.** Cell 54, 705-711 (1988).

52. **T.C. Brown et al.** Genome 31, 578-583 (1989).

53. **C. Muster-Nassal et al.** Proc. Natl. Acad. Sci. U.S.A. 83, 7618-7622 (1986).
54. **I. Varlet et al.** Proc. Natl. Acad. Sci. U.S.A. 87, 7883-7887 (1990).
55. **D.C. Thomas et al.** J. Biol. Chem. 266, 3744-3751 (1991).
56. **J.J. Holmes et al.** Proc. Natl. Acad. Sci. U.S.A. 87, 5837-5841 (1990).
57. **P. Branch et al.** Nature 362, 652-654 (1993).
58. **A. Kat et al.** Proc. Natl. Acad. Sci. U.S.A. 90, 6424-6428 (1993).
59. **K. Wiebauer et al.** Nature 339, 234-236 (1989).
60. **K. Wiebauer et al.** Proc. Natl. Acad. Sci. U.S.A. 87, 5842-5845 (1990).
61. **P. Neddermann et al.** J. Biol. Chem. 268, 21218-24 (1993).
62. **Kramer et al.** Mol. Cell Biol. 9:4432-40 (1989).
63. **Kramer et al.** J. Bacteriol. 171:5339-5346 (1989).

Description of the Invention

We have discovered mammalian genes which are involved in DNA mismatch repair. One of the genes, *hPMS1*, encodes a protein which is homologous to the yeast DNA mismatch repair protein PMS1. We have mapped the locations of *hPMS1* to human chromosome 7 and the mouse *PMS1* gene to mouse chromosome 5, band G. Another gene, *hMLH1* (MutL Homolog) encodes a protein which is homologous to the yeast DNA mismatch repair protein MLH1. We have mapped the locations of *hMLH1* to human chromosome 3p21.3-23 and to mouse chromosome 9, band E.

Studies[1,2] have demonstrated involvement of a human DNA mismatch repair gene homolog, *hMSH2,* on chromosome 2p in HNPCC. Based upon linkage data, a second HNPCC locus has been assigned to chromosome 3p21-23.[3] Examination of tumor DNA from the chromosome 3-linked kindreds revealed dinucleotide repeat instability similar to that observed for other HNPCC families[6] and several types of sporadic tumors.[7-10] Because dinucleotide repeat instability is characteristic of a defect in DNA mismatch repair, [5, 11, 12] we reasoned that HNPCC linked to chromosome 3p21-23 could result from a mutation in a second DNA mismatch repair gene.

Repair of mismatched DNA in *Escherichia coli* requires a number of genes including *mutS, mutL* and *mutH,* defects in any one of which result in

elevated spontaneous mutation rates.[13] Genetic analysis in the yeast *Saccharomyces cerevisiae* has identified three DNA mismatch repair genes: a *mutS* homolog, *MSH2*,[14] and two *mutL* homologs, *PMS1*[16] and *MLH1*.[4] Each of these three genes play an indispensable role in DNA replication fidelity, including the stabilization of dinucleotide repeats.[5]

We believe that *hMLH1* is the HNPCC gene previously linked to chromosome 3p based upon the similarity of the *hMLH1* gene product to the yeast DNA mismatch repair protein, MLH1,[4] the coincident location of the *hMLH1* gene and the HNPCC locus on chromosome 3, and *hMLH1* missense mutations which we found in affected individuals from chromosome 3-linked HNPCC families.

Our knowledge of the human and mouse *MLH1* and *PMS1* gene structures has many important uses. The gene sequence information can be used to screen individuals for cancer risk. Knowledge of the gene structures makes it possible to easily design PCR primers which can be used to selectively amplify portions of *hMLH1* and *hPMS1* genes for subsequent comparison to the normal sequence and cancer risk analysis. This type of testing also makes it possible to search for and characterize *hMLH1* and *hPMS1* cancer-linked mutations for the purpose of eventually focusing the cancer screening effort on specific gene loci. Specific characterization of cancer-linked mutations in *hMLH1* and *hPMS1* makes possible the production of other valuable diagnostic tools such as allele specific probes which may be used in screening tests to determine the presence or absence of specific gene mutations.

Additionally, the gene sequence information for *hMLH1* and/or *hPMS1* can be used, for example, in a two hybrid system, to search for other genes of related function which are candidates for cancer involvement.

The *hMLH1* and *hPMS1* gene structures are useful for making proteins which are used to develop antibodies directed to specific portions or the complete hMLH1 and hPMS1 proteins. Such antibodies can then be used to isolate the corresponding protein and possibly related proteins for research and diagnostic purposes.

The mouse *MLH1* and *PMS1* gene sequences are useful for producing mice that have mutations in the respective gene. The mutant mice are useful for studying the gene's function, particularly its relationship to cancer.

Methods for Isolating and Characterizing Mammalian *MLH1* and *PMS1* Genes

We have isolated and characterized four mammalian genes, i.e., human *MLH1* (*hMLH1*), human *PMS1* (*hPMS1*), mouse *MLH1* (*mPMS1*) and mouse *PMS1* (*mPMS1*). Due to the structural similarity between these genes, the methods we have employed to isolate and characterize them are generally the same. Figure 1 shows in broad terms, the experimental approach which we used to isolate and characterize the four genes. The following discussion refers to the step-by-step procedure shown in Figure 1.

Step 1 Design of degenerate oligonucleotide pools for PCR

Earlier reports indicated that portions of three MutL-like proteins, two from bacteria, MutL and HexB, and one from yeast, PMS1 are highly conserved.[16,18,19] After inspection of the amino acid sequences of HexB, MutL and PMS1 proteins, as shown in Figure 2, we designed pools of degenerate oligonucleotide pairs corresponding to two highly-conserved regions, KELVEN and GFRGEA, of the MutL-like proteins. The sequences (SEQ ID NOS: 139 and 140, respectively) of the degenerate oligonucleotides which we used to isolate the four genes are:

5'-CTTGATTCTAGAGC(T/C)TCNCCNC(T/G)(A/G)AANCC-3' and

5'-AGGTCGGAGCTCAA(A/G)GA(A/G)(T/C)TNGTNGANAA-3'.

The underlined sequences within the primers are *Xba*I and *Sac*I restriction endonuclease sites respectively. They were introduced in order to facilitate the cloning of the PCR-amplified fragments. In the design of the oligonucleotides, we took into account the fact that a given amino acid can be coded for by more than one DNA triplet (codon). The degeneracy within these sequences are indicated by multiple nucleotides within parentheses or N, for the presence of any base at that position.

Step 2 Reverse transcription and PCR on poly A+ selected mRNA isolated from human cells

We isolated messenger (poly A+ enriched) RNA from cultured human cells, synthesized double-stranded cDNA from the mRNA, and performed PCR with the degenerate oligonucleotides.[4] After trying a number of different PCR conditions, for example, adjusting the annealing temperature, we successfully amplified a DNA of the size predicted (~210bp) for a MutL-like protein.

Step 3 Cloning and sequencing of PCR-generated fragments; identification of two gene fragments representing human *PMS1* and *MLH1*

We isolated the PCR amplified material (~210bp) from an agarose gel and cloned this material into a plasmid (pUC19). We determined the DNA sequence of several different clones. The amino acid sequence inferred from the DNA sequence of two clones showed strong similarity to other known MutL-like proteins.[4,16,18,19] The predicted amino acid sequence for one of the clones was most similar to the yeast PMS1 protein. Therefore we named it *hPMS1*, for human *PMS1*. The second clone was found to encode a polypeptide that most closely resembles yeast MLH1 protein and was named, *hMLH1*, for human *MLH1*.

Step 4 Isolation of complete human and mouse *PMS1* and *MLH1* cDNA clones using the PCR fragments as probes

We used the 210bp PCR-generated fragments of the *hMLH1* and *hPMS1* cDNAs, as probes to screen both human and mouse cDNA libraries (from Stratagene, or as described in reference 30). A number of cDNAs were isolated that corresponded to these two genes. Many of the cDNAs were truncated at the 5' end. Where necessary, PCR techniques [31] were used to obtain the 5' -end of the gene in addition to further screening of cDNA libraries. Complete composite cDNA sequences were used to predict the amino acid sequence of the human and mouse, MLH1 and PMS1 proteins.

Step 5 Isolation of human and mouse, *PMS1* and *MLH1* genomic clones

Information on genomic and cDNA structure of the human *MLH1* and *PMS1* genes are necessary in order to thoroughly screen for mutations in cancer prone families. We have used human cDNA sequences as probes to isolate the genomic sequences of human *PMS1* and *MLH1*. We have isolated four cosmids and two P1 clones for *hPMS1*, that together are likely to contain most, if not all, of the cDNA (exon) sequence. For *hMLH1* we have isolated four overlapping λ-phage clones containing 5'-*MLH1* genomic sequences and four P1 clones (two full length clones and two which include the 5' coding end plus portions of the promoter region) P1 clone. PCR analysis using pairs of oligonucleotides specific to the 5' and 3' ends of the *hMLH1* cDNA, clearly indicates that the P1 clone contains the complete *hMLH1* cDNA information. Similarly, genomic clones for mouse *PMS1* and *MLH1* genes have been isolated and partially characterized (described in Step 8).

Step 6 Chromosome positional mapping of the human and mouse, *PMS1* and *MLH1* genes by fluorescence *in situ* hybridization

We used genomic clones isolated from human and mouse *PMS1* and *MLH1* for chromosomal localization by fluorescence *in situ* hybridization (FISH).[20,21] We mapped the human *MLH1* gene to chromosome 3p21.3-23, shown in Figure 7 as discussed in more detail below. We mapped the mouse *MLH1* gene to chromosome 9 band E, a region of synteny between mouse and human.[22] In addition to FISH techniques, we used PCR with a pair of *hMLH1*-specific oligonucleotides to analyze DNA from a rodent/human somatic cell hybrid mapping panel (Coriell Institute for Medial Research, Camden, N.J.). Our PCR results with the panel clearly indicate that *hMLH1* maps to chromosome 3. The position of *hMLH1* 3p21.3-23 is coincident to a region known to harbor a second locus for HNPCC based upon linkage data.

We mapped the *hPMS1* gene, as shown in Figure 12, to the long (q) arm of chromosome 7 (either 7q11 or 7q22) and the mouse *PMS1* to chromosome 5 band G, two regions of synteny between the human and the mouse.[22] We performed PCR using oligonucleotides specific to *hPMS1* on DNA from a

rodent/human cell panel. In agreement with the FISH data, the location of *hPMS1* was confirmed to be on chromosome 7. These observations assure us that our human map position for *hPMS1* to chromosome 7 is correct. The physical localization of *hPMS1* is useful for the purpose of identifying families which may potentially have a cancer linked mutation in *hPMS1*.

Step 7 Using genomic and cDNA sequences to identify mutations in *hPMS1* and *hMLH1* genes from HNPCC Families

We have analyzed samples collected from individuals in HNPCC families for the purpose of identifying mutations in *hPMS1* or *hMLH1* genes. Our approach is to design PCR primers based on our knowledge of the gene structures, to obtain exon/intron segments which we can compare to the known normal sequences. We refer to this approach as an "exon-screening".

Using cDNA sequence information we have designed and are continuing to design *hPMS1* and *hMLH1* specific oligonucleotides to delineate exon/intron boundaries within genomic sequences. The *hPMS1* and *hMLH1* specific oligonucleotides were used to probe genomic clones for the presence of exons containing that sequence. Oligonucleotides that hybridized were used as primers for DNA sequencing from the genomic clones. Exon-intron junctions were identified by comparing genomic with cDNA sequences.

Amplification of specific exons from genomic DNA by PCR and sequencing of the products is one method to screen HNPCC families for mutations.[1,2] We have identified genomic clones containing *hMLH1* cDNA information and have determined the structures of all intron/exon boundary regions which flanks the 19 exons of hMCH1.

We have used the exon-screening approach to examine the *MLH1* gene of individuals from HNPCC families showing linkage to chromosome 3.[3] As will be discussed in more detail below, we identified a mutation in the *MLH1* gene of one such family, consisting of a C to T substitution. We predict that the C to T mutation causes a serine to phenylalanine substitution in a highly-conserved region of the protein. We are continuing to identify HNPCC families from whom we can obtain samples in order to find additional mutations in *hMLH1* and *hPMS1* genes.

We are also using a second approach to identify mutations in *hPMS1* and *hMLH1*. The approach is to design *hPMS1* or *hMLH1* specific oligonucleotide primers to produce first-strand cDNA by reverse transcription off RNA. PCR using gene-specific primers will allow us to amplify specific regions from these genes. DNA sequencing of the amplified fragments will allow us to detect mutations.

Step 8 Design targeting vectors to disrupt mouse *PMS1* and *MLH1* genes in ES cells; study mice deficient in mismatch repair.

We constructed a gene targeting vector based on our knowledge of the genomic mouse *PMS1* DNA structure. We used the vector to disrupt the *PMS1* gene in mouse embryonic stem cells.[36] The cells were injected into mouse blastocysts which developed into mice that are chimeric (mixtures) for cells carrying the *PMS1* mutation. The chimeric animals will be used to breed mice that are heterozygous and homozygous for the *PMS1* mutation. These mice will be useful for studying the role of the *PMS1* gene in the whole organism.

Human *MLH1*

The following discussion is a more detailed explanation of our experimental work relating to *hMLH1*. As mentioned above, to clone mammalian *MLH1* genes, we used PCR techniques like those used to identify the yeast *MSH1, MSH2* and *MLH1* genes and the human *MSH2* gene.[1, 2, 4, 14] As template in the PCR, we used double-stranded cDNA synthesized from poly (A+) enriched RNA prepared from cultured primary human fibroblasts. The degenerate oligonucleotides were targeted at the N-terminal amino acid sequences KELVEN and GFRGEA (see Figure 3), two of the most conserved regions of the MutL family of proteins previously described for bacteria and yeast.[16,18,19] Two PCR products of the predicted size were identified, cloned and shown to encode a predicted amino acid sequence with homology to MutL-like proteins. These two fragments generated by PCR were used to isolate human cDNA and genomic DNA clones.

The oligonucleotide primers which we used to amplify human MutL-related sequences were 5' -

CTTGATTCTAGAGC(T/C)TCNCCNC(T/G)(A/G)AANCC-3' (SEQ ID NO: 139) and 5' - AGGTCGGAGCTCAA(A/G)GA(A/G)(T/C)TNGTNGANAA-3' (SEQ ID NO: 140). PCR was carried out in 50 μL reactions containing cDNA template, 1.0 μM each primer, 5 IU of Taq polymerase (C) 50 mM KCl, 10 mM Tris buffer pH 7.5 and 1.5 mM MgCl. PCR was carried out for 35 cycles of 1 minute at 94 C°, 1 minute at 43 C° and 1.5 minutes at 62 C°. Fragments of the expected size, approximately 212 bp, were cloned into pUC19 and sequenced. The cloned *MLH1* PCR products were labeled with a random primer labeling kit (RadPrime, Gibco BRL) and used to probe human cDNA and genomic cosmid libraries by standard procedures. DNA sequencing of double-stranded plasmid DNAs was performed as previously described.[1]

The *hMLH1* cDNA nucleotide sequence as shown in Figure 3 encodes an open reading frame of 2268 bp. Also shown in Figure 3 is the predicted protein sequence encoded for by the *hMLH1* cDNA. The underlined DNA sequences are the regions of cDNA that correspond to the degenerate PCR primers that were originally used to amplify a portion of the *MLH1* gene (nucleotides 118-135 and 343-359).

Figure 4A shows 19 nucleotide sequences corresponding to portions of *hMLH1*. Each sequence includes one of the 19 exons, in its entirety, surrounded by flanking intron sequences. Target PCR primer cites are underlined. More details relating to the derivation and uses of the sequences shown in Figure 4A, are set forth below.

As shown in Figure 5, the hMLH1 protein is comprised of 756 amino acids and shares 41% identity with the protein product of the yeast DNA mismatch repair gene, *MLH1*.[4] The regions of the hMLH1 protein most similar to yeast MLH1 correspond to amino acids 11 through 317, showing 55% identity, and the last 13 amino acids which are identical between the two proteins. Figure 5 shows an alignment of the predicted human MLH1 and *S. cerevisiae* MLH1 protein sequences. Amino acid identities are indicated by boxes, and gaps are indicated by dashes. The pair wise protein sequence alignment was performed with DNAStar MegAlign using the clustal method.[27] Pair wise alignment parameters were a ktuple of 1, gap penalty of 3, window of 5 and diagonals of 5.

Furthermore, as shown in Figure 13, the predicted amino acid sequences of the human and mouse MLH1 proteins show at least 74% identity.

Figure 6 shows a phylogenetic tree of MutL-related proteins. The phylogenetic tree was constructed using the predicted amino acid sequences of 7 MutL-related proteins: human MLH1; mouse MLH1; *S. cerevisiae* MLH1; *S. cerevisiae* PMS1; *E. coli*; MutL; *S. typhimurium* MutL and *S. pneumoniae* HexB. Required sequences were obtained from GenBank release 7.3. The phylogenetic tree was generated with the PILEUP program of the Genetics Computer Group software using a gap penalty of 3 and a length penalty of 0.1. The recorded DNA sequences of *hMLH1* and *hPMS1* have been submitted to GenBank.

hMLH1 Intron Location and Intron/Exon Boundary Structures

In our previous U.S. Patent Application No. 08/209,521, we described the nucleotide sequence of a complimentary DNA (cDNA) clone of a human gene, *hMLH1*. The cDNA sequence of *hMLH1* (SEQ ID NO: 4) is presented in this application in Figure 3. We note that there may be some variability between individuals *hMLH1* cDNA structures, resulting from polymorphisms within the human population, and the degeneracy of the genetic code.

In the present application, we report the results of our genomic sequencing studies. Specifically, we have cloned the human genomic region that includes the *hMLH1* gene, with specific focus on individual exons and surrounding intron/exon boundary structures. Toward the ultimate goal of designing a comprehensive and efficient approach to identify and characterize mutations which confer susceptibility to cancer, we believe it is important to know the wild-type sequences of intron structures which flank exons in the *hMLH1* gene. One advantage of knowing the sequence of introns near the exon boundaries, is that it makes it possible to design primer pairs for selectively amplifying entire individual exons. More importantly, it is also possible that a mutation in an intron region, which, for example, may cause a mRNA splicing error, could result in a defective gene product, i.e., susceptibility to cancer, without showing any abnormality in an exon region of the gene. We believe a comprehensive

screening approach requires searching for mutations, not only in the exon or cDNA, but also in the intron structures which flank the exon boundaries.

We have cloned the human genomic region that includes *hMLH1* using approaches which are known in the art, and other known approaches could have been used. We used PCR to screen a P1 human genomic library for the *hMLH1* gene. We obtained four clones, two that contained the whole gene and two which lacked the C-terminus. We characterized one of the full length clones by cycle sequencing, which resulted in our definition of all intron/exon junction sequences for both sides of the 19 *hMLH1* exons. We then designed multiple sets of PCR primers to amplify each individual exon (first stage primers) and verified the sequence of each exon and flanking intron sequence by amplifying several different genomic DNA samples and sequencing the resulting fragments using an ABI 373 sequencer. In addition, we have determined the sizes of each *hMLH1* exon using PCR methods. Finally, we devised a set of nested PCR primers (second stage primers) for reamplification of individual exons. We have used the second stage primers in a multi-plex method for analyzing HNPCC families and tumors for *hMLH1* mutations. Generally, in the nested PCR primer approach, we perform a first multi-plex amplification with four to eight sets of "first stage" primers, each directed to a different exon. We then reamplify individual exons from the product of the first amplification step, using a single set of second stage primers. Examples and further details relating to our use of the first and second stage primers are set forth below.

Through our genomic sequencing studies, we have identified all nineteen exons within the *hMLH1* gene, and have mapped the intron/exon boundaries. One aspect of the invention, therefore, is the individual exons of the *hMLH1* gene. Table 1 presents the nucleotide coordinates (i.e., the point of insertion of each intron within the coding region of the gene) of the *hMLH1* exons (SEQ ID NOS: 25-43). The presented coordinates are based on the *hMLH1* cDNA sequence, assigning position "1" to the "A" of the start "ATG" (which A is nucleotide 1 in SEQ ID NO: 4.

Table 1

Intron Number	cDNA Sequence Coordinates
intron 1	116 & 117
intron 2	207 & 208
intron 3	306 & 307
intron 4	380 & 381
intron 5	453 & 454
intron 6	545 & 546
intron 7	592 & 593
intron 8	677 & 678
intron 9	790 & 791
intron 10	884 & 885
intron 11	1038 & 1039
intron 12	1409 & 1410
intron 13	1558 & 1559
intron 14	1667 & 1668
intron 15	1731 & 1732
intron 16	1896 & 1897
intron 17	1989 & 1990
intron 18	2103 & 2104

We have also determined the nucleotide sequence of intron regions which flank exons of the *hMLH1* gene. SEQ ID NOS: 6-24 are individual exon sequences bounded by their respective upstream and downstream intron

sequences. The same nucleotide structures are shown in Fig. 4A, where the exons are numbered from N-terminus to C-terminus with respect to the chromosomal locus. The 5-digit numbers indicate the primers used to amplify the exon. All sequences are numbered assuming the A of the ATG codon is nucleotide 1. The numbers in ( ) are the nucleotide coordinates of the coding sequence found in the indicated exon. Uppercase is intron. Lowercase is exon or non-translated sequences found in the mRNA/cDNA clone. Lowercase and underlined sequences correspond to primers. The stop codon at 2269-2271 is in italics and underlined.

Table 2 presents the sequences of primer pairs ("first stage" primers) which we have used to amplify individual exons together with flanking intron structures.

Table 2

EXON NO.	PRIMER LOCATION	PRIMER NO.	PRIMER SEQ ID NO	PRIMER NUCLEOTIDE SEQUENCE
1	upstream	18442	44	5'aggcactgaggtgattggc
1	downstream	19109	45	5'tcgtagcccttaagtgagc
2	upstream	19689	46	5'aatatgtacattagagtagttg
2	downstream	19688	47	5'cagagaaaggtcctgactc
3	upstream	19687	48	5'agagatttggaaaatgagtaac
3	downstream	19786	49	5'acaatgtcatcacaggagg
4	upstream	18492	50	5'aacctttccctttggtgagg
4	downstream	18421	51	5'gattactctgagacctaggc
5	upstream	18313	52	5'gattttctcttttccccttggg
5	downstream	18179	53	5'caaacaaagcttcaacaatttac

EXON NO.	PRIMER LOCATION	PRIMER NO.	PRIMER SEQ ID NO	PRIMER NUCLEOTIDE SEQUENCE
6	upstream	18318	54	5'gggttttattttcaagtacttctatg
6	downstream	18317	55	5'gctcagcaactgttcaatgtatgagc
7	upstream	19009	56	5'ctagtgtgtgtttttggc
7	downstream	19135	57	5'cataaccttatctccacc
8	upstream	18197	58	5'ctcagccatgagacaataaatcc
8	downstream	18924	59	5'ggttcccaaataatgtgatgg
9	upstream	18765	60	5'caaaagcttcagaatctc
9	downstream	18198	61	5'ctgtgggtgtttcctgtgagtgg
10	upstream	18305	62	5'catgactttgtgtgaatgtacacc
10	downstream	18306	63	5'gaggagagcctgatagaacatctg
11	upstream	18182	64	5'gggctttttctccccctccc
11	downstream	19041	65	5'aaaatctgggctctcacg
12	upstream	18579	66	5'aattatacctcatactagc
12	downstream	18178	67	5'gttttattacagaataaaggagg
12	downstream	19070	68	5'aagccaaagttagaaggca
13	upstream	18420	69	5'tgcaacccacaaaatttggc
13	downstream	18443	70	5'ctttctccatttccaaaacc
14	upstream	19028	71	5'tggtgtctctagttctgg
14	downstream	18897	72	5'cattgttgtagtagctctgc
15	upstream	19025	73	5'cccatttgtcccaactgg

EXON NO.	PRIMER LOCATION	PRIMER NO.	PRIMER SEQ ID NO	PRIMER NUCLEOTIDE SEQUENCE
15	downstream	18575	74	5'cggtcagttgaaatgtcag
16	upstream	18184	75	5'catttggatgctccgttaaagc
16	downstream	18314	76	5'cacccggctggaaattttatttg
17	upstream	18429	77	5'ggaaaggcactggagaaatggg
17	downstream	18315	78	5'ccctccagcacacatgcatgtaccg
18	upstream	18444	79	5'taagtagtctgtgatctccg
18	downstream	18581	80	5'atgtatgaggtcctgtcc
19	upstream	18638	81	5'gacaccagtgtatgttgg
19	downstream	18637	82	5'gagaaagaagaacacatccc

Additionally, we have designed a set of "second stage" amplification primers, the structures of which are shown below in Table 3. We use the second stage primers in conjunction with the first stage primers in a nested amplification protocol, as described below.

Table 3

EXON NO.	PRIMER LOCATION	PRIMER NO.	PRIMER SEQ ID NO	PRIMER NUCLEOTIDE SEQUENCE
1	upstream	19295	83	5'tgtaaaacgacggccagtcact gaggtgattggctgaa
1	downstream	19446	84	*5'tagcccttaagtgagcccg
2	upstream	18685	85	5'tgtaaaacgacggccagttacat tagagtagttgcaga

EXON NO.	PRIMER LOCATION	PRIMER NO.	PRIMER SEQ ID NO	PRIMER NUCLEOTIDE SEQUENCE
2	downstream	19067	86	*5'aggtcctgactcttccatg
3	upstream	18687	87	5'tgtaaaacgacggccagtttgga aaatgagtaacatgatt
3	downstream	19068	88	*5'tgtcatcacaggaggatat
4	upstream	19294	89	5'tgtaaaacgacggccagtctttc cctttggtgaggtga
4	downstream	19077	90	*5'tactctgagacctaggccca
5	upstream	19301	91	5'tgtaaaacgacggccagttctct tttccccttgggattag
5	downstream	19046	92	*5'acaaagcttcaacaatttactc t
6	upstream	19711	93	5'tgtaaaacgacggccagtgtttt attttcaagtacttctatgaatt
6	downstream	19079	94	*5'cagcaactgttcaatgtatgag cact
7	upstream	19293	95	5'tgtaaaacgacggccagtgtgtg tgtttttggcaac
7	downstream	19435	96	*5'aaccttatctccaccagc
8	upstream	19329	97	5'tgtaaaacgacggccagtagcc atgagacaataaatccttg
8	downstream	19450	98	*5'tcccaaataatgtgatggaatg
9	upstream	19608	99	5'tgtaaaacgacggccagtaagc ttcagaatctctttt

EXON NO.	PRIMER LOCATION	PRIMER NO.	PRIMER SEQ ID NO	PRIMER NUCLEOTIDE SEQUENCE
9	downstream	19449	100	*5'tgggtgtttcctgtgagtggatt
10	upstream	19297	101	5'tgtaaaacgacggccagtacttt gtgtgaatgtacacctgtg
10	downstream	19081	102	*5'gagagcctgatagaacatctgt tg
11	upstream	19486	103	5'tgtaaaacgacggccagtcttttt ctccccctcccacta
11	downstream	19455	104	*5'tctgggctctcacgtct
12	upstream	20546	105	*5'cttattctgagtctctcc
12	downstream	20002	106	5'tgtaaaacgacggccagtgtttg ctcagaggctgc
12	upstream	19829	107	*5'gatggttcgtacagattcccg
12	downstream	19385	108	5'tgtaaaacgacggccagtttatt acagaataaaggaggtag
13	upstream	19300	109	5'tgtaaaacgacggccagtaacc cacaaaatttggctaag
13	downstream	19078	110	*5'tctccatttccaaaaccttg
14	upstream	19456	111	*5'tgtctctagttctggtgc
14	downstream	19472	112	5'tgtaaaacgacggccagttgttg tagtagctctgcttg
15	upstream	19697	113	*5'atttgtcccaactggttgta

EXON NO.	PRIMER LOCATION	PRIMER NO.	PRIMER SEQ ID NO	PRIMER NUCLEOTIDE SEQUENCE
15	downstream	19466	114	5'tgtaaaacgacggccagttcagt tgaaatgtcagaaagtg
16	upstream	19269	115	5'tgtaaaacgacggccagt
16	downstream	19047	116	*5'ccggctggaaattttatttggag
17	upstream	19298	117	5'tgtaaaacgacggccagtaggc actggagaaatgggatttg
17	downstream	19080	118	*5'tccagcacacatgcatgtaccg aaat
18	upstream	19436	119	*5'gtagtctgtgatctccgttt
18	downstream	19471	120	5'tgtaaaacgacggccagttatga ggtcctgtcctag
19	upstream	19447	121	*5'accagtgtatgttgggatg
19	downstream	19330	122	5'tgtaaaacgacggccagtgaaa gaagaacacatcccaca

In Table 3 an asteric (*) indicates that the 5' nucleotide is biotinylated. Exons 1-7, 10, 13 and 16-19 can be specifically amplified in PCR reactions containing either 1.5 mM or 3 mM $MgCl_2$. Exons 11 and 14 can only be specifically amplified in PCR reactions containing 1.5 mM $MgCl_2$ and exons 8, 9, 12 and 15 can only be specifically amplified in PCR reactions containing 3 mM $MgCL_2$. With respect to exon 12, the second stage amplification primers have been designed so that exon 12 is reamplified in two halves. The 20546 and 20002 primer set amplifies the N-terminal half. The primer set 19829 and 19835 amplifies the C-terminal half. An alternate primer for 18178 is 19070.

The *hMLH1* sequence information provided by our studies and disclosed in this application and preceding related applications, may be used to design a large number of different oligonucleotide primers for use in identifying *hMLH1* mutations that correlate with cancer susceptibility and/or with tumor development in an individual, including primers that will amplify more than one exon (and/or flanking intron sequences) in a single product band.

One of ordinary skill in the art would be familiar with considerations important to the design of PCR primers for use to amplify the desired fragment or gene.[37] These considerations may be similar, though not necessarily identical to those involved in design of sequencing primers, as discussed above. Generally it is important that primers hybridize relatively specifically (i.e. have a T_m of greater than about 55-degrees° C, and preferably around 60-degrees° C). For most cases, primers between about 17 and 25 nucleotides in length work well. Longer primers can be useful for amplifying longer fragments. In all cases, it is desirable to avoid using primers that are complementary to more than one sequence in the human genome, so that each pair of PCR primers amplifies only a single, correct fragment. Nevertheless, it is only absolutely necessary that the correct band be distinguishable from other product bands in the PCR reaction.

The exact PCR conditions (e.g. salt concentration, number of cycles, type of DNA polymerase, etc.) can be varied as known in the art to improve, for example, yield or specificity of the reaction. In particular, we have found it valuable to use nested primers in PCR reactions in order to reduce the amount of required DNA substrate and to improve amplification specificity.

Two examples follow. The first example illustrates use of a first stage primer pair (SEQ ID NOS: 69 and 70) to amplify intron/exon segment (SEQ ID NO: 18). The second example illustrates use of second stage primers to amplify a target intron/exon segment from the product of a first PCR amplification step employing first stage primers.

EXAMPLE 1: Amplification of *hMLH1* genomic clones from a P1 phage library

25ng genomic DNA (or 1ng of a P1 phage can be used) was used in PCR reactions including:

0.05mM dNTPs
50mM KCl
3mM Mg
10mM Tris-HCl pH 8.5
0.01% gelatin
5μM primers

Reactions were performed on a Perkin-Elmer Cetus model 9600 thermal cycler. Reactions were incubated at 95-degrees° C for 5 minutes, followed by 35 cycles (30 cycles from a P1 phage) of:

94-degrees° C for 30 seconds
55-degrees° C for 30 seconds
72-degrees° C for 1 minute.

A final 7 minute extension reaction was then performed at 72°-degrees C. Desirable P1 clones were those from which an approximately bp product band was produced.

EXAMPLE 2: Amplification of *hMLH1* sequences from genomic DNA using nested PCR primers

We performed two-step PCR amplification of *hMLH1* sequences from genomic DNA as follows. Typically, the first amplification was performed in a 25 microliter reaction including:

25ng of chromosomal DNA
Perkin-Elmer PCR buffer II (any suitable buffer could be used)
3mM $MgCl_2$
50μM each dNTP
Taq DNA polymerase
5μM primers (SEQ ID NOS: 69, 70)

and incubated at 95-degrees° C for 5 minutes, followed by 20 cycles of:

94-degrees° C for 30 seconds
55-degrees° C for 30 seconds.

The product band was typically small enough (less than an approximately 500 bp) that separate extension steps were not performed as part of each cycle. Rather, a single extension step was performed, at 72-degrees° C for 7 minutes, after the 20 cycles were completed. Reaction products were stored at 4-degrees° C.

The second amplification reaction, usually 25 or 50 microliters in volume, included:

1 or 2 microliters (depending on the volume of the reaction) of the first amplification reaction product

Perkin-Elmer PCR buffer II (any suitable buffer could be used)

3mM or $MgCl_2$

50 μM each dNTP

Taq DNA polymerase

5μM nested primers (SEQ ID NOS: 109, 110),

and was incubated at 95-degrees° C for 5 minutes, followed by 20-25 cycles of:

94-degrees° C for 30 seconds

55-degrees° C for 30 seconds

a single extension step was performed, at 72-degrees° C for 7 minutes, after the cycles were completed. Reaction products were stored at 4-degrees° C.

Any set of primers capable of amplifying a target *hMLH1* sequence can be used in the first amplification reaction. We have used each of the primer sets presented in Table 2 to amplify an individual *hMLH1* exon in the first amplification reaction. We have also used combinations of those primer sets, thereby amplifying multiple individual *hMLH1* exons in the first amplification reaction.

The nested primers used in the first amplification step were designed relative to the primers used in the first amplification reaction. That is, where a single set of primers is used in the first amplification reaction, the primers used in the second amplification reaction should be identical to the primers used in the first reaction except that the primers used in the second reaction should not include the 5'-most nucleotides of the first amplification reaction primers, and should extend sufficiently more at the 3' end that the T_m of the second amplification primers is approximately the same as the T_m of the first

amplification reaction primers. Our second reaction primers typically lacked the 3 5'-most nucleotides of the first amplification reaction primers, and extended approximately 3-6 nucleotides farther on the 3' end. SEQ ID NOS: 109, 110 are examples of nested primer pairs that could be used in a second amplification reaction when SEQ ID NOS: 69 and 70 were used in the first amplification reaction.

We have also found that it can be valuable to include a standard sequence at the 5' end of one of the second amplification reaction primers to prime sequencing reactions. Additionally, we have found it useful to biotinylate that last nucleotide of one or both of the second amplification reaction primers so that the product band can easily be purified using magnetic beads[40] and then sequencing reactions can be performed directly on the bead-associated products.[41-45]

For additional discussion of multiplex amplification and sequencing methods, see References by Zu et al. and Espelund et al.[46, 47]

hMLH1 Link to Cancer

As a first step to determine whether *hMLH1* was a candidate for the HNPCC locus on human chromosome 3p21-23,[3] we mapped *hMLH1* by fluorescence *in situ* hybridization (FISH).[20,21] We used two separate genomic fragments (data not shown) of the *hMLH1* gene in FISH analysis. Examination of several metaphase chromosome spreads localized *hMLH1* to chromosome 3p21.3-23.

Panel A of Figure 7 shows hybridization of *hMLH1* probes in a metaphase spread. Biotinylated *hMLH1* genomic probes were hybridized to banded human metaphase chromosomes as previously described.[20,21] Detection was performed with fluorescein isothiocyanate (FITC)-conjugated avidin (green signal); chromosomes, shown in blue, were counterstained with 4'6-diamino-2-phenylindole (DAPI). Images were obtained with a cooled CCD camera, enhanced, pseudocoloured and merged with the following programs: CCD Image Capture; NIH Image 1.4; Adobe Photoshop and Genejoin Maxpix respectively. Panel B of Figure 7 shows a composite of chromosome 3 from multiple

metaphase spreads aligned with the human chromosome 3 ideogram. Region of hybridization (distal portion of 3p21.3-23) is indicated in the ideogram by a vertical bar.

As independent confirmation of the location of *hMLH1* on chromosome 3, we used both PCR with a pair of *hMLH1*-specific oligonucleotides and Southern blotting with a *hMLH1*-specific probe to analyze DNA from the NIGMS2 rodent/human cell panel (Coriell Inst. for Med. Res., Camden, NJ, USA). Results of both techniques indicated chromosome 3 linkage. We also mapped the mouse *MLH1* gene by FISH to chromosome 9 band E. This is a position of synteny to human chromosome 3p.[22] Therefore, the *hMLH1* gene localizes to 3p21.3-23, within the genomic region implicated in chromosome 3-linked HNPCC families.[3]

Next, we analyzed blood samples from affected and unaffected individuals from two chromosome-3 candidate HNPCC families [3] for mutations. One family, Family 1, showed significant linkage (lod score = 3.01 at recombination fraction of 0) between HNPCC and a marker on 3p. For the second family, Family 2, the reported lod score (1.02) was below the commonly accepted level of significance, and thus only suggested linkage to the same marker on 3p. Subsequent linkage analysis of Family 2 with the microsatellite marker D3S1298 on 3p21.3 gave a more significant lod score of 1.88 at a recombination fraction of 0. Initially, we screened for mutations in two PCR-amplified exons of the *hMLH1* gene by direct DNA sequencing (Figure 4). We examined these two exons from three affected individuals of Family 1, and did not detect any differences from the expected sequence. In Family 2, we observed that four individuals affected with colon cancer are heterozygous for a C to T substitution in an exon encoding amino acids 41-69, which corresponds to a highly-conserved region of the protein (Figure 9). For one affected individual, we screened PCR-amplified cDNA for additional sequence differences. The combined sequence information obtained from the two exons and cDNA of this one affected individual represents 95% (i.e. all but the first 116 bp) of the open reading frame. We observed no nucleotide changes other than the C to T substitution. In addition, four individuals from Family 2, predicted to be carriers based upon

linkage data, and as yet unaffected with colon cancer, were found to be heterozygous for the same C to T substitution. Two of these predicted carriers are below and two are above the mean age of onset (50 years) in this particular family. Two unaffected individuals examined from this same family, both predicted by linkage data to be non carriers, showed the expected normal sequence at this position. Linkage analysis that includes the C to T substitution in Family 2 gives a lod score of 2.23 at a recombination fraction 0. Using low stringency cancer diagnostic criteria, we calculated a lod score of 2.53. These data indicate the C to T substitution shows significant linkage to the HNPCC in Family 2.

Figure 8 shows sequence chromatograms indicating a C to T transition mutation that produces a non-conservative amino acid substitution at position 44 of the hMLH1 protein. Sequence analysis of one unaffected (top panels, plus and minus strands) and one affected individual (lower panels, plus and minus strands) is presented. The position of the heterozygous nucleotide is indicated by an arrow. Analysis of the sequence chromatographs indicates that there is sufficient T signal in the C peak and enough A signal in the G peak for the affected individuals to be heterozygous at this site.

To determine whether this C to T substitution was a polymorphism, we sequenced this same exon amplified from the genomic DNA from 48 unrelated individuals and observed only the normal sequence. We have examined an additional 26 unrelated individuals using allele specific oligonucleotide (ASO) hybridization analysis.[33] The ASO sequences (SEQ ID NOS: 141 and 142, respectively) which we used are:

5'-ACTTGTGGATTTTGC-3' and

5'-ACTTGTGAATTTTGC-3'.

Based upon direct DNA sequencing and ASO analysis, none of these 74 unrelated individuals carry the C to T substitution. Therefore, the C to T substitution observed in Family 2 individuals is not likely to be a polymorphism. As mentioned above, we did not detect this same C to T substitution in affected individuals from a second chromosome 3-linked family, Family 1.[3] We are continuing to study individuals of Family 1 for mutations in *hMLH1*.

Table 4 below summarizes our experimental analysis of blood samples from affected and unaffected individuals from Family 2 and unrelated individuals.

Table 4

	Status	Number of Individuals with C to T Mutation/ Number of Individuals Tested
FAMILY 2	Affected	4/4
	Predicted Carriers	4/4
	Predicted Non-carriers	0/2
	Unrelated Individuals	0/74

Based on several criteria, we suggest that the observed C to T substitution in the coding region of *hMLH1* represents the mutation that is the basis for HNPCC in Family 2.[3] First, DNA sequence and ASO analysis did not detect the C to T substitution in 74 unrelated individuals. Thus, the C to T substitution is not simply a polymorphism. Second, the observed C to T substitution is expected to produce a serine to phenylalanine change at position 44 (See Figure 9). This amino acid substitution is a non-conservative change in a conserved region of the protein (Figures 3 and 9). Secondary structure predictions using Chou-Fasman parameters suggest a helix-turn-beta sheet structure with position 44 located in the turn. The observed Ser to Phe substitution, at position 44 lowers the prediction for this turn considerably, suggesting that the predicted amino acid substitution alters the conformation of the hMLH1 protein. The suggestion that the Ser to Phe substitution is a mutation which confers cancer susceptibility is further supported by our experiments which

show that an analogous substitution (alanine to phenylalanine) in a yeast *MLH1* gene results in a nonfunctional mismatch repair protein. In bacteria and yeast, a mutation affecting DNA mismatch repair causes comparable increases in the rate of spontaneous mutation including additions and deletions within dinucleotide repeats.[4,5,11,13,14,15,16] In humans, mutation of *hMSH2* is the basis of chromosome-2 HNPCC,[1,2] tumors which show microsatellite instability and an apparent defect in mismatch repair.[12] Chromosome 3-linked HNPCC is also associated with instability of dinucleotide repeats.[3] Combined with these observations, the high degree of conservation between the human MLH1 protein and the yeast DNA mismatch repair protein MLH1 suggests that hMLH1 is likely to function in DNA mismatch repair. During isolation of the *hMLH1* gene, we identified the *hPMS1* gene. This observation suggests that mammalian DNA mismatch repair, like that in yeast,[4] may require at least two MutL-like proteins.

It should be noted that it appears that different HNPCC families show different mutations in the *MLH1* gene. As explained above, affected individuals in Family 1 showed "tight linkage" between HNPCC and a locus in the region of 3p21-23. However, affected individuals in Family 1 do not have the C to T mutation found in Family 2. It appears that the affected individuals in Family 1 have a different mutation in their *MLH1* gene. Further, we have used the structure information and methods described in this application to find and characterize another *hMLH1* mutation which apparently confers cancer susceptibility in heterozygous carriers of the mutant gene in a large English HNPCC family. The *hMLH1* mutation in the English family is a +1 T frameshift which is predicted to lead to the synthesis of a truncated hMLH1 protein. Unlike, for example, sickle cell anemia, in which essentially all known affected individuals have the same mutation multiple *hMLH1* mutations have been discovered and linked to cancer. Therefore, knowledge of the entire cDNA sequence for *hMLH1* (and probably *hPMS1*), as well as genomic sequences particularly those that surround exons, will be useful and important for characterizing mutations in families identified as exhibiting a high frequency of cancer.

Subsequent to our discovery of a cancer conferring mutation in *hMLH1*, studies by others have resulted in the characterization of at least 5

additional mutations in *hMLH1*, each of which appears to have conferred cancer susceptibility to individuals in at least one HNPCC family. For example, Papadopoulos et al. indentified such as a mutation, characterized by an in-frame deletion of 165 base pairs between codons 578 to 632. In another family, Papadopoulos et al. observed an *hMLH1* mutation, characterized by a frame shift and substitution of new amino acids, namely, a 4 base pair deletion between codons 727 and 728. Papadopoulos et al. also reports an *hMLH1* cancer linked mutation, characterized by an extension of the COOH terminus, namely, a 4 base pair insertion between codons 755 and 756.[38]

In summary, we have shown that DNA mismatch repair gene *hMLH1* which is likely to be the hereditary nonpolyposis colon cancer gene previously localized by linkage analysis to chromosome 3p21-23.[3] Availability of the *hMLH1* gene sequence will facilitate the screening of HNPCC families for cancer-linked mutations. In addition, although loss of heterozygosity (LOH) of linked markers is not a feature of either the 2p or 3p forms of HNPCC,[3,6] LOH involving the 3p21.3-23 region has been observed in several human cancers.[24-26] This suggests the possibility that *hMLH1* mutation may play some role in these tumors.

Human *PMS1*

Human *PMS1* was isolated using the procedures discussed with reference to Figure 1. Figure 10 shows the entire *hPMS1* cDNA nucleotide sequence. Figure 11 shows an alignment of the predicted human and yeast PMS1 protein sequences. We determined by FISH analysis that human *PMS1* is located on chromosome 7. Subsequent to our discovery of *hPMS1*, others have identified mutations in the gene which appear to confer HNPCC susceptibility.[39]

Mouse *MLH1*

Using the procedure outlined above with reference to Figure 1, we have determined a partial nucleotide sequence of mouse *MLH1* cDNA, as shown in Figure 12 (SEQ ID NO: 135). Figure 13 shows the corresponding predicted amino acid sequence for mMLH1 protein (SEQ ID NO: 136) in comparison to

the predicted hMLH1 protein sequence (SEQ ID NO: 5). Comparison of the mouse and human MLH1 proteins as well as the comparison of hMLH1 with yeast MLH1 proteins, as shown in Figure 9, indicate a high degree of conservation.

Mouse *PMS1*

Using the procedures discussed above with reference to Figure 1, we isolated and sequenced the mouse *PMS1* gene, as shown in Figure 14 (SEQ ID NO: 137). This cDNA sequence encodes a predicted protein of 864 amino acids (SEQ ID NO: 138), as shown in Figure 15, where it is compared to the predicted amino acid sequence for hPMS1 (SEQ ID NO: 133). The degree of identity between the predicted mouse and human PMS1 proteins is high, as would be expected between two mammals. Similarly, as noted above, there is a strong similarity between the human PMS1 protein and the yeast DNA mismatch repair protein PMS1, as shown in Figure 11. The fact that yeast PMS1 and MLH1 function in yeast to repair DNA mismatches, strongly suggests that human and mice PMS1 and MLH1 are also mismatch repair proteins.

Uses for Mouse *MLH1* and *PMS1*

We believe our isolation and characterization of *mMLH1* and *mPMS1* genes will have many research applications. For example, as already discussed above, we have used our knowledge of the *mPMS1* gene to produce antibodies which react specifically with hPMS1. We have already explained that antibodies directed to the human proteins, MLH1 or PMS1 may be used for both research purposes as well as diagnostic purposes.

We also believe that our knowledge of *mPMS1* and *mMLH1* will be useful for constructing mouse models in order to study the consequences of DNA mismatch repair defects. We expect that *mPMS1* or *mMLH1* defective mice will be highly prone to cancer because chromosome 2p and 3p-associated HNPCC are each due to a defect in a mismatch repair gene.[1,2] As noted above, we have already produced chimeric mice which carry an *mPMS1* defective gene. We are currently constructing mice heterozygous for *mPMS1* or *mMLH1* mutation. These

heterozygous mice should provide useful animal models for studying human cancer, in particular HNPCC. The mice will be useful for analysis of both intrinsic and extrinsic factors that determine cancer risk and progression. Also, cancers associated with mismatch repair deficiency may respond differently to conventional therapy in comparison to other cancers. Such animal models will be useful for determining if differences exist, and allow the development of regimes for the effective treatment of these types of tumors. Such animal models may also be used to study the relationship between hereditary versus dietary factors in carcinogenesis.

Distinguishing Mutations From Polymorphisms

For studies of cancer susceptibility and for tumor identification and characterization, it is important to distinguish "mutations" from "polymorphisms". A "mutation" produces a "non-wild-type allele" of a gene. A non-wild-type allele of a gene produces a transcript and/or a protein product that does not function normally within a cell. "Mutations" can be any alteration in nucleotide sequence including insertions, deletions, substitutions, and rearrangements.

"Polymorphisms", on the other hand, are sequence differences that are found within the population of normally-functioning (i.e., "wild-type") genes. Some polymorphisms result from the degeneracy of the nucleic acid code. That is, given that most amino acids are encoded by more than one triplet codon, many different nucleotide sequences can encode the same polypeptide. Other polymorphisms are simply sequence differences that do not have a significant effect on the function of the gene or encoded polypeptide. For example, polypeptides can often tolerate small insertions or deletions, or "conservative" substitutions in their amino acid sequence without significantly altering function of the polypeptide.

"Conservative" substitutions are those in which a particular amino acid is substituted by another amino acid of similar chemical characteristics. For example, the amino acids are often characterized as "non-polar (hydrophobic)" including alanine, leucine, isoleucine, valine, proline, phenylaline, tryptophan, and methionine; "polar neutral", including glycine, serine, threonine, cysteine, tyrosine,

asparagine, and glutamine; "positively charged (basic)", including arginine, lysine, and histidine; and "negatively charged (acidic)", including aspartic acid and glutamic acid. A substitution of one amino acid for another amino acid in the same group is generally considered to be "conservative", particularly if the side groups of the two relevant amino acids are of a similar size.

The first step in identifying a mutation or polymorphism in a mismatch repair gene sequence involves identification, using available techniques including those described herein, of a mismatch repair gene, (or gene fragment) sequence that differs from a known, normal (e.g. wild-type) sequence of the same mismatch repair gene (or gene fragment). For example, a *hMLH1* gene (or gene fragment) sequence could be identified that differs in at least one nucleotide position from a known normal (e.g. wild-type) *hMLH1* sequence such as any of SEQ ID NOS: 6-24.

Mutations can be distinguished from polymorphisms using any of a variety of methods, perhaps the most direct of which is data collection and correlation with tumor development. That is, for example, a subject might be identified whose *hMLH1* gene sequence differs from a sequence reported in SEQ ID. NOS: 6-24, but who does not have cancer and has no family history of cancer. Particularly if other, preferably senior, members of that subject's family have *hMLH1* gene sequences that differ from SEQ ID NOS: 6-24 in the same way(s), it is likely that subject's *hMLH1* gene sequence could be categorized as a "polymorphism". If other, unrelated individuals are identified with the same *hMLH1* gene sequence and no family history of cancer, the categorization may be confirmed.

Mutations that are responsible for conferring genetic susceptibility to cancer can be identified because, among other things, such mutations are likely to be present in all tissues of an affected individual and in the germ line of at least one of that individual's parents, and are not likely to be found in unrelated families with no history of cancer.

When distinguishing mutations from polymorphisms, it can sometimes be valuable to evaluate a particular sequence difference in the presence of at least one known mismatch repair gene mutation. In some

instances, a particular sequence change will not have a detectable effect (i.e., will appear to be a polymorphism) when assayed alone, but will, for example, increase the penetrance of a known mutation, such that individuals carrying both the apparent polymorphism difference and a known mutation have higher probability of developing cancer than do individuals carrying only the mutation. Sequence differences that have such an effect are properly considered to be mutations, albeit weak ones.

As discussed above and previously (U.S. Patent Application Nos. 08/168,877 and 08/209,521), mutations in mismatch repair genes or gene products produced non-wild-type versions of those genes or gene products. Some mutations can therefore be distinguished from polymorphisms by their functional characteristics in *in vivo* or *in vitro* mismatch repair assays. Any available mismatch repair assay can be used to analyze these characteristics.[49-63] It is generally desirable to utilize more than one mismatch repair assay before classifying a sequence change as a polymorphism, since some mutations will have effects that will not be observed in all assays.

For example, a mismatch repair gene containing a mutation would not be expected to be able to replace an endogenous copy of the same gene in a host cell without detectably affecting mismatch repair in that cell; whereas a mismatch repair gene containing a sequence polymorphism would be expected to be able to replace an endogenous copy of the same gene in a host cell without detectably affecting mismatch repair in that cell. We note that for such "replacement" studies, it is generally desirable to introduce the gene to be tested into a host cell of the same (or at least closely related) species as the cell from which the test gene was derived, to avoid complications due to, for example, the inability of a gene product from one species to interact with other mismatch repair gene products from another species. Similarly, a mutant mismatch repair protein would not be expected to function normally in an *in vitro* mismatch repair system (preferably from a related organism); whereas a polymorphic mismatch repair protein would be expected to function normally.

The methods described herein and previously allow identification of different kinds of mismatch repair gene mutations. The following examples

illustrate protocols for distinguishing mutations from polymorphisms in DNA mismatch repair genes.

EXAMPLE 3: We have developed a system for testing in yeast, *S. cerevisiae* the functional significance of mutations found in either the *hMLH1* or *hPMS1* genes. The system is described in this application using as an example, the serine (SER) to phenylalanine (PHE) causing mutation in *hMLH1* that we found in a family with HNPCC, as described above. We have derived a yeast strain that it is essentially deleted for its *MLH1* gene and hence is a strong mutator (i.e., 1000 fold above the normal rate in a simple genetic marker assay involving reversion from growth dependence on a given amino acid to independence (reversion of the hom3-10 allele, Prolla, Christie and Liskay, Mol Cell Biol, 14:407-415, 1994). When we placed the normal yeast *MLH1* gene (complete with all known control regions) on a yeast plasma that is stably maintained as a single copy into the MLH1-deleted strain, the mutator phenotype is fully corrected using the reversion to amino acid independence assay. However, if we introduce a deleted copy of the yeast *MLH1* there is no correction. We next tested the mutation that in the HNPCC family caused a SER to PHE alteration. We found that the resultant mutant yeast protein cannot correct the mutator phenotype, strongly suggesting that the alteration from the wild-type gene sequence probably confers cancer susceptibility, and is therefore classified as a mutation, not a polymorphism. We subsequently tested proteins engineered to contain other amino acids at the "serene" position and found that most changes result in a fully mutant, or at least partially mutant phenotype.

As other "point" mutations in *MLH1* and *PMS1* genes are found in cancer families, they can be engineered into the appropriate yeast homolog gene and their consequence on protein function studied. In addition, we have identified a number of highly conserved amino acids in both the *MLH1* and *PMS1* genes. We also have evidence that *hMLH1* interacts with yeast *PMS1*. This finding raises the possibility that mutations observed in the *hMLH1* gene can be more directly tested in the yeast system. We plan to systematically make mutations that will alter the amino acid at these conserved positions and determine what amino acid substitutions are tolerated and which are not. By

collecting mutation information relating to *hMLH1* and *hPMS1*, both by determining and documenting actual found mutations in HNPCC families, and by artificially synthesizing mutants for testing in experimental systems, it may be eventually possible to practice a cancer susceptibility testing protocol which, once the individuals *hMLH1* or *hPMS1* structure is determined, only requires comparison of that structure to known mutation versus polymorphism data.

EXAMPLE 4: Another method which we have employed to study physical interactions between *hMLH1* and *hPMS1*, can also be used to study whether a particular alteration in a gene product results in a change in the degree of protein-protein interaction. Information concerning changes in protein-protein interaction may demonstrate or confirm whether a particular genomic variation is a mutation or a polymorphism. Following our labs findings on the interaction between yeast MLH1 and PMS1 proteins *in vitro* and *in vivo*, (U.S. Patent Application Serial No. 08/168,877), the interaction between the human counterparts of these two DNA mismatch repair proteins was tested. The human MLH1 and human PMS1 proteins were tested for *in vitro* interaction using maltose binding protein (MBP) affinity chromatography. hMLH1 protein was prepared as an MBP fusion protein, immobilized on an amylose resin column via the MBP, and tested for binding to hPMS1, synthesized *in vitro*. The hPMS1 protein bound to the MBP-hMLH1 matrix, whereas control proteins showed no affinity for the matrix. When the hMLH1 protein, translated *in vitro*, was passed over an MBP-hPMS1 fusion protein matrix, the hMLH1 protein bound to the MBP-hPMS1 matrix, whereas control proteins did not.

Potential *in vivo* interactions between hMLH1 and hPMS1 were tested using the yeast "two hybrid" system.[28] Our initial results indicate that hMLH1 and hPMS1 interact *in vivo* in yeast. The same system can also be used to detect changes in protein-protein interaction which result from changes in gene or gene product structure and which have yet to be classified as either a polymorphism or a mutation which confers cancer susceptibility.

Detection of HNPCC Families and Their Mutation(s)

It has been estimated that approximately 1,000,000 individuals in the United States carry (are heterozygous for) an HNPCC mutant gene.[29] Furthermore, estimates suggest that 50-60% of HNPCC families segregate mutations in the *MSH2* gene that resides on chromosome 2p.[1,2] Another significant fraction appear to be associated with the HNPCC gene that maps to chromosome 3p21-22, presumably due to *hMLH1* mutations such as the C to T transition discussed above. Identification of families that segregate mutant alleles of either the *hMSH2* or *hMLH1* gene, and the determination of which individuals in these families actually have the mutation will be of great utility in the early intervention into the disease. Such early intervention will likely include early detection through screening and aggressive follow-up treatment of affected individuals. In addition, determination of the genetic basis for both familial and sporadic tumors could direct the method of therapy in the primary tumor, or in recurrences.

Initially, HNPCC candidate families will be diagnosed partly through the study of family histories, most likely at the local level, e.g., by hospital oncologists. One criterion for HNPCC is the observation of microsatellite instability in individual's tumors.[3,6] The presenting patient would be tested for mutations in *hMSH2*, *hMLH1*, *hPMS1* and other genes involved in DNA mismatch repair as they are identified. This is most easily done by sampling blood from the individual. Also highly useful would be freshly frozen tumor tissue. It is important to note for the screening procedure, that affected individuals are heterozygous for the offending mutation in their normal tissues.

The available tissues, e.g., blood and tumor, are worked up for PCR-based mutation analysis using one or both of the following procedures:

1) Linkage analysis with a microsatellite marker tightly linked to the *hMLH1* gene.

One approach to identify cancer prone families with a *hMLH1* mutation is to perform linkage analysis with a highly polymorphic marker located within or tightly linked to *hMLH1*. Microsatellites are highly polymorphic and therefore are very useful as markers in linkage analysis. Because we possess the

hMLH1 gene on a single large genomic fragment in a P1 phage clone (~100kbp), it is very likely that one or more microsatellites, e.g., tracts of dinucleotide repeats, exist within, or very close to, the *hMLH1* gene. At least one such microsatellite has been reported.[38] Once such markers have been identified, PCR primers will be designed to amplify the stretches of DNA containing the microsatellites. DNA of affected and unaffected individuals from a family with a high frequency of cancer will be screened to determine the segregation of the *MLH1* markers and the presence of cancer. The resulting data can be used to calculate a lod score and hence determine the likelihood of linkage between *hMLH1* and the occurrence of cancer. Once linkage is established in a given family, the same polymorphic marker can be used to test other members of the kindred for the likelihood of their carrying the *hMLH1* mutation.

2) Sequencing of reverse transcribed cDNA.

a) RNA from affected individuals, unaffected and unrelated individuals is reverse transcribed (RT'd), followed by PCR to amplify the cDNA in 4-5 overlapping portions.[34,37] It should be noted that for the purposes of PCR, many different oligonucleotide primer pair sequences may potentially be used to amplify relevant portions of an individual's *hMLH1* or *hPMS1* gene for genetic screening purposes. With the knowledge of the cDNA structures for the genes, it is a straight-forward exercise to construct primer pairs which are likely to be effective for specifically amplifying selected portions of the gene. While primer sequences are typically between 20 to 30 bases long, it may be possible to use shorter primers, potentially as small as approximately 13 bases, to amplify specifically selected gene segments. The principal limitation on how small a primer sequence may be is that it must be long enough to hybridize specifically to the targeted gene segment. Specificity of PCR is generally improved by lengthening primers and/or employing nested pairs of primers.

The PCR products, in total representing the entire cDNA, are then sequenced and compared to known wild-type sequences. In most cases a mutation will be observed in the affected individual. Ideally, the nature of mutation will indicate that it is likely to inactivate the gene product. Otherwise,

the possibility that the alteration is not simply a polymorphism must be determined.

b) Certain mutations, e.g., those affecting splicing or resulting in translation stop codons, can destabilize the messenger RNA produced from the mutant gene and hence comprise the normal RT-based mutation detection method. One recently reported technique can circumvent this problem by testing whether the mutant cDNA can direct the synthesis of normal length protein in a coupled *in vitro* transcription/translation system.[32]

3) Direct sequencing of genomic DNA.

A second route to detect mutations relies on examining the exons and the intron/exon boundaries by PCR cycle sequencing directly off a DNA template.[1,2] This method requires the use of oligonucleotide pairs, such as those described in Tables 2 and 3 above, that amplify individual exons for direct PCR cycle sequencing. The method depends upon genomic DNA sequence information at each intron/exon boundary (50bp, or greater, for each boundary). The advantage of the technique is two fold. First, because DNA is more stable than RNA, the condition of the material used for PCR is not as important as it is for RNA-based protocols. Second, most any mutation within the actual transcribed region of the gene, including those in an intron affecting splicing, will be detectable.

For each candidate gene, mutation detection may require knowledge of both the entire cDNA structure, and all intron/exon boundaries of the genomic structure. With such information, the type of causal mutation in a particular family can be determined. In turn, a more specific and efficient mutation detection scheme can be adapted for the particular family. Screening for the disease (HNPCC) is complex because it has a genetically heterogeneous basis in the sense that more than one gene is involved, and for each gene, multiple types of mutations are involved.[2] Any given family is highly likely to segregate one particular mutation. However, as the nature of the mutation in multiple families is determined, the spectrum of the most prevalent mutations in the population will be determined. In general, determination of the most frequent mutations will direct and streamline mutation detection.

Because HNPCC is so prevalent in the human population, carrier detection at birth could become part of standardized neonatal testing. Families at risk can be identified and all members not previously tested can be tested. Eventually, all affected kindreds could be determined.

Mode of Mutation Screening and Testing

DNA-based Testing

Initial testing, including identifying likely HNPCC families by standard diagnosis and family history study, will likely be done in local and smaller DNA diagnosis laboratories. However, large scale testing of multiple family members, and certainly population wide testing, will ultimately require large efficient centralized commercial facilities.

Tests will be developed based on the determination of the most common mutations for the major genes underlying HNPCC, including at least the *hMSH2* gene on chromosome 2p and the *MLH1* gene on chromosome 3p. A variety of tests are likely to be developed. For example, one possibility is a set of tests employing oligonucleotide hybridizations that distinguish the normal vs. mutant alleles.[33] As already noted, our knowledge of the nucleotide structures for *hMLH1*, *hPMS1* and *hMSH2* genes makes possible the design of numerous oligonucleotide primer pairs which may be used to amplify specific portions of an individual's mismatch repair gene for genetic screening and cancer risk analysis. Our knowledge of the genes' structures also makes possible the design of labeled probes which can be quickly used to determine the presence or absence of all or a portion of one of the DNA mismatch repair genes. For example, allele-specific oligomer probes (ASO) may be designed to distinguish between alleles. ASOs are short DNA segments that are identical in sequence except for a single base difference that reflects the difference between normal and mutant alleles. Under the appropriate DNA hybridization conditions, these probes can recognize a single base difference between two otherwise identical DNA sequences. Probes can be labeled radioactively or with a variety of non-radioactive reporter molecules, for example, fluorescent or chemiluminescent moieties. Labeled probes are then used to analyze the PCR sample for the presence of the disease-

causing allele. The presence or absence of several different disease-causing genes can readily be determined in a single sample. The length of the probe must be long enough to avoid non-specific binding to nucleotide sequences other than the target. All tests will depend ultimately on accurate and complete structural information relating to *hMLH1*, *hMSH2*, *hPMS1* and other DNA mismatch repair genes implicated in HNPCC.

Protein Detection-Based Screening

Tests based on the functionality of the protein product, *per se*, may also be used. The protein-examining tests will most likely utilize antibody reagents specific to either the hMLH1, hPMS1 and hMSH2 proteins or other related "cancer" gene products as they are identified.

For example, a frozen tumor specimen can be cross-sectioned and prepared for antibody staining using indirect fluorescence techniques. Certain gene mutations are expected to alter or destabilize the protein structure sufficiently such as to give an altered or reduced signal after antibody staining. It is likely that such tests will be performed in cases where gene involvement in a family's cancer has yet to be established. We are in the process of developing diagnostic monoclonal antibodies against the human MLH1 and PMS1 proteins. We are overexpressing MLH1 and PMS1 human proteins in bacteria. We will purify the proteins, inject them into mice and derive protein specific monoclonal antibodies which can be used for diagnostic and research purposes.

Identification and Characterization of DNA Mismatch Repair Tumors

In addition to their usefulness in diagnosing cancer susceptibility in a subject, nucleotide sequences that are homologous to a bacterial mismatch repair gene can be valuable for, among other things, use in the identification and characterization of mismatch-repair-defective tumors. Such identification and characterization is valuable because mismatch-repair-defective tumors may respond better to particular therapy regimens. For example, mismatch-repair-defective tumors might be sensitive to DNA damaging agents, especially when administered in combination with other therapeutic agents.

Defects in mismatch repair genes need not be present throughout an individual's tissues to contribute to tumor formation in that individual. Spontaneous mutation of a mismatch repair gene in a particular cell or tissue can contribute to tumor formation in that tissue. In fact, at least in some cases, a single mutation in a mismatch repair gene is not sufficient for tumor development. In such instances, an individual with a single mutation in a mismatch repair gene is susceptible to cancer, but will not develop a tumor until a secondary mutation occurs. Additionally, in some instances, the same mismatch repair gene mutation that is strictly tumor-associated in an individual will be responsible for conferring cancer susceptibility in a family with a hereditary predisposition to cancer development.

In yet another aspect of the invention, the sequence information we have provided can be used with methods known in the art to analyze tumors (or tumor cell lines) and to identify tumor-associated mutations in mismatch repair genes. Preferably, it is possible to demonstrate that these tumor-associated mutations are not present in non-tumor tissues from the same individual. The information described in this application is particularly useful for the identification of mismatch repair gene mutations within tumors (or tumor cell lines) that display genomic instability of short repeated DNA elements.

The sequence information and testing protocols of the present invention can also be used to determine whether two tumors are related, i.e., whether a second tumor is the result of metastasis from an earlier found first tumor which exhibits a particular DNA mismatch repair gene mutation.

Isolating Additional Genes of Related Function

Proteins that interact physically with either *hMLH1* and/or *hPMS1*, are likely to be involved in DNA mismatch repair. By analogy to *hMLH1* and *hMSH2*, mutations in the genes which encode for such proteins would be strong candidates for potential cancer linkage. A powerful molecular genetic approach using yeast, referred to as a "two-hybrid system", allows the relatively rapid detection and isolation of genes encoding proteins that interact with a gene product of interest, e.g., *hMLH1*.[28]

The two-hybrid system involves two plasmid vectors each intended to encode a fusion protein. Each of the two vectors contains a portion, or domain, of a transcription activator. The yeast cell used in the detection scheme contains a "reporter" gene. The activator alone cannot activate transcription. However, if the two domains are brought into close proximity then transcription may occur. The cDNA for the protein of interest, e.g., *hMLH1* is inserted within a reading frame in one of the vectors. This is termed the "bait". A library of human cDNAs, inserted into a second plasmid vector so as to make fusions with the other domain of the transcriptional activator, is introduced into the yeast cells harboring the "bait" vector. If a particular yeast cell receives a library member that contains a human cDNA encoding a protein that interacts with hMLH1 protein, this interaction will bring the two domains of the transcriptional activator into close proximity, activate transcription of the reporter gene and the yeast cell will turn blue. Next, the insert is sequenced to determine whether it is related to any sequence in the data base. The same procedure can be used to identify yeast proteins in DNA mismatch repair or a related process. Performing the yeast and human "hunts" in parallel has certain advantages. The function of novel yeast homologs can be quickly determined in yeast by gene disruption and subsequent examination of the genetic consequences of being defective in the new found gene. These yeast studies will help guide the analysis of novel human "hMLH1-or hPMS1-interacting" proteins in much the same way that the yeast studies on *PMS1* and *MLH1* have influenced our studies of the human *MLH1* and *PMS1* genes.

Production of Antibodies

By using our knowledge of the DNA sequences for *hMLH1* and *hPMS1*, we can synthesize all or portions of the predicted protein structures for the purpose of producing antibodies. One important use for antibodies directed to hMLH1 and hPMS1 proteins will be for capturing other proteins which may be involved in DNA mismatch repair. For example, by employing coimmuno-precipitation techniques, antibodies directed to either hMLH1 or hPMS1 may be precipitated along with other associated proteins which are functionally and/or physically related. Another important use for antibodies will be for the purpose

of isolating hMLH1 and hPMS1 proteins from tumor tissue. The hMLH1 and hPMS1 proteins from tumors can then be characterized for the purpose of determining appropriate treatment strategies.

We are in the process of developing monoclonal antibodies directed to the hMLH1 and hPMS1 proteins.

EXAMPLE 5: We have also used the following procedure to produce polyclonal antibodies directed to the human and mouse forms of PMS1 protein.

We inserted a 3' fragment of the mouse *PMS1* cDNA in the bacterial expression plasmid vector, pET (Novagen, Madison, WI). The expected expressed portion of the mouse PMS1 protein corresponds to a region of approximately 200 amino acids at the end of the PMS1 protein. This portion of the mPMS1 is conserved with yeast PMS1 but is not conserved with either the human or the mouse MLH1 proteins. One reason that we selected this portion of the PMS1 protein for producing antibodies is that we did not want the resulting antibodies to cross-react with MLH1. The mouse PMS1 protein fragment was highly expressed in *E. coli.*, purified from a polyacrylamide gel and the eluted protein was then prepared for animal injections. Approximately 2 mg of the PMS1 protein fragment was sent to the Pocono Rabbit Farm (PA) for injections into rabbits. Sera from rabbits multiple times was tittered against the PMS1 antigen using standard ELISA techniques. Rabbit antibodies specific to mouse PMS1 protein were affinity-purified using columns containing immobilized mouse PMS1 protein. The affinity-purified polyclonal antibody preparation was tested further using Western blotting and dot blotting. We found that the polyclonal antibodies recognized, not only the mouse PMS1 protein, but also the human PMS1 protein which is very similar. Based upon the Western blots, there is no indication that other proteins were recognized strongly by our antibody, including either the human or mouse MLH1 proteins.

DNA Mismatch Repair Defective Mice

EXAMPLE 6: In order to create a experimental model system for studying DNA mismatch repair defects and resultant cancer in a whole animal

system we have derived DNA mismatch repair defective mice using embryonic stem (ES) cell technology. Using genomic DNA containing a portion of the *mPMS1* gene we constructed a vector that upon homologous recombination causes disruption of the chromosomal *mPMS1* gene. Mouse ES cells from the 129 mouse strain were confirmed to contain a disrupted *mPMS1* allele. The ES cells were injected into C57/BL6 host blastocysts to produce animals that were chimeric or a mixture of 129 and C57/BL6 cells. The incorporation of the ES cells was determined by the presence of patches of agouti coat coloring (indicative of ES cell contribution). All male chimeras were bred with C57/BL6 female mice.

Subsequently, twelve offspring (F_2) were born in which the agouti coat color was detected indicating the germline transmission of genetic material from the ES cells. Analysis of DNA extracted from the tail tips of the twelve offspring indicated that six of the animals were heterozygous (contained one wild-type and one mutant allele) for the *mPMS1* mutation. Of the six heterozygous animals, three were female, (animals F_2-8, F_2-11 and F_2-12) and three were males (F_2, F_2-10 and F_2-13). Four breeding pens were set up to obtain mice that were homozygous for *mPMS1* mutation, and additional heterozygous mice. Breeding pen #1 which contained animals F_2-11 and F_2-10, yielded a total of thirteen mice in three litters, four of which have been genotyped. Breeding pen #2 (animals F_2-8 and F_2-13) gave twenty-two animals and three litters, three of which have been genotyped. Of the seven animals genotyped, three homozygous female animals have been identified. One animal died at six weeks of age from unknown causes. The remaining homozygous females are alive and healthy at twelve weeks of age. The results indicate that *mPMS1* homozygous defective mice are viable.

Breeding pens #3 and #4 were used to backcross the *mPMS1* mutation into the C57/BL6 background. Breeding pen #3 (animal F_2-12 crossed to a C57/BL6 mouse) produced twenty-one animals in two litters, nine of which have been genotyped. Breeding pen #4 (animal F_2-6 crossed with a C57/BL6 mouse) gave eight mice. In addition, the original male chimera (breeding pen #5) has produced thirty-one additional offspring.

To genotype the animals, a series of PCR primers have been developed that are used to identify mutant and wild-type *mPMS1* genes. They are: (SEQ ID NOS: 143-148, respectively)

Primer 1: 5'TTCGGTGACAGATTTGTAAATG-3'

Primer 2: 5'TTTACGGAGCCCTGGC-3'

Primer 3: 5'TCACCATAAAAATAGTTTCCCG-3'

Primer 4: 5'TCCTGGATCATATTTTCTGAGC-3'

Primer 5: 5'TTTCAGGTATGTCCTGTTACCC-3'

Primer 6: 5'TGAGGCAGCTTTTAAGAAACTC-3'

Primers 1+2 (5'targeted)

Primers 1+3 (5'untargeted)

Primers 4+5 (3'targeted)

Primers 4+6 (3'untargeted)

The mice we have developed provide an animal model system for studying the consequences of defects in DNA mismatch repair and resultant HNPCC. The long term survival of mice homozygous and heterozygous for the *mPMS1* mutation and the types and timing of tumors in these mice will be determined. The mice will be screened daily for any indication of cancer onset as indicated by a hunched appearance in combination with deterioration in coat condition. These mice carrying *mPMS1* mutation will be used to test the effects of other factors, environmental and genetic, on tumor formation. For example, the effect of diet on colon and other type of tumors can be compared for normal mice versus those carrying *mPMS1* mutation either in the heterozygous or homozygous genotype. In addition, the *mPMS1* mutation can be put into different genetic backgrounds to learn about interactions between genes of the mismatch repair pathway and other genes involved in human cancer, for example, p53. Mice carrying *mPMS1* mutations will also be useful for testing the efficacy of somatic gene therapy on the cancers that arise in mice, for example, the expected colon cancers. Further, isogenic fibroblast cell lines from the homozygous and heterozygous *mPMS1* mice can be established for use in various cellular studies, including the determination of spontaneous mutation rates.

We are currently constructing a vector for disrupting the mouse *mMLH1* gene to derive mice carrying mutation in *mMLH1*. We will compare mice carrying defects in *mPMS1* to mice carrying defects in *mMLH1*. In addition, we will construct mice that carry mutations in both genes to see whether there is a synergistic effect of having mutations in two HNPCC genes. Other studies on the *mMLH1* mutant mice will be as described above for the *mPMS1* mutant mice.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Liskay, Robert M.
Bronner, C. Eric
Baker, Sean M.
Bollag, Roni J.
Kolodner, Richard D.

(ii) TITLE OF INVENTION: COMPOSITIONS AND METHODS RELATING TO DNA MISMATCH REPAIR GENES

(iii) NUMBER OF SEQUENCES: 148

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Kolisch, Hartwell, Dickinson, McCormack & Heuser

(B) STREET: 520 S.W. Yamhill Street, Suite 200

(C) CITY: Portland

(D) STATE: Oregon

(E) COUNTRY: U.S.A.

(F) ZIP: 97204

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Van Rysselberghe, Pierre C.
(B) REGISTRATION NUMBER: 33,557
(C) REFERENCE/DOCKET NUMBER: OHSU 306B
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (503) 224-6655
(B) TELEFAX: (503) 295-6679
(C) TELEX: 360619

(2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 361 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
Met Pro Ile Gln Val Leu Pro Pro Gln Leu Ala Asn Gln Ile Ala Ala
1               5                  10                  15
Gly Glu Val Val Glu Arg Pro Ala Ser Val Val Lys Glu Leu Val Glu
            20                  25                  30
Asn Ser Leu Asp Ala Gly Ala Thr Arg Val Asp Ile Asp Ile Glu Arg
        35                  40                  45
Gly Gly Ala Lys Leu Ile Arg Ile Arg Asp Asn Gly Cys Gly Ile Lys
    50                  55                  60
Lys Glu Glu Leu Ala Leu Ala Leu Ala Arg His Ala Thr Ser Lys Ile
65                  70                  75                  80
Ala Ser Leu Asp Asp Leu Glu Ala Ile Ile Ser Leu Gly Phe Arg Gly
                85                  90                  95
Glu Ala Leu Ala Ser Ile Ser Ser Val Ser Arg Leu Thr Leu Thr Ser
            100                 105                 110
Arg Thr Ala Glu Gln Ala Glu Ala Trp Gln Ala Tyr Ala Glu Gly Arg
        115                 120                 125
```

```
Asp Met Asp Val Thr Val Lys Pro Ala Ala His Pro Val Gly Thr Thr
    130                 135                 140
Leu Glu Val Leu Asp Leu Phe Tyr Asn Thr Pro Ala Arg Arg Lys Phe
145                 150                 155                 160
Met Arg Thr Glu Lys Thr Glu Phe Asn His Ile Asp Glu Ile Ile Arg
                165                 170                 175
Arg Ile Ala Leu Ala Arg Phe Asp Val Thr Leu Asn Leu Ser His Asn
            180                 185                 190
Gly Lys Leu Val Arg Gln Tyr Arg Ala Val Ala Lys Asp Gly Gln Lys
        195                 200                 205
Glu Arg Arg Leu Gly Ala Ile Cys Gly Thr Pro Phe Leu Glu Gln Ala
    210                 215                 220
Leu Ala Ile Glu Trp Gln His Gly Asp Lys Thr Lys Arg Gly Trp Val
225                 230                 235                 240
Ala Asp Pro Asn His Thr Thr Thr Ala Leu Thr Glu Ile Gln Tyr Cys
                245                 250                 255
Tyr Val Asn Gly Arg Met Met Arg Asp Arg Leu Ile Asn His Ala Ile
            260                 265                 270
Arg Gln Ala Cys Glu Asp Lys Leu Gly Ala Asp Gln Gln Pro Ala Phe
        275                 280                 285
Val Leu Tyr Leu Glu Ile Asp Pro His Gln Val Asp Val Asn Val His
    290                 295                 300
Pro Ala Lys His Glu Val Arg Phe His Gln Ser Arg Leu Val His Asp
305                 310                 315                 320
Phe Ile Tyr Gln Gly Val Leu Ser Val Leu Gln Gln Gln Thr Glu Thr
                325                 330                 335
Ala Leu Pro Leu Glu Glu Ile Ala Pro Ala Pro Arg His Val Gln Glu
            340                 345                 350
Asn Arg Ile Ala Ala Gly Arg Asn His
        355                 360
```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 538 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
Met Ser His Ile Ile Glu Leu Pro Glu Met Leu Ala Asn Gln Ile Ala
1               5                   10                  15
Ala Gly Glu Val Ile Glu Arg Pro Ala Ser Val Cys Lys Glu Leu Val
            20                  25                  30
Glu Asn Ala Ile Asp Ala Gly Ser Ser Gln Ile Ile Ile Glu Ile Glu
        35                  40                  45
```

```
Glu Ala Gly Leu Lys Lys Val Gln Ile Thr Asp Asn Gly His Gly Ile
    50                  55                  60
Ala His Asp Glu Val Glu Leu Ala Leu Arg Arg His Ala Thr Ser Lys
65                  70                  75                  80
Ile Lys Asn Gln Ala Asp Leu Phe Arg Ile Arg Thr Leu Gly Phe Arg
                85                  90                  95
Gly Glu Ala Leu Pro Ser Ile Ala Ser Val Ser Val Leu Thr Leu Leu
            100                 105                 110
Thr Ala Val Asp Gly Ala Ser His Gly Thr Lys Leu Val Ala Arg Gly
        115                 120                 125
Gly Glu Val Glu Glu Val Ile Pro Ala Thr Ser Pro Val Gly Thr Lys
    130                 135                 140
Val Cys Val Glu Asp Leu Phe Phe Asn Thr Pro Ala Arg Leu Lys Tyr
145                 150                 155                 160
Met Lys Ser Gln Gln Ala Glu Leu Ser His Ile Ile Asp Ile Val Asn
                165                 170                 175
Arg Leu Gly Leu Ala His Pro Glu Ile Ser Phe Ser Leu Ile Ser Asp
            180                 185                 190
Gly Lys Glu Met Thr Arg Thr Ala Gly Thr Gly Gln Leu Arg Gln Ala
        195                 200                 205
Ile Ala Gly Ile Tyr Gly Leu Val Ser Ala Lys Lys Met Ile Glu Ile
    210                 215                 220
```

```
Glu Asn Ser Asp Leu Asp Phe Glu Ile Ser Gly Phe Val Ser Leu Pro
225                 230                 235                 240
Glu Leu Thr Arg Ala Asn Arg Asn Tyr Ile Ser Leu Phe Ile Asn Gly
                245                 250                 255
Arg Tyr Ile Lys Asn Phe Leu Leu Asn Arg Ala Ile Leu Asp Gly Phe
            260                 265                 270
Gly Ser Lys Leu Met Val Gly Arg Phe Pro Leu Ala Val Ile His Ile
        275                 280                 285
His Ile Asp Pro Tyr Leu Ala Asp Val Asn Val His Pro Thr Lys Gln
    290                 295                 300
Glu Val Arg Ile Ser Lys Glu Lys Glu Leu Met Thr Leu Val Ser Glu
305                 310                 315                 320
Ala Ile Ala Asn Ser Leu Lys Glu Gln Thr Leu Ile Pro Asp Ala Leu
                325                 330                 335
Glu Asn Leu Ala Lys Ser Thr Val Arg Asn Arg Glu Lys Val Glu Gln
            340                 345                 350
Thr Ile Leu Pro Leu Ser Phe Pro Glu Leu Glu Phe Phe Gly Gln Met
        355                 360                 365
His Gly Thr Tyr Leu Phe Ala Gln Gly Arg Asp Gly Leu Tyr Ile Ile
    370                 375                 380
Asp Gln His Ala Ala Gln Glu Arg Val Lys Tyr Glu Glu Tyr Arg Glu
385                 390                 395                 400
Ser Ile Gly Asn Val Asp Gln Ser Gln Gln Gln Leu Leu Val Pro Tyr
                405                 410                 415
Ile Phe Glu Phe Pro Ala Asp Asp Ala Leu Arg Leu Lys Glu Arg Met
            420                 425                 430
Pro Leu Leu Glu Glu Val Gly Val Phe Leu Ala Glu Tyr Gly Glu Asn
        435                 440                 445
Gln Phe Ile Leu Arg Glu His Pro Ile Trp Met Ala Glu Glu Glu Ile
    450                 455                 460
Glu Ser Gly Ile Tyr Glu Met Cys Asp Met Leu Leu Leu Thr Lys Glu
465                 470                 475                 480
Val Ser Ile Lys Lys Tyr Arg Ala Glu Leu Ala Ile Met Met Ser Cys
                485                 490                 495

Lys Arg Ser Ile Lys Ala Asn His Arg Ile Asp Asp His Ser Ala Arg
            500                 505                 510
Gln Leu Leu Tyr Gln Leu Ser Gln Cys Asp Asn Pro Tyr Asn Cys Pro
        515                 520                 525
His Gly Arg Pro Val Leu Val His Phe Thr
    530                 535
```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 607 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```
Met Phe His His Ile Glu Asn Leu Leu Ile Glu Thr Glu Lys Arg Cys
1               5                  10                  15
Lys Gln Lys Glu Gln Arg Tyr Ile Pro Val Lys Tyr Leu Phe Ser Met
            20                  25                  30
Thr Gln Ile His Gln Ile Asn Asp Ile Asp Val His Arg Ile Thr Ser
        35                  40                  45
Gly Gln Val Ile Thr Asp Leu Thr Thr Ala Val Lys Glu Leu Val Asp
    50                  55                  60
Asn Ser Ile Asp Ala Asn Ala Asn Gln Ile Glu Ile Ile Phe Lys Asp
65                  70                  75                  80
Tyr Gly Leu Glu Ser Ile Glu Cys Ser Asp Asn Gly Asp Gly Ile Asp
                85                  90                  95
Pro Ser Asn Tyr Glu Phe Leu Ala Leu Lys His Tyr Thr Ser Lys Ile
            100                 105                 110
Ala Lys Phe Gln Asp Val Ala Lys Val Gln Thr Leu Gly Phe Arg Gly
        115                 120                 125
Glu Ala Leu Ser Ser Leu Cys Gly Ile Ala Lys Leu Ser Val Ile Thr
    130                 135                 140

Thr Thr Ser Pro Pro Lys Ala Asp Lys Glu Leu Tyr Asp Met Val Gly
145                 150                 155                 160
His Ile Thr Ser Lys Thr Thr Thr Ser Arg Asn Lys Gly Thr Thr Val
                165                 170                 175
Leu Val Ser Gln Leu Phe His Asn Leu Pro Val Arg Gln Lys Glu Phe
            180                 185                 190
Ser Lys Thr Phe Lys Arg Gln Phe Thr Lys Cys Leu Thr Val Ile Gln
        195                 200                 205
Gly Tyr Ala Ile Ile Asn Ala Ala Ile Lys Phe Ser Val Trp Asn Ile
    210                 215                 220
Thr Pro Lys Gly Lys Lys Asn Leu Ile Leu Ser Thr Met Arg Asn Ser
225                 230                 235                 240
Ser Met Arg Lys Asn Ile Ser Ser Val Phe Gly Ala Gly Gly Met Arg
                245                 250                 255
Gly Glu Leu Glu Val Asp Leu Val Leu Asp Leu Asn Pro Phe Lys Asn
            260                 265                 270
Arg Met Leu Gly Lys Tyr Thr Asp Asp Pro Asp Phe Leu Asp Leu Asp
        275                 280                 285
```

Tyr Lys Ile Arg Val Lys Gly Tyr Ile Ser Gln Asn Ser Phe Gly Cys
290 295 300
Gly Arg Asn Ser Lys Asp Arg Gln Phe Ile Tyr Val Asn Lys Arg Pro
305 310 315 320
Val Glu Tyr Ser Thr Leu Leu Lys Cys Cys Asn Glu Val Tyr Lys Thr
325 330 335
Phe Asn Asn Val Gln Phe Pro Ala Val Phe Leu Asn Leu Glu Leu Pro
340 345 350
Met Ser Leu Ile Asp Val Asn Val Thr Pro Asp Lys Arg Val Ile Leu
355 360 365
Leu His Asn Glu Arg Ala Val Ile Asp Ile Phe Lys Thr Thr Leu Ser
370 375 380
Asp Tyr Tyr Asn Arg Gln Glu Leu Ala Leu Pro Lys Arg Met Cys Ser
385 390 395 400
Gln Ser Glu Gln Gln Ala Gln Lys Arg Leu Leu Thr Glu Val Phe Asp
405 410 415

Asp Asp Phe Lys Lys Met Glu Val Val Gly Gln Phe Asn Leu Gly Phe
420 425 430
Ile Ile Val Thr Arg Lys Val Asp Asn Lys Ser Asp Leu Phe Ile Val
435 440 445
Asp Gln His Ala Ser Asp Glu Lys Tyr Asn Phe Glu Thr Leu Gln Ala
450 455 460
Val Thr Val Phe Lys Ser Gln Lys Leu Ile Ile Pro Gln Pro Val Glu
465 470 475 480
Leu Ser Val Ile Asp Glu Leu Val Val Leu Asp Asn Leu Pro Val Phe
485 490 495
Glu Lys Asn Gly Phe Lys Leu Lys Ile Asp Glu Glu Glu Glu Phe Gly
500 505 510
Ser Arg Val Lys Leu Leu Ser Leu Pro Thr Ser Lys Gln Thr Leu Phe
515 520 525
Asp Leu Gly Asp Phe Asn Glu Leu Ile His Leu Ile Lys Glu Asp Gly
530 535 540
Gly Leu Arg Arg Asp Asn Ile Arg Cys Ser Lys Ile Arg Ser Met Phe
545 550 555 560
Ala Met Arg Ala Cys Arg Ser Ser Ile Met Ile Gly Lys Pro Leu Asn
565 570 575
Lys Lys Thr Met Thr Arg Val Val His Asn Leu Ser Glu Leu Asp Lys
580 585 590
Pro Trp Asn Cys Pro His Gly Arg Pro Thr Met Arg His Leu Met
595 600 605

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2484 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CTTGGCTCTT CTGGCGCCAA AATGTCGTTC GTGGCAGGGG TTATTCGGCG GCTGGACGAG 60
ACAGTGGTGA ACCGCATCGC GGCGGGGGAA GTTATCCAGC GGCCAGCTAA TGCTATCAAA 120
GAGATGATTG AGAACTGTTT AGATGCAAAA TCCACAAGTA TTCAAGTGAT TGTTAAAGAG 180
GGAGGCCTGA AGTTGATTCA GATCCAAGAC AATGGCACCG GGATCAGGAA AGAAGATCTG 240
GATATTGTAT GTGAAAGGTT CACTACTAGT AAACTGCAGT CCTTTGAGGA TTTAGCCAGT 300
ATTTCTACCT ATGGCTTTCG AGGTGAGGCT TTGGCCAGCA TAAGCCATGT GGCTCATGTT 360
ACTATTACAA CGAAAACAGC TGATGGAAAG TGTGCATACA GAGCAAGTTA CTCAGATGGA 420
AAACTGAAAG CCCCTCCTAA ACCATGTGCT GGCAATCAAG GGACCCAGAT CACGGTGGAG 480
GACCTTTTTT ACAACATAGC CACGAGGAGA AAAGCTTTAA AAAATCCAAG TGAAGAATAT 540
GGGAAAATTT TGGAAGTTGT TGGCAGGTAT TCAGTACACA ATGCAGGCAT TAGTTTCTCA 600
GTTAAAAAAC AAGGAGAGAC AGTAGCTGAT GTTAGGACAC TACCCAATGC CTCAACCGTG 660
GACAATATTC GCTCCATCTT TGGAAATGCT GTTAGTCGAG AACTGATAGA AATTGGATGT 720
GAGGATAAAA CCCTAGCCTT CAAAATGAAT GGTTACATAT CCAATGCAAA CTACTCAGTG 780
AAGAAGTGCA TCTTCTTACT CTTCATCAAC CATCGTCTGG TAGAATCAAC TTCCTTGAGA 840
AAAGCCATAG AAACAGTGTA TGCAGCCTAT TTGCCCAAAA ACACACACCC ATTCCTGTAC 900
CTGAGTTTAG AAATCAGTCC CCAGAATGTG GATGTTAATG TGCACCCCAC AAAGCATGAA 960
GTTCACTTCC TGCACGAGGA GAGCATCCTG GAGCGGGTGC AGCAGCACAT CGAGAGCAAG 1020
CTCCTGGGCT CCAATTCCTC CAGGATGTAC TTCACCCAGA CTTTGCTACC AGGACTTGCT 1080
GGCCCCTCTG GGGAGATGGT TAAATCCACA ACAAGTCTGA CCTCGTCTTC TACTTCTGGA 1140
AGTAGTGATA AGGTCTATGC CCACCAGATG GTTCGTACAG ATTCCCGGGA ACAGAAGCTT 1200
GATGCATTTC TGCAGCCTCT GAGCAAACCC CTGTCCAGTC AGCCCCAGGC CATTGTCACA 1260
GAGGATAAGA CAGATATTTC TAGTGGCAGG GCTAGGCAGC AAGATGAGGA GATGCTTGAA 1320
CTCCCAGCCC CTGCTGAAGT GGCTGCCAAA AATCAGAGCT TGGAGGGGGA TACAACAAAG 1380
GGGACTTCAG AAATGTCAGA GAAGAGAGGA CCTACTTCCA GCAACCCCAG AAAGAGACAT 1440
CGGGAAGATT CTGATGTGGA AATGGTGGAA GATGATTCCC GAAAGGAAAT GACTGCAGCT 1500
TGTACCCCCC GGAGAAGGAT CATTAACCTC ACTAGTGTTT TGAGTCTCCA GGAAGAAATT 1560
AATGAGCAGG GACATGAGGT TCTCCGGGAG ATGTTGCATA ACCACTCCTT CGTGGGCTGT 1620
GTGAATCCTC AGTGGGCCTT GGCACAGCAT CAAACCAAGT TATACCTTCT CAACACCACC 1680
AAGCTTAGTG AAGAACTGTT CTACCAGATA CTCATTTATG ATTTTGCCAA TTTTGGTGTT 1740
CTCAGGTTAT CGGAGCCAGC ACCGCTCTTT GACCTTGCCA TGCTTGCCTT AGATAGTCCA 1800
GAGAGTGGCT GGACAGAGGA AGATGGTCCC AAAGAAGGAC TTGCTGAATA CATTGTTGAG 1860
TTTCTGAAGA AGAAGGCTGA GATGCTTGCA GACTATTTCT CTTTGGAAAT TGATGAGGAA 1920
GGGAACCTGA TTGGATTACC CCTTCTGATT GACAACTATG TGCCCCCTTT GGAGGGACTG 1980
CCTATCTTCA TTCTTCGACT AGCCACTGAG GTGAATTGGG ACGAAGAAAA GGAATGTTTT 2040
GAAAGCCTCA GTAAAGAATG CGCTATGTTC TATTCCATCC GGAAGCAGTA CATATCTGAG 2100
GAGTCGACCC TCTCAGGCCA GCAGAGTGAA GTGCCTGGCT CCATTCCAAA CTCCTGGAAG 2160
TGGACTGTGG AACACATTGT CTATAAAGCC TTGCGCTCAC ACATTCTGCC TCCTAAACAT 2220

TTCACAGAAG ATGGAAATAT CCTGCAGCTT GCTAACCTGC CTGATCTATA CAAAGTCTTT 2280
GAGAGGTGTT AAATATGGTT ATTTATGCAC TGTGGGATGT GTTCTTCTTT CTCTGTATTC 2340
CGATACAAAG TGTTGTATCA AAGTGTGATA TACAAAGTGT ACCAACATAA GTGTTGGTAG 2400
CACTTAAGAC TTATACTTGC CTTCTGATAG TATTCCTTTA TACACAGTGG ATTGATTATA 2460
AATAAATAGA TGTGTCTTAA CATA 2484

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 756 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Ser Phe Val Ala Gly Val Ile Arg Arg Leu Asp Glu Thr Val Val
1 5 10 15
Asn Arg Ile Ala Ala Gly Glu Val Ile Gln Arg Pro Ala Asn Ala Ile
20 25 30
Lys Glu Met Ile Glu Asn Cys Leu Asp Ala Lys Ser Thr Ser Ile Gln
35 40 45
Val Ile Val Lys Glu Gly Gly Leu Lys Leu Ile Gln Ile Gln Asp Asn
50 55 60
Gly Thr Gly Ile Arg Lys Glu Asp Leu Asp Ile Val Cys Glu Arg Phe
65 70 75 80
Thr Thr Ser Lys Leu Gln Ser Phe Glu Asp Leu Ala Ser Ile Ser Thr
85 90 95
Tyr Gly Phe Arg Gly Glu Ala Leu Ala Ser Ile Ser His Val Ala His
100 105 110
Val Thr Ile Thr Thr Lys Thr Ala Asp Gly Lys Cys Ala Tyr Arg Ala
115 120 125
Ser Tyr Ser Asp Gly Lys Leu Lys Ala Pro Pro Lys Pro Cys Ala Gly
130 135 140
Asn Gln Gly Thr Gln Ile Thr Val Glu Asp Leu Phe Tyr Asn Ile Ala
145 150 155 160
Thr Arg Arg Lys Ala Leu Lys Asn Pro Ser Glu Glu Tyr Gly Lys Ile
165 170 175
Leu Glu Val Val Gly Arg Tyr Ser Val His Asn Ala Gly Ile Ser Phe
180 185 190
Ser Val Lys Lys Gln Gly Glu Thr Val Ala Asp Val Arg Thr Leu Pro
195 200 205
Asn Ala Ser Thr Val Asp Asn Ile Arg Ser Ile Phe Gly Asn Ala Val
210 215 220
Ser Arg Glu Leu Ile Glu Ile Gly Cys Glu Asp Lys Thr Leu Ala Phe
225 230 235 240

```
Lys Met Asn Gly Tyr Ile Ser Asn Ala Asn Tyr Ser Val Lys Lys Cys
                245                 250                 255
Ile Phe Leu Leu Phe Ile Asn His Arg Leu Val Glu Ser Thr Ser Leu
            260                 265                 270
Arg Lys Ala Ile Glu Thr Val Tyr Ala Ala Tyr Leu Pro Lys Asn Thr
        275                 280                 285
His Pro Phe Leu Tyr Leu Ser Leu Glu Ile Ser Pro Gln Asn Val Asp
    290                 295                 300
Val Asn Val His Pro Thr Lys His Glu Val His Phe Leu His Glu Glu
305                 310                 315                 320
Ser Ile Leu Glu Arg Val Gln Gln His Ile Glu Ser Lys Leu Leu Gly
                325                 330                 335
Ser Asn Ser Ser Arg Met Tyr Phe Thr Gln Thr Leu Leu Pro Gly Leu
            340                 345                 350
Ala Gly Pro Ser Gly Glu Met Val Lys Ser Thr Thr Ser Leu Thr Ser
        355                 360                 365
Ser Ser Thr Ser Gly Ser Ser Asp Lys Val Tyr Ala His Gln Met Val
    370                 375                 380
Arg Thr Asp Ser Arg Glu Gln Lys Leu Asp Ala Phe Leu Gln Pro Leu
385                 390                 395                 400

Ser Lys Pro Leu Ser Ser Gln Pro Gln Ala Ile Val Thr Glu Asp Lys
                405                 410                 415
Thr Asp Ile Ser Ser Gly Arg Ala Arg Gln Gln Asp Glu Glu Met Leu
            420                 425                 430
Glu Leu Pro Ala Pro Ala Glu Val Ala Ala Lys Asn Gln Ser Leu Glu
        435                 440                 445
Gly Asp Thr Thr Lys Gly Thr Ser Glu Met Ser Glu Lys Arg Gly Pro
    450                 455                 460
Thr Ser Ser Asn Pro Arg Lys Arg His Arg Glu Asp Ser Asp Val Glu
465                 470                 475                 480
Met Val Glu Asp Asp Ser Arg Lys Glu Met Thr Ala Ala Cys Thr Pro
                485                 490                 495
Arg Arg Arg Ile Ile Asn Leu Thr Ser Val Leu Ser Leu Gln Glu Glu
            500                 505                 510
Ile Asn Glu Gln Gly His Glu Val Leu Arg Glu Met Leu His Asn His
        515                 520                 525
Ser Phe Val Gly Cys Val Asn Pro Gln Trp Ala Leu Ala Gln His Gln
    530                 535                 540
Thr Lys Leu Tyr Leu Leu Asn Thr Thr Lys Leu Ser Glu Glu Leu Phe
545                 550                 555                 560
Tyr Gln Ile Leu Ile Tyr Asp Phe Ala Asn Phe Gly Val Leu Arg Leu
                565                 570                 575
Ser Glu Pro Ala Pro Leu Phe Asp Leu Ala Met Leu Ala Leu Asp Ser
            580                 585                 590
```

```
Pro Glu Ser Gly Trp Thr Glu Glu Asp Gly Pro Lys Glu Gly Leu Ala
        595                 600                 605
Glu Tyr Ile Val Glu Phe Leu Lys Lys Lys Ala Glu Met Leu Ala Asp
    610                 615                 620
Tyr Phe Ser Leu Glu Ile Asp Glu Glu Gly Asn Leu Ile Gly Leu Pro
625                 630                 635                 640
Leu Leu Ile Asp Asn Tyr Val Pro Pro Leu Glu Gly Leu Pro Ile Phe
                645                 650                 655
Ile Leu Arg Leu Ala Thr Glu Val Asn Trp Asp Glu Glu Lys Glu Cys
            660                 665                 670

Phe Glu Ser Leu Ser Lys Glu Cys Ala Met Phe Tyr Ser Ile Arg Lys
        675                 680                 685
Gln Tyr Ile Ser Glu Glu Ser Thr Leu Ser Gly Gln Gln Ser Glu Val
    690                 695                 700
Pro Gly Ser Ile Pro Asn Ser Trp Lys Trp Thr Val Glu His Ile Val
705                 710                 715                 720
Tyr Lys Ala Leu Arg Ser His Ile Leu Pro Pro Lys His Phe Thr Glu
                725                 730                 735
Asp Gly Asn Ile Leu Gln Leu Ala Asn Leu Pro Asp Leu Tyr Lys Val
            740                 745                 750
Phe Glu Arg Cys
        755
```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 397 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```
TGGCTGGATG CTAAGCTACA GCTGAAGGAA GAACGTGAGC ACGAGGCACT GAGGTGATTG   60
GCTGAAGGCA CTTCCGTTGA GCATCTAGAC GTTTCCTTGG CTCTTCTGGC GCCAAAATGT  120
CGTTCGTGGC AGGGGTTATT CGGCGGCTGG ACGAGACAGT GGTGAACCGC ATCGCGGCGG  180
GGGAAGTTAT CCAGCGGCCA GCTAATGCTA TCAAAGAGAT GATTGAGAAC TGGTACGGAG  240
GGAGTCGAGC CGGGCTCACT TAAGGGCTAC GACTTAACGG GCCGCGTCAC TCAATGGCGC  300
GGACACGCCT CTTTCCCCGG GCAGAGGCAT GTACAGCGCA TGCCCACAAC GGCGGAGGCC  360
GCCGGGTTCC CTACGTGCCA TAAGCCTTCT CCTTTTC                           397
```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 393 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```
AAACACGTTA ATGAGGCACT ATTGTTTGTA TTTGGAGTTT GTTATCATTG CTTGGCTCAT   60
ATTAAAATAT GTACATTAGA GTAGTTGCAG ACTGATAAAT TATTTTCTGT TTGATTTGCC  120
AGTTTAGATG CAAAATCCAC AAGTATTCAA GTGATTGTTA AAGAGGGAGG CCTGAAGTTG  180
ATTCAGATCC AAGACAATGG CACCGGGATC AGGGTAAGTA AAACCTCAAA GTAGCAGGAT  240
GTTTGTGCGC TTCATGGAAG AGTCAGGACC TTTCTCTGTT CTGGAAACTA GGCTTTTGCA  300
GATGGGATTT TTTCACTGAA AAATTCAACA CCAACAATAA ATATTTATTG AGTACCTATT  360
ATTTGCGGGG CACTGTTCAG GGGATGTGTC AGT                               393
```

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 352 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```
TTTCCTGGAT TAATCAAGAA ATGGAATTCA AAGAGATTTG GAAAATGAGT AACATGATTA   60
TTTACTCATC TTTTTGGTAT CTAACAGAAA GAAGATCTGG ATATTGTATG TGAAAGGTTC  120
ACTACTAGTA AACTGCAGTC CTTTGAGGAT TTAGCCAGTA TTTCTACCTA TGGCTTTCGA  180
GGTGAGGTAA GCTAAAGATT CAAGAAATGT GTAAAATATC CTCCTGTGAT GACATTGTCT  240
GTCATTTGTT AGTATGTATT TCTCAACATA GATAAATAAG GTTTGGTACC TTTTACTTGT  300
TAAATGTATG CAAATCTGAG CAAACTTAAT GAACTTTAAC TTTCAAAGAC TG          352
```

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 287 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

```
TGGAAGCAGC AGCAGATAAC CTTTCCCTTT GGTGAGGTGA CAGTGGGTGA CCCAGCAGTG   60
AGTTTTTCTT TCAGTCTATT TTCTTTTCTT CCTTAGGCTT TGGCCAGCAT AAGCCATGTG  120
GCTCATGTTA CTATTACAAC GAAAACAGCT GATGGAAAGT GTGCATACAG GTATAGTGCT  180
GACTTCTTTT ACTCATATAT ATTCATTCTG AAATGTATTT TGGGCCTAGG TCTCAGAGTA  240
ATCCTGTCTC AACACCAGTG TTATCTTTGG CAGAGATCTT GAGTACG                287
```

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 336 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

```
TTGATATGAT TTTCTCTTTT CCCCTTGGGA TTAGTATCTA TCTCTCTACT GGATATTAAT   60
TTGTTATATT TTCTCATTAG AGCAAGTTAC TCAGATGGAA AACTGAAAGC CCCTCCTAAA  120
CCATGTGCTG GCAATCAAGG GACCCAGATC ACGGTAAGAA TGGTACATGG GAGAGTAAAT  180
TGTTGAAGCT TTGTTTGTAT AAATATTGGA ATAAAAAATA AAATTGCTTC TAAGTTTTCA  240
GGGTAATAAT AAAATGAATT TGCACTAGTT AATGGAGGTC CCAAGATATC CTCTAAGCAA  300
GATAAATGAC TATTGGCTTT TTGGCATGGC AGCCTG                             336
```

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 275 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

```
GCTTTTGCCA GGACCATCTT GGGTTTTATT TTCAAGTACT TCTATGAATT TACAAGAAAA   60
ATCAATCTTC TGTTCAGGTG GAGGACCTTT TTTACAACAT AGCCACGAGG AGAAAAGCTT  120
TAAAAAATCC AAGTGAAGAA TATGGGAAAA TTTTGGAAGT TGTTGGCAGG TACAGTCCAA  180
AATCTGGGAG TGGGTCTCTG AGATTTGTCA TCAAAGTAAT GTGTTCTAGT GCTCATACAT  240
TGAACAGTTG CTGAGCTAGA TGGTGAAAAG TAAAA                              275
```

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 389 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

```
CAGCAACCTA TAAAAGTAGA GAGGAGTCTG TGTTTTGACG CAGCACCTTT AGCATTTTTA   60
TTTGGATGAA GTTTCTGCTG GTTTATTTTT CTGTGGGTAA AATATTAATA GGCTGTATGG  120
AGATATTTTT CTTTATATGT ACCTTTGTTT AGATTACTCA ACTCCACTAA TTTATTTAAC  180
TAAAAGGGGG CTCTGACATC TAGTGTGTGT TTTTGGCAAC TCTTTTCTTA CTCTTTTGTT  240
TTTCTTTTCC AGGTATTCAG TACACAATGC AGGCATTAGT TTCTCAGTTA AAAAAGTAAG  300
TTCTTGGTTT ATGGGGGATG GTTTTGTTTT ATGAAAAGAA AAAAGGGGAT TTTTAATAGT  360
TTGCTGGTGG AGATAAGGTT ATGATGTTT                                     389
```

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 381 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

ATGTTTCAGT CTCAGCCATG AGACAATAAA TCCTTGTGTC TTCTGCTGTT TGTTTATCAG 60
CAAGGAGAGA CAGTAGCTGA TGTTAGGACA CTACCCAATG CCTCAACCGT GGACAATATT 120
CGCTCCATCT TTGGAAATGC TGTTAGTCGG TATGTCGATA ACCTATATAA AAAAATCTTT 180
TACATTTATT ATCTTGGTTT ATCATTCCAT CACATTATTT GGGAACCTTT CAAGATATTA 240
TGTGTGTTAA GAGTTTGCTT TAGTCAAATA CACAGGCTTG TTTTATGCTT CAGATTTGTT 300
AATGGAGTTC TTATTTCACG TAATCAACAC TTTCTAGGTG TATGTAATCT CCTAGATTCT 360
GTGGCGTGAA TCATGTGTTC T 381

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 526 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

ACTGAGTAGG GTAGGTGGGT GAGTGGGTGG GTGGGTGGGT GGGTGGATGG ATGGATGGGA 60
GGATGGGTGG GTGAATGGGT GAACAGACAA ATGGATGGAT GAATGGACAG GCACAGGAGG 120
ACCTCAAATG GACCAAGTCT TCGGGGCCCT CATTTCACAA AGTTAGTTTA TGGGAAGGAA 180
CCTTGTGTTT TTAAATTCTG ATTCTTTTGT AATGTTTGAG TTTTGAGTAT TTTCAAAAGC 240
TTCAGAATCT CTTTTCTAAT AGAGAACTGA TAGAAATTGG ATGTGAGGAT AAAACCCTAG 300
CCTTCAAAAT GAATGGTTAC ATATCCAATG CAAACTACTC AGTGAAGAAG TGCATCTTCT 360
TACTCTTCAT CAACCGTAAG TTAAAAAGAA CCACATGGGA AATCCACTCA CAGGAAACAC 420
CCACAGGGAA TTTTATGGGA CCATGGAAAA ATTTCTGAGT CCATAGGTTT GATTAAACAT 480
GGAGAAACCT CATGGCAAAG TTTGGTTTTA TTGGGAAGCA TGTATA 526

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 434 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

ATAGTGGGCT GGAAAGTGGC CACAGGTAAA GGTGCACCTT TCTTCCTGGG GATGTGATGT 60
GCATATCACT ACAGAAATGT CTTTCCTGAG GTGATGTCAT GACTTTGTGT GAATGTACAC 120
CTGTGACCTC ACCCCTCAGG ACAGTTTTGA ACTGGTTGCT TTCTTTTTAT TGTTTAGATC 180

GTCTGGTAGA ATCAACTTCC TTGAGAAAAG CCATAGAAAC AGTGTATGCA GCCTATTTGC 240
CCAAAAACAC ACACCCATTC CTGTACCTCA GGTAATGTAG CACCAAACTC CTCAACCAAG 300
ACTCACAAGG AACAGATGTT CTATCAGGCT CTCCTCTTTG AAAGAGATGA GCATGCTAAT 360
AGTACAATCA GAGTGAATCC CATACACCAC TGGCAAAAGG ATGTTCTGTC CCTTCTTACA 420
GGTACAAGGC ACAG 434

(2) INFORMATION FOR SEQ ID NO:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 458 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CTTACGCAAA GCTACACAGC TCTTAAGTAG CAGTGCCAAT ATTTGAACAC ACTCAGACTC 60
GAGCCTGAGG TTTTGACCAC TGTGTCATCT GGCCTCAAAT CTTCTGGCCA CCACATACAC 120
CATATGTGGG CTTTTTCTCC CCCTCCCACT ATCTAAGGTA ATTGTTCTCT CTTATTTTCC 180
TGACAGTTTA GAAATCAGTC CCCAGAATGT GGATGTTAAT GTGCACCCCA CAAAGCATGA 240
AGTTCACTTC CTGCACGAGG AGAGCATCCT GGAGCGGGTG CAGCAGCACA TCGAGAGCAA 300
GCTCCTGGGC TCCAATTCCT CCAGGATGTA CTTCACCCAG GTCAGGGCGC TTCTCATCCA 360
GCTACTTCTC TGGGGCCTTT GAAATGTGCC CGGCCAGACG TGAGAGCCCA GATTTTTGCT 420
GTTATTTAGG AACTTTTTTT GAAGTATTAC CTGGATAG 458

(2) INFORMATION FOR SEQ ID NO:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 618 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GATAATTATA CCTCATACTA GCTTCTTTCT TAGTACTGCT CCATTTGGGG ACCTGTATAT 60
CTATACTTCT TATTCTGAGT CTCTCCACTA TATATATATA TATATATATA TTTTTTTTTT 120
TTTTTTTTTT TAATACAGAC TTTGCTACCA GGACTTGCTG GCCCCTCTGG GGAGATGGTT 180
AAATCCACAA CAAGTCTGAC CTCGTCTTCT ACTTCTGGAA GTAGTGATAA GGTCTATGCC 240
CACCAGATGG TTCGTACAGA TTCCCGGGAA CAGAAGCTTG ATGCATTTCT GCAGCCTCTG 300
AGCAAACCCC TGTCCAGTCA GCCCCAGGCC ATTGTCACAG AGGATAAGAC AGATATTTCT 360
AGTGGCAGGG CTAGGCAGCA AGATGAGGAG ATGCTTGAAC TCCCAGCCCC TGCTGAAGTG 420
GCTGCCAAAA ATCAGAGCTT GGAGGGGGAT ACAACAAAGG GGACTTCAGA AATGTCAGAG 480
AAGAGAGGAC CTACTTCCAG CAACCCCAGG TATGGCCTTT TGGGAAAAGT ACAGCCTACC 540
TCCTTTATTC TGTAATAAAA CTGCCTTCTA ACTTTGGCTT TTCATGAATC ACTTGCATCT 600
TCTCTCTGCC GACTTCCC 618

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 478 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CTGTGCTCCA GCACAGGTCA TCCAGCTCTG TAGACCAGCG CAGAGAAGTT GCTTGCTCCC 60
AAATGCAACC CACAAAATTT GGCTAAGTTT AAAAACAAGA ATAATAATGA TCTGCACTTC 120
CTTTTCTTCA TTGCAGAAAG AGACATCGGG AAGATTCTGA TGTGGAAATG GTGGAAGATG 180
ATTCCCGAAA GGAAATGACT GCAGCTTGTA CCCCCCGGAG AAGGATCATT AACCTCACTA 240
GTGTTTTGAG TCTCCAGGAA GAAATTAATG AGCAGGGACA TGAGGGTACG TAAACGCTGT 300
GGCCTGCCTG GGATGCATAG GGCCTCAACT GCCAAGGTTT TGGAAATGGA GAAAGCAGTC 360
ATGTTGTCAG AGTGGCACTA CAGTTTTGAT GGGCAAGCTC CTCTTCCTTT ACTAACCCAC 420
AATAGCATCA GCTTAAAGAC AATTTTTGAT TGGGAGAAAA GGGAGAAAAT AATCTCTG 478

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 377 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CAGTTTTCAC CAGGAGGCTC AAATCAGGCC TTTGCTTACT TGGTGTCTCT AGTTCTGGTG 60
CCTGGTGCTT TGGTCAATGA AGTGGGGTTG GTAGGATTCT ATTACTTACC TGTTTTTTGG 120
TTTTATTTTT TGTTTTGCAG TTCTCCGGGA GATGTTGCAT AACCACTCCT TCGTGGGCTG 180
TGTGAATCCT CAGTGGGCCT TGGCACAGCA TCAAACCAAG TTATACCTTC TCAACACCAC 240
CAAGCTTAGG TAAATCAGCT GAGTGTGTGA ACAAGCAGAG CTACTACAAC AATGGTCCAG 300
GGAGCACAGG CACAAAAGCT AAGGAGAGCA GCATGAAGGT AGTTGGGAAG GGCACAGGCT 360
TTGGAGTCAG CACATGT 377

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 325 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CCCCTGGTTG AAGCGTTGGA ATCCCACTCT TTGGAAGATT GTGTTAGACT GTTAACCAGA 60
TTCCACAGCC AGGCAGAACT ATGTCTGTCT CATCCATGTG TCAGGGATTA CGTCTCCCAT 120
TTGTCCCAAC TGGTTGTATC TCAAGCATGA ATTCAGCTTT TCCTTAAAGT CACTTCATTT 180
TTATTTTCAG TGAAGAACTG TTCTACCAGA TACTCATTTA TGATTTTGCC AATTTTGGTG 240

TTCTCAGGTT ATCGGTAAGT TTAGATCCTT TTCACTTCTG ACATTTCAAC TGACCGCCCC 300
GCAAACAGTA GCTCTCCACT AAATA 325

(2) INFORMATION FOR SEQ ID NO:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 341 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
CATTTATGGT TTCTCACCTG CCATTCTGAT AGTGGATTCT TGGGAATTCA GGCTTCATTT 60
GGATGCTCCG TTAAAGCTTG CTCCTTCATG TTCTTGCTTC TTCCTAGGAG CCAGCACCGC 120
TCTTTGACCT TGCCATGCTT GCCTTAGATA GTCCAGAGAG TGGCTGGACA GAGGAAGATG 180
GTCCCAAAGA AGGACTTGCT GAATACATTG TTGAGTTTCT GAAGAAGAAG GCTGAGATGC 240
TTGCAGACTA TTTCTCTTTG GAAATTGATG AGGTGTGACA GCCATTCTTA TACTTCTGTT 300
GTATTCTCCA AATAAAATTT CCAGCCGGGT GCATTGGCTC A 341

(2) INFORMATION FOR SEQ ID NO:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 260 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
CAGATAGGAG GCACAAGGCC TGGGAAAGGC ACTGGAGAAA TGGGATTTGT TTAAACTATG 60
ACAGCATTAT TTCTTGTTCC CTTGTCCTTT TTCCTGCAAG CAGGAAGGGA ACCTGATTGG 120
ATTACCCCTT CTGATTGACA ACTATGTGCC CCCTTTGGAG GGACTGCCTA TCTTCATTCT 180
TCGACTAGCC ACTGAGGTCA GTGATCAAGC AGATACTAAG CATTTCGGTA CATGCATGTG 240
TGCTGGAGGG AAAGGGCAAA 260

(2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 340 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
CTATATCTTC CCAGCAATAT TCACAGTCCG TTTACAGTTT TAACGCCTAA AGTATCACAT 60
TTCGTTTTTT AGCTTTAAGT AGTCTGTGAT CTCCGTTTAG AATGAGAATG TTTAAATTCG 120
TACCTATTTT GAGGTATTGA ATTTCTTTGG ACCAGGTGAA TTGGGACGAA GAAAAGGAAT 180
GTTTTGAAAG CCTCAGTAAA GAATGCGCTA TGTTCTATTC CATCCGGAAG CAGTACATAT 240

CTGAGGAGTC GACCCTCTCA GGCCAGCAGG TACAGTGGTG ATGCACACTG GCACCCCAGG 300
ACTAGGACAG GACCTCATAC ATCTTAGGAG ATGAAACTTG 340

(2) INFORMATION FOR SEQ ID NO:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 563 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
AATCCTCTTG TGTTCAGGCC TGTGGATCCC TGAGAGGCTA GCCCACAAGA TCCACTTCAA 60
AAGCCCTAGA TAACACCAAG TCTTTCCAGA CCCAGTGCAC ATCCCATCAG CCAGGACACC 120
AGTGTATGTT GGGATGCAAA CAGGGAGGCT TATGACATCT AATGTGTTTT CCAGAGTGAA 180
GTGCCTGGCT CCATTCCAAA CTCCTGGAAG TGGACTGTGG AACACATTGT CTATAAAGCC 240
TTGCGCTCAC ACATTCTGCC TCCTAAACAT TTCACAGAAG ATGGAAATAT CCTGCAGCTT 300
GCTAACCTGC CTGATCTATA CAAAGTCTTT GAGAGGTGTT AAATATGGTT ATTTATGCAC 360
TGTGGGATGT GTTCTTCTTT CTCTGTATTC CGATACAAAG TGTTGTATCA AAGTGTGATA 420
TACAAAGTGT ACCAACATAA GTGTTGGTAG CACTTAAGAC TTATACTTGC CTTCTGATAG 480
TATTCCTTTA TACACAGTGG ATTGATTATA AATAAATAGA TGTGTCTTAA CATAATTTCT 540
TATTTAATTT TATTATGTAT ATA 563

(2) INFORMATION FOR SEQ ID NO:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 137 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:
CTTGGCTCTT CTGGCGCCAA AATGTCGTTC GTGGCAGGGG TTATTCGGCG GCTGGACGAG 60
ACAGTGGTGA ACCGCATCGC GGCGGGGGAA GTTATCCAGC GGCCAGCTAA TGCTATCAAA 120
GAGATGATTG AGAACTG 137

(2) INFORMATION FOR SEQ ID NO:26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 91 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:
TTTAGATGCA AAATCCACAA GTATTCAAGT GATTGTTAAA GAGGGAGGCC TGAAGTTGAT 60
TCAGATCCAA GACAATGGCA CCGGGATCAG G 91

(2) INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 99 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:
AAAGAAGATC TGGATATTGT ATGTGAAAGG TTCACTACTA GTAAACTGCA GTCCTTTGAG 60
GATTTAGCCA GTATTTCTAC CTATGGCTTT CGAGGTGAG 99

(2) INFORMATION FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 74 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:
GCTTTGGCCA GCATAAGCCA TGTGGCTCAT GTTACTATTA CAACGAAAAC AGCTGATGGA 60
AAGTGTGCAT ACAG 74

(2) INFORMATION FOR SEQ ID NO:29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 73 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
AGCAAGTTAC TCAGATGGAA AACTGAAAGC CCCTCCTAAA CCATGTGCTG GCAATCAAGG 60
GACCCAGATC ACG 73

(2) INFORMATION FOR SEQ ID NO:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 92 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:
GTGGAGGACC TTTTTTACAA CATAGCCACG AGGAGAAAAG CTTTAAAAAA TCCAAGTGAA 60
GAATATGGGA AAATTTTGGA AGTTGTTGGC AG 92

(2) INFORMATION FOR SEQ ID NO:31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:
GTATTCAGTA CACAATGCAG GCATTAGTTT CTCAGTTAAA AAA 43

(2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 89 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
CAAGGAGAGA CAGTAGCTGA TGTTAGGACA CTACCCAATG CCTCAACCGT GGACAATATT 60
CGCTCCATCT TTGGAAATGC TGTTAGTCG 89

(2) INFORMATION FOR SEQ ID NO:33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
AGAACTGATA GAAATTGGAT GTGAGGATAA AACCCTAGCC TTCAAAATGA ATGGTTACAT 60
ATCCAATGCA AACTACTCAG TGAAGAAGTG CATCTTCTTA CTCTTCATCA ACC 113

(2) INFORMATION FOR SEQ ID NO:34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 94 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:
ATCGTCTGGT AGAATCAACT TCCTTGAGAA AAGCCATAGA AACAGTGTAT GCAGCCTATT 60
TGCCCAAAAA CACACACCCA TTCCTGTACC TCAG 94

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 154 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

TTTAGAAATC AGTCCCCAGA ATGTGGATGT TAATGTGCAC CCCACAAAGC ATGAAGTTCA 60
CTTCCTGCAC GAGGAGAGCA TCCTGGAGCG GGTGCAGCAG CACATCGAGA GCAAGCTCCT 120
GGGCTCCAAT TCCTCCAGGA TGTACTTCAC CCAG 154

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 371 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

ACTTTGCTAC CAGGACTTGC TGGCCCCTCT GGGGAGATGG TTAAATCCAC AACAAGTCTG 60
ACCTCGTCTT CTACTTCTGG AAGTAGTGAT AAGGTCTATG CCCACCAGAT GGTTCGTACA 120
GATTCCCGGG AACAGAAGCT TGATGCATTT CTGCAGCCTC TGAGCAAACC CCTGTCCAGT 180
CAGCCCCAGG CCATTGTCAC AGAGGATAAG ACAGATATTT CTAGTGGCAG GGCTAGGCAG 240
CAAGATGAGG AGATGCTTGA ACTCCCAGCC CCTGCTGAAG TGGCTGCCAA AAATCAGAGC 300
TTGGAGGGGG ATACAACAAA GGGGACTTCA GAAATGTCAG AGAAGAGAGG ACCTACTTCC 360
AGCAACCCCA G 371

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 149 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

AAAGAGACAT CGGGAAGATT CTGATGTGGA AATGGTGGAA GATGATTCCC GAAAGGAAAT 60
GACTGCAGCT TGTACCCCCC GGAGAAGGAT CATTAACCTC ACTAGTGTTT TGAGTCTCCA 120
GGAAGAAATT AATGAGCAGG GACATGAGG 149

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 109 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

TTCTCCGGGA GATGTTGCAT AACCACTCCT TCGTGGGCTG TGTGAATCCT CAGTGGGCCT 60

TGGCACAGCA TCAAACCAAG TTATACCTTC TCAACACCAC CAAGCTTAG 109

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 64 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

TGAAGAACTG TTCTACCAGA TACTCATTTA TGATTTTGCC AATTTTGGTG TTCTCAGGTT 60

ATCG 64

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 165 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

GAGCCAGCAC CGCTCTTTGA CCTTGCCATG CTTGCCTTAG ATAGTCCAGA GAGTGGCTGG 60

ACAGAGGAAG ATGGTCCCAA AGAAGGACTT GCTGAATACA TTGTTGAGTT TCTGAAGAAG 120

AAGGCTGAGA TGCTTGCAGA CTATTTCTCT TTGGAAATTG ATGAG 165

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 93 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

GAAGGGAACC TGATTGGATT ACCCCTTCTG ATTGACAACT ATGTGCCCCC TTTGGAGGGA 60

CTGCCTATCT TCATTCTTCG ACTAGCCACT GAG 93

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 114 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

GTGAATTGGG ACGAAGAAAA GGAATGTTTT GAAAGCCTCA GTAAAGAATG CGCTATGTTC 60

TATTCCATCC GGAAGCAGTA CATATCTGAG GAGTCGACCC TCTCAGGCCA GCAG 114

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 360 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

AGTGAAGTGC CTGGCTCCAT TCCAAACTCC TGGAAGTGGA CTGTGGAACA CATTGTCTAT 60

AAAGCCTTGC GCTCACACAT TCTGCCTCCT AAACATTTCA CAGAAGATGG AAATATCCTG 120

CAGCTTGCTA ACCTGCCTGA TCTATACAAA GTCTTTGAGA GGTGTTAAAT ATGGTTATTT 180

ATGCACTGTG GGATGTGTTC TTCTTTCTCT GTATTCCGAT ACAAAGTGTT GTATCAAAGT 240

GTGATATACA AAGTGTACCA ACATAAGTGT TGGTAGCACT TAAGACTTAT ACTTGCCTTC 300

TGATAGTATT CCTTTATACA CAGTGGATTG ATTATAAATA AATAGATGTG TCTTAACATA 360

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION: 1

(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

AGGCACTGAG GTGATTGGC 19

(2) INFORMATION FOR SEQ ID NO:45:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:
TCGTAGCCCT TAAGTGAGC 19

(2) INFORMATION FOR SEQ ID NO:46:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:
AATATGTACA TTAGAGTAGT TG 22

(2) INFORMATION FOR SEQ ID NO:47:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:
CAGAGAAAGG TCCTGACTC 19

(2) INFORMATION FOR SEQ ID NO:48:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:
AGAGATTTGG AAAATGAGTA AC 22

(2) INFORMATION FOR SEQ ID NO:49:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:
ACAATGTCAT CACAGGAGG 19

(2) INFORMATION FOR SEQ ID NO:50:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:
AACCTTTCCC TTTGGTGAGG 20

(2) INFORMATION FOR SEQ ID NO:51:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:
GATTACTCTG AGACCTAGGC 20

(2) INFORMATION FOR SEQ ID NO:52:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:
GATTTTCTCT TTTCCCCTTG GG 22

(2) INFORMATION FOR SEQ ID NO:53:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:
CAAACAAAGC TTCAACAATT TAC 23

(2) INFORMATION FOR SEQ ID NO:54:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:
GGGTTTTATT TTCAAGTACT TCTATG 26

(2) INFORMATION FOR SEQ ID NO:55:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:
GCTCAGCAAC TGTTCAATGT ATGAGC 26

(2) INFORMATION FOR SEQ ID NO:56:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:
CTAGTGTGTG TTTTTGGC 18

(2) INFORMATION FOR SEQ ID NO:57:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:
CATAACCTTA TCTCCACC 18

(2) INFORMATION FOR SEQ ID NO:58:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:
CTCAGCCATG AGACAATAAA TCC 23

(2) INFORMATION FOR SEQ ID NO:59:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:
GGTTCCCAAA TAATGTGATG G 21

(2) INFORMATION FOR SEQ ID NO:60:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:
CAAAAGCTTC AGAATCTC 18

(2) INFORMATION FOR SEQ ID NO:61:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:
CTGTGGGTGT TTCCTGTGAG TGG 23

(2) INFORMATION FOR SEQ ID NO:62:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:
CATGACTTTG TGTGAATGTA CACC 24

(2) INFORMATION FOR SEQ ID NO:63:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:
GAGGAGAGCC TGATAGAACA TCTG 24

(2) INFORMATION FOR SEQ ID NO:64:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:
GGGCTTTTTC TCCCCCTCCC 20

(2) INFORMATION FOR SEQ ID NO:65:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:
AAAATCTGGG CTCTCACG 18

(2) INFORMATION FOR SEQ ID NO:66:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:
AATTATACCT CATACTAGC 19

(2) INFORMATION FOR SEQ ID NO:67:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:
GTTTTATTAC AGAATAAAGG AGG 23

(2) INFORMATION FOR SEQ ID NO:68:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:
AAGCCAAAGT TAGAAGGCA 19

(2) INFORMATION FOR SEQ ID NO:69:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:
TGCAACCCAC AAAATTTGGC 20

(2) INFORMATION FOR SEQ ID NO:70:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:
CTTTCTCCAT TTCCAAAACC 20

(2) INFORMATION FOR SEQ ID NO:71:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:
TGGTGTCTCT AGTTCTGG 18

(2) INFORMATION FOR SEQ ID NO:72:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:
CATTGTTGTA GTAGCTCTGC 20

(2) INFORMATION FOR SEQ ID NO:73:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:
CCCATTTGTC CCAACTGG 18

(2) INFORMATION FOR SEQ ID NO:74:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:
CGGTCAGTTG AAATGTCAG 19

(2) INFORMATION FOR SEQ ID NO:75:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:
CATTTGGATG CTCCGTTAAA GC 22

(2) INFORMATION FOR SEQ ID NO:76:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:
CACCCGGCTG GAAATTTTAT TTG 23

(2) INFORMATION FOR SEQ ID NO:77:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:
GGAAAGGCAC TGGAGAAATG GG 22

(2) INFORMATION FOR SEQ ID NO:78:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:
CCCTCCAGCA CACATGCATG TACCG 25

(2) INFORMATION FOR SEQ ID NO:79:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:
TAAGTAGTCT GTGATCTCCG 20

(2) INFORMATION FOR SEQ ID NO:80:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:
ATGTATGAGG TCCTGTCC 18

(2) INFORMATION FOR SEQ ID NO:81:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:
GACACCAGTG TATGTTGG 18

(2) INFORMATION FOR SEQ ID NO:82:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:
GAGAA AAG AACACATCCC 20

(2) INFORMATION FOR SEQ ID NO:83:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:
TGTAAAACGA CGGCCAGTCA CTGAGGTGAT TGGCTGAA 38

(2) INFORMATION FOR SEQ ID NO:84:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:
TAGCCCTTAA GTGAGCCCG 19

(2) INFORMATION FOR SEQ ID NO:85:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:
TGTAAAACGA CGGCCAGTTA CATTAGAGTA GTTGCAGA 38

(2) INFORMATION FOR SEQ ID NO:86:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:
AGGTCCTGAC TCTTCCATG 19

(2) INFORMATION FOR SEQ ID NO:87:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:
TGTAAAACGA CGGCCAGTTT GGAAAATGAG TAACATGATT 40

(2) INFORMATION FOR SEQ ID NO:88:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:
TGTCATCACA GGAGGATAT 19

(2) INFORMATION FOR SEQ ID NO:89:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:
TGTAAAACGA CGGCCAGTCT TTCCCTTTGG TGAGGTGA 38

(2) INFORMATION FOR SEQ ID NO:90:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:
TACTCTGAGA CCTAGGCCCA 20

(2) INFORMATION FOR SEQ ID NO:91:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:
TGTAAAACGA CGGCCAGTTC TCTTTTCCCC TTGGGATTAG 40

(2) INFORMATION FOR SEQ ID NO:92:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:
ACAAAGCTTC AACAATTTAC TCT 23

(2) INFORMATION FOR SEQ ID NO:93:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:
TGTAAAACGA CGGCCAGTGT TTTATTTTCA AGTACTTCTA TGAATT 46

(2) INFORMATION FOR SEQ ID NO:94:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:
CAGCAACTGT TCAATGTATG AGCACT 26

(2) INFORMATION FOR SEQ ID NO:95:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:
TGTAAAACGA CGGCCAGTGT GTGTGTTTTT GGCAAC 36

(2) INFORMATION FOR SEQ ID NO:96:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:
AACCTTATCT CCACCAGC 18

(2) INFORMATION FOR SEQ ID NO:97:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:
TGTAAAACGA CGGCCAGTAG CCATGAGACA ATAAATCCTT G 41

(2) INFORMATION FOR SEQ ID NO:98:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:
TCCCAAATAA TGTGATGGAA TG 22

(2) INFORMATION FOR SEQ ID NO:99:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:
TGTAAAACGA CGGCCAGTAA GCTTCAGAAT CTCTTTT 37

(2) INFORMATION FOR SEQ ID NO:100:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:
TGGGTGTTTC CTGTGAGTGG ATT 23

(2) INFORMATION FOR SEQ ID NO:101:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:
TGTAAAACGA CGGCCAGTAC TTTGTGTGAA TGTACACCTG TG 42

(2) INFORMATION FOR SEQ ID NO:102:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:
GAGAGCCTGA TAGAACATCT GTTG 24

(2) INFORMATION FOR SEQ ID NO:103:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:
TGTAAAACGA CGGCCAGTCT TTTTCTCCCC CTCCCACTA 39

(2) INFORMATION FOR SEQ ID NO:104:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:
TCTGGGCTCT CACGTCT 17

(2) INFORMATION FOR SEQ ID NO:105:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:
CTTATTCTGA GTCTCTCC 18

(2) INFORMATION FOR SEQ ID NO:106:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:
TGTAAAACGA CGGCCAGTGT TTGCTCAGAG GCTGC 35

(2) INFORMATION FOR SEQ ID NO:107:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:
GATGGTTCGT ACAGATTCCC G 21

(2) INFORMATION FOR SEQ ID NO:108:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:
TGTAAAACGA CGGCCAGTTT ATTACAGAAT AAAGGAGGTA G 41

(2) INFORMATION FOR SEQ ID NO:109:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:
TGTAAAACGA CGGCCAGTAA CCCACAAAAT TTGGCTAAG 39

(2) INFORMATION FOR SEQ ID NO:110:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:
TCTCCATTTC CAAAACCTTG 20

(2) INFORMATION FOR SEQ ID NO:111:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:
TGTCTCTAGT TCTGGTGC 18

(2) INFORMATION FOR SEQ ID NO:112:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:
TGTAAAACGA CGGCCAGTTG TTGTAGTAGC TCTGCTTG 38

(2) INFORMATION FOR SEQ ID NO:113:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:
ATTTGTCCCA ACTGGTTGTA 20

(2) INFORMATION FOR SEQ ID NO:114:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:
TGTAAAACGA CGGCCAGTTC AGTTGAAATG TCAGAAGTG 39

(2) INFORMATION FOR SEQ ID NO:115:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:
TGTAAAACGA CGGCCAGT 18

(2) INFORMATION FOR SEQ ID NO:116:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:
CCGGCTGGAA ATTTTATTTG GAG 23

(2) INFORMATION FOR SEQ ID NO:117:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:
TGTAAAACGA CGGCCAGTAG GCACTGGAGA AATGGGATTT G 41

(2) INFORMATION FOR SEQ ID NO:118:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:
TCCAGC CAC ATGCATGTAC CGAAAT 26

(2) INFORMATION FOR SEQ ID NO:119:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primer directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:
GTAGTCTGTG ATCTCCGTTT 20

(2) INFORMATION FOR SEQ ID NO:120:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:
TGTAAAACGA CGGCCAGTTA TGAGGTCCTG TCCTAG 36

(2) INFORMATION FOR SEQ ID NO:121:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:
ACCAGTGTAT GTTGGGATG 19

(2) INFORMATION FOR SEQ ID NO:122:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= "primers directed to genomic intron DNA"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:
TGTAAAACGA CGGCCAGTGA AAGAAGAACA CATCCCACA 39

(2) INFORMATION FOR SEQ ID NO:123:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 770 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

```
Met Ser Leu Arg Ile Lys Ala Leu Asp Ala Ser Val Val Asn Lys Ile
1               5                  10                  15
Ala Ala Gly Glu Ile Ile Ile Ser Pro Val Asn Ala Leu Lys Glu Met
            20                  25                  30
Met Glu Asn Ser Ile Asp Ala Asn Ala Thr Met Ile Asp Ile Leu Val
        35                  40                  45
Lys Glu Gly Gly Ile Lys Val Leu Gln Ile Thr Asp Asn Gly Ser Gly
    50                  55                  60
Ile Asn Lys Ala Asp Leu Pro Ile Leu Cys Glu Arg Phe Thr Thr Ser
65                  70                  75                  80
Lys Leu Gln Lys Phe Glu Asp Leu Ser Gln Ile Gln Thr Tyr Gly Phe
                85                  90                  95
Arg Gly Glu Ala Leu Ala Ser Ile Ser His Val Ala Arg Val Thr Val
            100                 105                 110
Thr Thr Lys Val Lys Glu Asp Arg Cys Ala Trp Arg Val Ser Tyr Ala
        115                 120                 125
Glu Gly Lys Met Leu Glu Ser Pro Lys Pro Val Ala Gly Lys Asp Gly
    130                 135                 140
Thr Thr Ile Leu Val Glu Asp Leu Phe Phe Asn Ile Pro Ser Arg Leu
145                 150                 155                 160
Arg Ala Leu Arg Ser His Asn Asp Glu Tyr Ser Lys Ile Leu Asp Val
                165                 170                 175
Val Gly Arg Tyr Ala Ile His Ser Lys Asp Ile Gly Phe Ser Cys Lys
            180                 185                 190
Lys Phe Gly Asp Ser Asn Tyr Ser Leu Ser Val Lys Pro Ser Tyr Thr
        195                 200                 205
Val Gln Asp Arg Ile Arg Thr Val Phe Asn Lys Ser Val Ala Ser Asn
    210                 215                 220
Leu Ile Thr Phe His Ile Ser Lys Val Glu Asp Leu Asn Leu Glu Ser
225                 230                 235                 240
Val Asp Gly Lys Val Cys Asn Leu Asn Phe Ile Ser Lys Lys Ser Ile
                245                 250                 255
Ser Leu Ile Phe Phe Ile Asn Asn Arg Leu Val Thr Cys Asp Leu Leu
            260                 265                 270
Arg Arg Ala Leu Asn Ser Val Tyr Ser Asn Tyr Leu Pro Lys Gly Phe
        275                 280                 285
```

```
Arg Pro Phe Ile Tyr Leu Gly Ile Val Ile Asp Pro Ala Ala Val Asp
    290                 295                 300
Val Asn Val His Pro Thr Lys Arg Glu Val Arg Phe Leu Ser Gln Asp
305                 310                 315                 320
Glu Ile Ile Glu Lys Ile Ala Asn Gln Leu His Ala Glu Leu Ser Ala
                325                 330                 335
Ile Asp Thr Ser Arg Thr Phe Lys Ala Ser Ser Ile Ser Thr Asn Lys
            340                 345                 350
Pro Glu Ser Leu Ile Pro Phe Asn Asp Thr Ile Glu Ser Asp Arg Asn
        355                 360                 365
Arg Lys Ser Leu Arg Gln Ala Gln Val Val Glu Asn Ser Tyr Thr Thr
    370                 375                 380
Ala Asn Ser Gln Leu Arg Lys Ala Lys Arg Gln Glu Asn Lys Leu Val
385                 390                 395                 400
Arg Ile Asp Ala Ser Gln Ala Lys Ile Thr Ser Phe Leu Ser Ser Ser
                405                 410                 415
Gln Gln Phe Asn Phe Glu Gly Ser Ser Thr Lys Arg Gln Leu Ser Glu
            420                 425                 430
Pro Lys Val Thr Asn Val Ser His Ser Gln Glu Ala Glu Lys Leu Thr
        435                 440                 445
Leu Asn Glu Ser Glu Gln Pro Arg Asp Ala Asn Thr Ile Asn Asp Asn
    450                 455                 460
Asp Leu Lys Asp Gln Pro Lys Lys Lys Gln Lys Gln Leu Gly Asp Tyr
465                 470                 475                 480
Lys Val Pro Ser Ile Ala Asp Asp Glu Lys Asn Ala Leu Pro Ile Ser
                485                 490                 495
Lys Asp Gly Tyr Ile Arg Val Pro Lys Glu Arg Val Asn Val Asn Leu
            500                 505                 510
Thr Ser Ile Lys Lys Leu Arg Glu Lys Val Asp Asp Ser Ile His Arg
        515                 520                 525
Glu Leu Thr Asp Ile Phe Ala Asn Leu Asn Tyr Val Gly Val Val Asp
    530                 535                 540
Glu Glu Arg Arg Leu Ala Ala Ile Gln His Asp Leu Lys Leu Phe Leu
545                 550                 555                 560
Ile Asp Tyr Gly Ser Val Cys Tyr Glu Leu Phe Tyr Gln Ile Gly Leu
                565                 570                 575
Thr Asp Phe Ala Asn Phe Gly Lys Ile Asn Leu Gln Ser Thr Asn Val
            580                 585                 590
Ser Asp Asp Ile Val Leu Tyr Asn Leu Leu Ser Glu Phe Asp Glu Leu
        595                 600                 605
Asn Asp Asp Ala Ser Lys Glu Lys Ile Ile Ser Lys Ile Trp Asp Met
    610                 615                 620
Ser Ser Met Leu Asn Glu Tyr Tyr Ser Ile Glu Leu Val Asn Asp Gly
625                 630                 635                 640
```

```
Leu Asp Asn Asp Leu Lys Ser Val Lys Leu Lys Ser Leu Pro Leu Leu
                645                 650                 655
Leu Lys Gly Tyr Ile Pro Ser Leu Val Lys Leu Pro Phe Phe Ile Tyr
            660                 665                 670
Arg Leu Gly Lys Glu Val Asp Trp Glu Asp Glu Gln Glu Cys Leu Asp
        675                 680                 685
Gly Ile Leu Arg Glu Ile Ala Leu Leu Tyr Ile Pro Asp Met Val Pro
    690                 695                 700
Lys Val Asp Thr Leu Asp Ala Ser Leu Ser Glu Asp Glu Lys Ala Gln
705                 710                 715                 720
Phe Ile Asn Arg Lys Glu His Ile Ser Ser Leu Leu Glu His Val Leu
                725                 730                 735
Phe Pro Cys Ile Lys Arg Arg Phe Leu Ala Pro Arg His Ile Leu Lys
            740                 745                 750
Asp Val Val Glu Ile Ala Asn Leu Pro Asp Leu Tyr Lys Val Phe Glu
        755                 760                 765
Arg Cys
    770
```

(2) INFORMATION FOR SEQ ID NO:124:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 64 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

```
Val Asn Arg Ile Ala Ala Gly Glu Val Ile Gln Arg Pro Ala Asn Ala
1               5                   10                  15
Ile Lys Glu Met Ile Glu Asn Cys Leu Asp Ala Lys Phe Thr Ser Ile
            20                  25                  30
Gln Val Ile Val Lys Glu Gly Gly Leu Lys Leu Ile Gln Ile Gln Asp
        35                  40                  45
Asn Gly Thr Gly Ile Arg Lys Glu Asp Leu Asp Ile Val Cys Glu Arg
    50                  55                  60
```

(2) INFORMATION FOR SEQ ID NO:125:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 64 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

Val Asn Arg Ile Ala Ala Gly Glu Val Ile Gln Arg Pro Ala Asn Ala
1 5 10 15
Ile Lys Glu Met Ile Glu Asn Cys Leu Asp Ala Lys Ser Thr Ser Ile
20 25 30
Gln Val Ile Val Lys Glu Gly Gly Leu Lys Leu Ile Gln Ile Gln Asp
35 40 45
Asn Gly Thr Gly Ile Arg Lys Glu Asp Leu Asp Ile Val Cys Glu Arg
50 55 60

(2) INFORMATION FOR SEQ ID NO:126:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 52 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

Pro Ala Asn Ala Ile Lys Glu Met Ile Glu Asn Cys Leu Asp Ala Lys
1 5 10 15
Ser Thr Asn Ile Gln Val Val Val Lys Glu Gly Gly Leu Lys Leu Ile
20 25 30
Gln Ile Gln Asp Asn Gly Thr Gly Ile Arg Lys Glu Asp Leu Asp Ile
35 40 45
Val Cys Glu Arg
50

(2) INFORMATION FOR SEQ ID NO:127:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 64 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:

Val Asn Lys Ile Ala Ala Gly Glu Ile Ile Ile Ser Pro Val Asn Ala
1 5 10 15
Leu Lys Glu Met Met Glu Asn Ser Ile Asp Ala Asn Ala Thr Met Ile
20 25 30
Asp Ile Leu Val Lys Glu Gly Gly Ile Lys Val Leu Gln Ile Thr Asp
35 40 45
Asn Gly Ser Gly Ile Asn Lys Ala Asp Leu Pro Ile Leu Cys Glu Arg
50 55 60

(2) INFORMATION FOR SEQ ID NO:128:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 64 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:

```
Val His Arg Ile Thr Ser Gly Gln Val Ile Thr Asp Leu Thr Thr Ala
1               5                  10                  15
Val Lys Glu Leu Val Asp Asn Ser Ile Asp Ala Asn Ala Asn Gln Ile
            20                  25                  30
Glu Ile Ile Phe Lys Asp Tyr Gly Leu Glu Ser Ile Glu Cys Ser Asp
        35                  40                  45
Asn Gly Asp Gly Ile Asp Pro Ser Asn Tyr Glu Phe Leu Ala Leu Lys
    50                  55                  60
```

(2) INFORMATION FOR SEQ ID NO:129:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 64 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

```
Ala Asn Gln Ile Ala Ala Gly Glu Val Val Glu Arg Pro Ala Ser Val
1               5                  10                  15
Val Lys Glu Leu Val Glu Asn Ser Leu Asp Ala Gly Ala Thr Arg Ile
            20                  25                  30
Asp Ile Asp Ile Glu Arg Gly Gly Ala Lys Leu Ile Arg Ile Arg Asp
        35                  40                  45
Asn Gly Cys Gly Ile Lys Lys Asp Glu Leu Ala Leu Ala Leu Ala Arg
    50                  55                  60
```

(2) INFORMATION FOR SEQ ID NO:130:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 64 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

```
Ala Asn Gln Ile Ala Ala Gly Glu Val Val Glu Arg Pro Ala Ser Val
1               5                  10                  15
```

```
Val Lys Glu Leu Val Glu Asn Ser Leu Asp Ala Gly Ala Thr Arg Val
            20                  25                  30
Asp Ile Asp Ile Glu Arg Gly Gly Ala Lys Leu Ile Arg Ile Arg Asp
        35                  40                  45
Asn Gly Cys Gly Ile Lys Lys Glu Glu Leu Ala Leu Ala Leu Ala Arg
    50                  55                  60
```

(2) INFORMATION FOR SEQ ID NO:131:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 64 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

```
Ala Asn Gln Ile Ala Ala Gly Glu Val Ile Glu Arg Pro Ala Ser Val
1               5                   10                  15
Cys Lys Glu Leu Val Glu Asn Ala Ile Asp Ala Gly Ser Ser Gln Ile
            20                  25                  30
Ile Ile Glu Ile Glu Glu Ala Gly Leu Lys Lys Val Gln Ile Thr Asp
        35                  40                  45
Asn Gly His Gly Ile Ala His Asp Glu Val Glu Leu Ala Leu Arg Arg
    50                  55                  60
```

(2) INFORMATION FOR SEQ ID NO:132:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2687 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(viii) POSITION IN GENOME:

(B) MAP POSITION: 7q

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

```
CCATGGAGCG AGCTGAGAGC TCGAGTACAG AACCTGCTAA GGCCATCAAA CCTATTGATC   60
GGAAGTCAGT CCATCAGATT TGCTCTGGGC AGGTGGTACT GAGTCTAAGC ACTGCGGTAA  120
AGGAGTTAGT AGAAAACAGT CTGGATGCTG GTGCCACTAA TATTGATCTA AAGCTTAAGG  180
ACTATGGAGT GGATCTTATT GAAGTTTCAG ACAATGGATG TGGGGTAGAA GAAGAAAACT  240
TCGAAGGCTT AACTCTGAAA CATCACACAT CTAAGATTCA AGAGTTTGCC GACCTAACTC  300
AGGTTGAAAC TTTTGGCTTT CGGGGGGAAG CTCTGAGCTC ACTTTGTGCA CTGAGCGATG  360
TCACCATTTC TACCTGCCAC GCATCGGCGA AGGTTGGAAC TCGACTGATG TTTGATCACA  420
ATGGGAAAAT TATCCAGAAA ACCCCCTACC CCCGCCCCAG AGGGACCACA GTCAGCGTGC  480
AGCAGTTATT TTCCACACTA CCTGTGCGCC ATAAGGAATT TCAAAGGAAT ATTAAGAAGG  540
AGTATGCCAA AATGGTCCAG GTCTTACATG CATACTGTAT CATTTCAGCA GGCATCCGTG  600
TAAGTTGCAC CAATCAGCTT GGACAAGGAA AACGACAGCC TGTGGTATGC ACAGGTGGAA  660
```

GCCCCAGCAT AAAGGAAAAT ATCGGCTCTG TGTTTGGGCA GAAGCAGTTG CAAAGCCTCA 720
TTCCTTTTGT TCAGCTGCCC CCTAGTGACT CCGTGTGTGA AGAGTACGGT TTGAGCTGTT 780
CGGATGCTCT GCATAATCTT TTTTACATCT CAGGTTTCAT TTCACAATGC ACGCATGGAG 840
TTGGAAGGAG TTCAACAGAC AGACAGTTTT TCTTTATCAA CCGGCGGCCT TGTGACCCAG 900
CAAAGGTCTG CAGACTCGTG AATGAGGTCT ACCACATGTA TAATCGACAC CAGTATCCAT 960
TTGTTGTTCT TAACATTTCT GTTGATTCAG AATGCGTTGA TATCAATGTT ACTCCAGATA 1020
AAAGGCAAAT TTTGCTACAA GAGGAAAAGC TTTTGTTGGC AGTTTTAAAG ACCTCTTTGA 1080
TAGGAATGTT TGATAGTGAT GTCAACAAGC TAAATGTCAG TCAGCAGCCA CTGCTGGATG 1140
TTGAAGGTAA CTTAATAAAA ATGCATGCAG CGGATTTGGA AAAGCCCATG GTAGAAAAGC 1200
AGGATCAATC CCCTTCATTA AGGACTGGAG AAGAAAAAAA AGACGTGTCC ATTTCCAGAC 1260
TGCGAGAGGC CTTTTCTCTT CGTCACACAA CAGAGAACAA GCCTCACAGC CCAAAGACTC 1320
CAGAACCAAG AAGGAGCCCT CTAGGACAGA AAAGGGGTAT GCTGTCTTCT AGCACTTCAG 1380
GTGCCATCTC TGACAAAGGC GTCCTGAGAT CTCAGAAAGA GGCAGTGAGT TCCAGTCACG 1440
GACCCAGTGA CCCTACGGAC AGAGCGGAGG TGGAGAAGGA CTCGGGGCAC GGCAGCACTT 1500
CCGTGGATTC TGAGGGGTTC AGCATCCCAG ACACGGGCAG TCACTGCAGC AGCGAGTATG 1560
CGGCCAGCTC CCCAGGGGAC AGGGGCTCGC AGGAACATGT GGACTCTCAG GAGAAAGCGC 1620
CTGAAACTGA CGACTCTTTT TCAGATGTGG ACTGCCATTC AAACCAGGAA GATACCGGAT 1680
GTAAATTTCG AGTTTTGCCT CAGCCAACTA ATCTCGCAAC CCCAAACACA AAGCGTTTTA 1740
AAAAAGAAGA AATTCTTTCC AGTTCTGACA TTTGTCAAAA GTTAGTAAAT ACTCAGGACA 1800
TGTCAGCCTC TCAGGTTGAT TGAGCTGTGA AAATTAATAA GAAAGTTGTG CCCCTGGACT 1860
TTTCTATGAG TTCTTTAGCT AAACGAATAA AGCAGTTACA TCATGAAGCA CAGCAAAGTG 1920
AAGGGGAACA GAATTACAGG AAGTTTAGGG CAAAGATTTG TCCTGGAGAA AATCAAGCAG 1980
CCGAAGATGA ACTAAGAAAA GAGATAAGTA AAACGATGTT TGCAGAAATG GAAATCATTG 2040
GTCAGTTTAA CCTGGGATTT ATAATAACCA AACTGAATGA GGATATCTTC ATAGTGGACC 2100
AGCATGCCAC GGACGAGAAG TATAACTTCG AGATGCTGCA GCAGCACACC GTGCTCCAGG 2160
GGCAGAGGCT CATAGCACCT CAGACTCTCA ACTTAACTGC TGTTAATGAA GCTGTTCTGA 2220
TAGAAAATCT GGAAATATTT AGAAAGAATG GCTTTGATTT TGTTATCGAT GAAAATGCTC 2280
CAGTCACTGA AAGGGCTAAA CTGATTTCCT TGCCAACTAG TAAAAACTGG ACCTTCGGAC 2340
CCCAGGACGT CGATGAACTG ATCTTCATGC TGAGCGACAG CCCTGGGGTC ATGTGCCGCC 2400
CTTCCCGAGT CAAGCAGATG TTTGCCTCCA GAGCCTGCCG GAAGTCGGTG ATGATTGGGA 2460
CTGCTCTCAA CACAAGCGAA TGAAGAAACT GATCACCCAC ATGGGGGAGA TGGGCCACCC 2520
CTGGAACTGT CCCCATGGAA GGCCACCATG AGACACATCG CCAACCTGGG TGTCATTTCT 2580
CAGAACTGAC CGTAGTCACT GTATGGAATA ATTGGTTTTA TCGCAGATTT TTATGTTTTG 2640
AAAGACAGAG TCTTCACTAA CCTTTTTTGT TTTAAAATGA AACCTGC 2687

(2) INFORMATION FOR SEQ ID NO:133:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 862 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:

Met Glu Arg Ala Glu Ser Ser Ser Thr Glu Pro Ala Lys Ala Ile Lys
1 5 10 15

```
Pro Ile Asp Arg Lys Ser Val His Gln Ile Cys Ser Gly Gln Val Val
            20                  25                  30
Leu Ser Leu Ser Thr Ala Val Lys Glu Leu Val Glu Asn Ser Leu Asp
        35                  40                  45
Ala Gly Ala Thr Asn Ile Asp Leu Lys Leu Lys Asp Tyr Gly Val Asp
    50                  55                  60
Leu Ile Glu Val Ser Asp Asn Gly Cys Gly Val Glu Glu Glu Asn Phe
65                  70                  75                  80
Glu Gly Leu Thr Leu Lys His His Thr Ser Lys Ile Gln Glu Phe Ala
                85                  90                  95
Asp Leu Thr Gln Val Glu Thr Phe Gly Phe Arg Gly Glu Ala Leu Ser
            100                 105                 110
Ser Leu Cys Ala Leu Ser Asp Val Thr Ile Ser Thr Cys His Ala Ser
        115                 120                 125
Ala Lys Val Gly Thr Arg Leu Met Phe Asp His Asn Gly Lys Ile Ile
    130                 135                 140
Gln Lys Thr Pro Tyr Pro Arg Pro Arg Gly Thr Thr Val Ser Val Gln
145                 150                 155                 160
Gln Leu Phe Ser Thr Leu Pro Val Arg His Lys Glu Phe Gln Arg Asn
                165                 170                 175
Ile Lys Lys Glu Tyr Ala Lys Met Val Gln Val Leu His Ala Tyr Cys
            180                 185                 190
Ile Ile Ser Ala Gly Ile Arg Val Ser Cys Thr Asn Gln Leu Gly Gln
        195                 200                 205
Gly Lys Arg Gln Pro Val Val Cys Ile Gly Gly Ser Pro Ser Ile Lys
    210                 215                 220
Glu Asn Ile Gly Ser Val Phe Gly Gln Lys Gln Leu Gln Ser Leu Ile
225                 230                 235                 240
Pro Phe Val Gln Leu Pro Pro Ser Asp Ser Val Cys Glu Glu Tyr Gly
                245                 250                 255
Leu Ser Cys Ser Asp Ala Leu His Asn Leu Phe Tyr Ile Ser Gly Phe
            260                 265                 270
Ile Ser Gln Cys Thr His Gly Val Gly Arg Ser Ser Thr Asp Arg Gln
        275                 280                 285
Phe Phe Phe Ile Asn Arg Arg Pro Cys Asp Pro Ala Lys Val Cys Arg
    290                 295                 300
Leu Val Asn Glu Val Tyr His Met Tyr Asn Arg His Gln Tyr Pro Phe
305                 310                 315                 320
Val Val Leu Asn Ile Ser Val Asp Ser Glu Cys Val Asp Ile Asn Val
                325                 330                 335
Thr Pro Asp Lys Arg Gln Ile Leu Leu Gln Glu Glu Lys Leu Leu Leu
            340                 345                 350
Ala Val Leu Lys Thr Ser Leu Ile Gly Met Phe Asp Ser Asp Val Asn
        355                 360                 365
```

```
Lys Leu Asn Val Ser Gln Gln Pro Leu Leu Asp Val Glu Gly Asn Leu
    370                 375                 380
Ile Lys Met His Ala Ala Asp Leu Glu Lys Pro Met Val Glu His Gln
385                 390                 395                 400
Asp Gln Ser Pro Ser Leu Arg Ile Gly Glu Glu Lys Lys Asp Val Ser
                405                 410                 415
Ile Ser Arg Leu Arg Glu Ala Phe Ser Leu Arg His Thr Thr Glu Asn
            420                 425                 430
Lys Pro His Ser Pro Lys Thr Pro Glu Pro Arg Arg Ser Pro Leu Gly
        435                 440                 445
Gln Lys Arg Gly Met Leu Ser Ser Ser Thr Ser Gly Ala Ile Ser Asp
    450                 455                 460
Lys Gly Val Leu Arg Ser Gln Lys Glu Ala Val Ser Ser Ser His Gly
465                 470                 475                 480
Pro Ser Asp Pro Thr Asp Arg Ala Glu Val Glu Lys Asp Ser Gly His
                485                 490                 495
Gly Ser Thr Ser Val Asp Ser Glu Gly Phe Ser Ile Pro Asp Thr Gly
            500                 505                 510
Ser His Cys Ser Ser Glu Tyr Ala Ala Ser Ser Pro Gly Asp Arg Gly
        515                 520                 525
Ser Gln Glu His Val Asp Ser Gln Glu Lys Ala Pro Glu Thr Asp Asp
    530                 535                 540
Ser Phe Ser Asp Val Asp Cys His Ser Asn Gln Glu Asp Thr Gly Cys
545                 550                 555                 560
Lys Phe Arg Val Leu Pro Gln Pro Ile Asn Leu Ala Thr Pro Asn Thr
                565                 570                 575
Lys Arg Phe Lys Lys Glu Glu Ile Leu Ser Ser Ser Asp Ile Cys Gln
            580                 585                 590
Lys Leu Val Asn Thr Gln Asp Met Ser Ala Ser Gln Val Asp Val Ala
        595                 600                 605
Val Lys Ile Asn Lys Lys Val Val Pro Leu Asp Phe Ser Met Ser Ser
    610                 615                 620
Leu Ala Lys Arg Ile Lys Gln Leu His His Glu Ala Gln Gln Ser Glu
625                 630                 635                 640
Gly Glu Gln Asn Tyr Arg Lys Phe Arg Ala Lys Ile Cys Pro Gly Glu
                645                 650                 655
Asn Gln Ala Ala Glu Asp Glu Leu Arg Lys Glu Ile Ser Lys Thr Met
            660                 665                 670
Phe Ala Glu Met Glu Ile Ile Gly Gln Phe Asn Leu Gly Phe Ile Ile
        675                 680                 685
Thr Lys Leu Asn Glu Asp Ile Phe Ile Val Asp Gln His Ala Thr Asp
    690                 695                 700
Glu Lys Tyr Asn Phe Glu Met Leu Gln Gln His Thr Val Leu Gln Gly
705                 710                 715                 720
```

```
Gln Arg Leu Ile Ala Pro Gln Thr Leu Asn Leu Thr Ala Val Asn Glu
                725                 730                 735
Ala Val Leu Ile Glu Asn Leu Glu Ile Phe Arg Lys Asn Gly Phe Asp
            740                 745                 750
Phe Val Ile Asp Glu Asn Ala Pro Val Thr Glu Arg Ala Lys Leu Ile
        755                 760                 765
Ser Leu Pro Thr Ser Lys Asn Trp Thr Phe Gly Pro Gln Asp Val Asp
    770                 775                 780
Glu Leu Ile Phe Met Leu Ser Asp Ser Pro Gly Val Met Cys Arg Pro
785                 790                 795                 800
Ser Arg Val Lys Gln Met Phe Ala Ser Arg Ala Cys Arg Lys Ser Val
                805                 810                 815
Met Ile Gly Thr Ala Leu Asn Thr Ser Glu Met Lys Lys Leu Ile Thr
            820                 825                 830
His Met Gly Glu Met Gly His Pro Trp Asn Cys Pro His Gly Arg Pro
        835                 840                 845
Thr Met Arg His Ile Ala Asn Leu Gly Val Ile Ser Gln Asn
    850                 855                 860
```

(2) INFORMATION FOR SEQ ID NO:134:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:

```
Met Phe His His Ile Glu Asn Leu Leu Ile Glu Thr Glu Lys Arg Cys
1               5                   10                  15
Lys Gln Lys Glu Gln Arg Tyr Ile Pro Val Lys Tyr Leu Phe Ser Met
            20                  25                  30
Thr Gln Ile His Gln Ile Asn Asp Ile Asp Val His Arg Ile Thr Ser
        35                  40                  45
Gly Gln Val Ile Thr Asp Leu Thr Thr Ala Val Lys Glu Leu Val Asp
    50                  55                  60
Asn Ser Ile Asp Ala Asn Ala Asn Gln Ile Glu Ile Ile Phe Lys Asp
65                  70                  75                  80
Tyr Gly Leu Glu Ser Ile Glu Cys Ser Asp Asn Gly Asp Gly Ile Asp
                85                  90                  95
Pro Ser Asn Tyr Glu Phe Leu Ala Leu Lys His Tyr Thr Ser Lys Ile
            100                 105                 110
Ala Lys Phe Gln Asp Val Ala Lys Val Gln Thr Leu Gly Phe Arg Gly
        115                 120                 125
Glu Ala Leu Ser Ser Leu Cys Gly Ile Ala Lys Leu Ser Val Ile Thr
    130                 135                 140
```

```
Thr Thr Ser Pro Pro Lys Ala Asp Lys Leu Glu Tyr Asp Met Val Gly
145                 150                 155                 160
His Ile Thr Ser Lys Thr Thr Ser Arg Asn Lys Gly Thr Thr Val Leu
                165                 170                 175
Val Ser Gln Leu Phe His Asn Leu Pro Val Arg Gln Lys Glu Phe Ser
            180                 185                 190
Lys Thr Phe Lys Arg Gln Phe Thr Lys Cys Leu Thr Val Ile Gln Gly
        195                 200                 205
Tyr Ala Ile Ile Asn Ala Ala Ile Lys Phe Ser Val Trp Asn Ile Thr
    210                 215                 220
Pro Lys Gly Lys Lys Asn Leu Ile Leu Ser Thr Met Arg Asn Ser Ser
225                 230                 235                 240
Met Arg Lys Asn Ile Ser Ser Val Phe Gly Ala Gly Gly Met Phe Gly
                245                 250                 255
Leu Glu Glu Val Asp Leu Val Leu Asp Leu Asn Pro Phe Lys Asn Arg
            260                 265                 270
Met Leu Gly Lys Tyr Thr Asp Asp Pro Asp Phe Leu Asp Leu Asp Tyr
        275                 280                 285
Lys Ile Arg Val Lys Gly Tyr Ile Ser Gln Asn Ser Phe Gly Cys Gly
    290                 295                 300
Arg Asn Ser Lys Asp Arg Gln Phe Ile Tyr Val Asn Lys Arg Pro Val
305                 310                 315                 320
Glu Tyr Ser Thr Leu Leu Lys Cys Cys Asn Glu Val Tyr Lys Thr Phe
                325                 330                 335
Asn Asn Val Gln Phe Pro Ala Val Phe Leu Asn Leu Glu Leu Pro Met
            340                 345                 350
Ser Leu Ile Asp Val Asn Val Thr Pro Asp Lys Arg Val Ile Leu Leu
        355                 360                 365
His Asn Glu Arg Ala Val Ile Asp Ile Phe Lys Thr Thr Leu Ser Asp
    370                 375                 380
Tyr Tyr Asn Arg Gln Glu Leu Ala Leu Pro Lys Arg Met Cys Ser Gln
385                 390                 395                 400
Ser Glu Gln Gln Ala Gln Lys Arg Leu Lys Thr Glu Val Phe Asp Asp
                405                 410                 415
Arg Ser Thr Thr His Glu Ser Asp Asn Glu Asn Tyr His Thr Ala Arg
            420                 425                 430
Ser Glu Ser Asn Gln Ser Asn His Ala His Phe Asn Ser Thr Thr Gly
        435                 440                 445
Val Ile Asp Lys Ser Asn Gly Thr Glu Leu Thr Ser Val Met Asp Gly
    450                 455                 460
Asn Tyr Thr Asn Val Thr Asp Val Ile Gly Ser Glu Cys Glu Val Ser
465                 470                 475                 480
Val Asp Ser Ser Val Val Leu Asp Glu Gly Asn Ser Ser Thr Pro Thr
                485                 490                 495
```

```
Lys Lys Leu Pro Ser Ile Lys Thr Asp Ser Gln Asn Leu Ser Asp Leu
            500                 505                 510
Asn Leu Asn Asn Phe Ser Asn Pro Glu Phe Gln Asn Ile Thr Ser Pro
        515                 520                 525
Asp Lys Ala Arg Ser Leu Glu Lys Val Val Glu Glu Pro Val Tyr Phe
    530                 535                 540
Asp Ile Asp Gly Glu Lys Phe Gln Glu Lys Ala Val Leu Ser Gln Ala
545                 550                 555                 560
Asp Gly Leu Val Phe Val Asp Asn Glu Cys His Glu His Thr Asn Asp
                565                 570                 575
Cys Cys His Gln Glu Arg Arg Gly Ser Thr Asp Ile Glu Gln Asp Asp
            580                 585                 590
Glu Ala Asp Ser Ile Tyr Ala Glu Ile Glu Pro Val Glu Ile Asn Val
        595                 600                 605
Arg Thr Pro Leu Lys Asn Ser Arg Lys Ser Ile Ser Lys Asp Asn Tyr
    610                 615                 620
Arg Ser Leu Ser Asp Gly Leu Thr His Arg Lys Phe Glu Asp Glu Ile
625                 630                 635                 640
Leu Glu Tyr Asn Leu Ser Thr Lys Asn Phe Lys Glu Ile Ser Lys Asn
                645                 650                 655
Gly Lys Gln Met Ser Ser Ile Ile Ser Lys Arg Lys Ser Glu Ala Gln
            660                 665                 670
Glu Asn Ile Ile Lys Asn Lys Asp Glu Leu Glu Asp Phe Glu Gln Gly
        675                 680                 685
Glu Lys Tyr Leu Thr Leu Thr Val Ser Lys Asn Asp Phe Lys Lys Met
    690                 695                 700
Glu Val Val Gly Gln Phe Asn Leu Gly Phe Ile Ile Val Thr Arg Lys
705                 710                 715                 720
Val Asp Asn Lys Ser Lys Leu Phe Ile Val Asp Gln His Ala Ser Asp
                725                 730                 735
Glu Lys Tyr Asn Phe Glu Thr Leu Gln Ala Val Thr Val Phe Lys Ser
            740                 745                 750
Gln Lys Leu Ile Ile Pro Gln Pro Val Glu Leu Ser Val Ile Asp Glu
        755                 760                 765
Leu Val Val Leu Asp Asn Leu Pro Val Phe Glu Lys Asn Gly Phe Lys
    770                 775                 780
Leu Lys Ile Asp Glu Glu Glu Glu Phe Gly Ser Arg Val Lys Leu Leu
785                 790                 795                 800
Ser Leu Pro Thr Ser Lys Gln Thr Leu Phe Asp Leu Gly Asp Phe Asn
                805                 810                 815
Glu Leu Ile His Leu Ile Lys Glu Asp Gly Gly Leu Arg Arg Asp Asn
            820                 825                 830
Ile Arg Cys Ser Lys Ile Arg Ser Met Phe Ala Met Arg Ala Cys Arg
        835                 840                 845
```

```
Ser Ser Ile Met Ile Gly Lys Pro Leu Asn Lys Lys Thr Met Thr Arg
    850                 855                 860
Val Val His Asn Leu Ser Glu Leu Asp Lys Pro Trp Asn Cys Pro His
865                 870                 875                 880
Gly Arg Pro Thr Met Arg His Leu Met Glu Ile Arg Asp Trp Ser Ser
                885                 890                 895
Phe Ser Lys Asp Tyr Glu Ile
            900
```

(2) INFORMATION FOR SEQ ID NO:135:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2577 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

```
TTCCGGCCAA TGCTATCAAA GAGATGATAG AAAACTGTTT AGATGCAAAA TCTACAAATA   60
TTCAAGTGGT TGTTAAGGAA GGTGGCCTGA AGCTAATTCA GATCCAAGAC AATGGCACTG  120
GAATCAGGAA GGAAGATCTG GATATTGTGT GTGAGAGGTT CACTACGAGT AAACTGCAGA  180
CTTTTGAGGA TTTAGCCAGT ATTTCTACCT ATGGCTTTCG TGGTGAGCAT TTGGCAAGCA  240
TAAGTCATGT GGCCCATGTC ACTATTACAA CCAAAACAGC TGATGGGAAA TGTGCGTACA  300
GAGCAAGTTA CTCAGATGGA AAGCTGCAAG CCCCTCCTAA ACCCTGTGCA GGCAACCAGG  360
GCACCCTGAT CACGGTGGAA GACCTTTTTT ACAACATAAT CACAAGGAGG AAAGCTTTAA  420
AAAATCCAAG TGAAGAGTAC GGAAAAATTT TGGAAGTTGT TGGCAGGTAT TCAATACACA  480
ATTCAGGCAT TAGTATCTCA GTTAAAAAAC AAGGTGAGAC AGTATCTGAT GTCAGAACAC  540
TGCCCAATGC CACAACCGTG GACAA[illegible]TTC GCTCCATCTT TGGAAATGCG GTTAGTCGAG  600
AACTGATAGA AGTTGGGTGT GAG[illegible]AAAA CCCTAGCTTT CAAAATGAAT GGCTATATAT  660
CGAATGCAAA GTATTCAGTG AA[illegible]GTGCA TTTTCCTACT CTTCATCAAC CACCGTCTGG  720
TAGAATCAGC TGCCTTGAGA AAAGCCATTG AAACTGTATA TGCAGCATAC TTGCCAAAAA  780
CACACACCCA TTCCTGTACC TCAGTTTGAA ATCAGCCCTC AGAACGTGAC GTCAATGTAC  840
ACCCCACCAA GACAGAAGTT CATTTTCTGC ACGAGGAGAG CATTCTGCAG CGTGTGCAGC  900
AGCACATTGA GAGCAAGCTG CTGGGCTCCA ATTCCTCCAG GATGTATTTC ACCCAGACCT  960
TGCTTCCAGG ACTTGCTGGG CCTCTGGGGA GGCAGCTAGA CCCACGACAG GGGTGGCTTC 1020
CTCATCCACT AGTGGAAGTG GCGACAAGGT CTACGCTTAC CAGATGTCGC GTACGGACTC 1080
CCGGGATCAG AAGCTTGACG CCTTTCTGCA GCCTGTAACC AGCCTTGTGC CCAGCCAGCC 1140
CCAGGACCCT CGCCCTGTCC GAGGGGCCAG GACAGAGGGC TCTCCTGAAA GGGCCACGCG 1200
GGAGGATGAG GAGATGCTTG CTCTCCCAGC CCCCGCTGAA GCAGCTGCTG AGAGTGAGAA 1260
CTTGGAGAGG GAATCACTAA TGGAGACTTC AGACGCAGCC CAGAAAGCGG CACCCACTTC 1320
CAGTCCAGGA AGCTCCAGAA AGAGTCATCG GGAGGACTCT GATGTGGAAA TGGTGGAAAA 1380
TGCTTCCGGG AAGGAAATGA CAGCTGCTTG CTACCCCAGG AGGAGGATCA TTAACCTCAC 1440
CAGCGTCTTG AGTCTCCAGG AAGAGATTAG TGAGCGGTGC CATGAGACTC TCCGGGAGAT 1500
ACTCCGTAAC CATTCCTTTG TGGGCTGTGT GAATCCTCAG TGGGCCTTGG CACAGCACCA 1560
GACCAAGCTA TACCTCCTCA ACACTACCAA GCTCAGTGAA GAGCTGTTCT ACCAGATACT 1620
CATTTATGAT TTTGCCAACT TTGGTGTTCT GAGGTTATCG GAACCAGCGC CACTCTTCGA 1680
CCTGGCCATG CTGGCTTAGA CAGTCCTGAA AGTGGCTGGA CAGAGGACGA CGGCCCGAAG 1740
```

AAGGGCTTGC AGAGTACATT GTCGAGTTTC TGAAGAGAAG CGAGATGCTT GCAGACTATT 1800
CTCTGTGAGA TCGATGAGAA GGGAACCTGA TTGATTACTC TTCTGATGAC AGCTATGTGC 1860
CACCTTTGGA GGGACTGCCT ATCTTCATTC TTCGACTGGC CACTGAGGTG AATTGGGTGA 1920
AGAAAAGGAG TGTTTTGAAA GTCTCAGTAA AGAATGTGCT ATGTTTTACT CCATTCGGAA 1980
GCAGTATATA CTGGAGGAGT CGACCCTCTC AGGCCAGCAG AGTGACATGC CTGGCTCCAC 2040
GTCAAAGCCC TGGAAGTGGA CTGTGGAGCA CATTATCTAT AAAGCCTTCC GCTCACACCT 2100
CCTACCTCCG AAGCATTTCA CAGAAGATGG CAATGTCCTG CAGCTTGCCA ACCTGCCAGA 2160
TCTATACAAA GTCTTTGAGC GGTGTTAAAT ACAATCATAG CCACCGTAGA GACTGCATGA 2220
CCATCCAAGG CGAAGTGTAT GGTACTAATC TGGAAGCCAC AGAATAGGAC ACTTGGTTTC 2280
AGCTCCAGGG TTTTCAGTGC TCACTATTCT TGTTCTGTAT CCCAGTATTG GTGCTGCAAC 2340
TTAATGTACT TCACCTGTGG ATTGGCTGCA AATAAACTCA CGTGTATTGG AAAAAAGGAA 2400
TTCCTGCAGC CCGGGGGATC CACTAGTTCT AGAGCGGCCG CCACCGGTGG AGCTCCAGCT 2460
TTTGTTCCCT TTAGTGAGGG TTAATTTCGA GCTTGGCGTA ATCATGGTCA TAGCTGTTTC 2520
CTGTGTGAAA TTGTTATCCG CTCACAATTC CACACAACAT ACGAGCCGGA AGCATAA 2577

(2) INFORMATION FOR SEQ ID NO:136:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 728 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:

Pro Ala Asn Ala Ile Lys Glu Met Ile Glu Asn Cys Leu Asp Ala Lys
1 5 10 15
Ser Thr Asn Ile Gln Val Val Val Lys Glu Gly Gly Leu Lys Leu Ile
20 25 30
Gln Ile Gln Asp Asn Gly Thr Gly Ile Arg Lys Glu Asp Leu Asp Ile
35 40 45
Val Cys Glu Arg Phe Thr Thr Ser Lys Leu Gln Thr Phe Glu Asp Leu
50 55 60
Ala Ser Ile Ser Thr Tyr Gly Phe Arg Gly Glu His Leu Ala Ser Ile
65 70 75 80
Ser His Val Ala His Val Thr Ile Thr Thr Lys Thr Ala Asp Gly Lys
85 90 95
Cys Ala Tyr Arg Ala Ser Tyr Ser Asp Gly Lys Leu Gln Ala Pro Pro
100 105 110
Lys Pro Cys Ala Gly Asn Gln Gly Thr Leu Ile Thr Val Glu Asp Leu
115 120 125
Phe Tyr Asn Ile Ile Thr Arg Arg Lys Ala Leu Lys Asn Pro Ser Glu
130 135 140
Glu Tyr Gly Lys Ile Leu Glu Val Val Gly Arg Tyr Ser Ile His Asn
145 150 155 160
Ser Gly Ile Ser Ile Ser Val Lys Lys Gln Gly Glu Thr Val Ser Asp
165 170 175

```
Val Arg Thr Leu Pro Asn Ala Thr Thr Val Asp Asn Ile Arg Ser Ile
            180                 185                 190
Phe Gly Asn Ala Val Ser Arg Glu Leu Ile Glu Val Gly Cys Glu Asp
        195                 200                 205
Lys Thr Leu Ala Phe Lys Met Asn Gly Tyr Ile Ser Asn Ala Lys Tyr
    210                 215                 220
Ser Val Lys Lys Cys Ile Phe Leu Leu Phe Ile Asn His Arg Leu Val
225                 230                 235                 240
Glu Ser Ala Ala Leu Arg Lys Ala Ile Glu Thr Val Tyr Ala Ala Tyr
                245                 250                 255
Leu Pro Lys Thr His Thr His Ser Cys Thr Ser Val Glx Asn Gln Pro
            260                 265                 270
Ser Glu Arg Asp Val Asn Val His Pro Thr Lys Thr Glu Val His Phe
        275                 280                 285
Leu His Glu Glu Ser Ile Leu Gln Arg Val Gln Gln His Ile Glu Ser
    290                 295                 300
Lys Leu Leu Gly Ser Asn Ser Ser Arg Met Val Phe His Pro Asp Leu
305                 310                 315                 320
Ala Ser Arg Thr Cys Trp Ala Ser Gly Glu Ala Ala Arg Pro Thr Thr
                325                 330                 335
Gly Val Ala Ser Ser Ser Thr Ser Gly Ser Gly Asp Lys Val Tyr Ala
            340                 345                 350
Tyr Gln Met Ser Arg Thr Asp Ser Arg Asp Gln Lys Leu Asp Ala Phe
        355                 360                 365
Leu Gln Pro Val Ser Ser Leu Val Pro Ser Gln Pro Gln Asp Pro Arg
    370                 375                 380
Pro Val Arg Gly Ala Arg Thr Glu Gly Ser P   Glu Arg Ala Thr Arg
385                 390                 395                 400
Glu Asp Glu Glu Met Leu Ala Leu Pro Ala Pro Ala Glu Ala Ala Ala
                405                 410                 415
Glu Ser Glu Asn Leu Glu Arg Glu Ser Leu Met Glu Thr Ser Asp Ala
            420                 425                 430
Ala Gln Lys Ala Ala Pro Thr Ser Ser Pro Gly Ser Ser Arg Lys Ser
        435                 440                 445
His Arg Glu Asp Ser Asp Val Glu Met Val Glu Asn Ala Ser Gly Lys
    450                 455                 460
Glu Met Thr Ala Ala Cys Tyr Pro Arg Arg Arg Ile Ile Asn Leu Thr
465                 470                 475                 480
Ser Val Leu Ser Leu Gln Glu Glu Ile Ser Glu Arg Cys His Glu Thr
                485                 490                 495
Leu Arg Glu Ile Leu Arg Asn His Ser Phe Val Gly Cys Val Asn Pro
            500                 505                 510
Gln Trp Ala Leu Ala Gln His Gln Thr Lys Leu Tyr Leu Leu Asn Thr
        515                 520                 525
```

```
Thr Lys Leu Ser Glu Glu Leu Phe Tyr Gln Ile Leu Ile Tyr Asp Phe
    530                 535                 540
Ala Asn Phe Gly Val Leu Arg Leu Ser Glu Pro Ala Pro Leu Phe Asp
545                 550                 555                 560
Leu Ala Met Leu Ala Glx Thr Val Leu Lys Val Ala Gly Gln Arg Thr
                565                 570                 575
Thr Ala Arg Arg Arg Ala Cys Arg Val His Cys Arg Val Ser Glu Glu
            580                 585                 590
Lys Arg Asp Ala Cys Arg Leu Phe Ser Val Arg Ser Met Arg Arg Glu
        595                 600                 605
Pro Asp Glx Leu Leu Phe Glx Glx Gln Leu Cys Ala Thr Phe Gly Gly
    610                 615                 620
Thr Ala Tyr Leu His Ser Ser Thr Gly His Glx Gly Glu Leu Gly Glu
625                 630                 635                 640
Glu Lys Glu Cys Phe Glu Ser Leu Ser Lys Glu Cys Ala Met Phe Tyr
                645                 650                 655
Ser Ile Arg Lys Gln Tyr Ile Leu Glu Glu Ser Thr Leu Ser Gly Gln
            660                 665                 670
Gln Ser Asp Met Pro Gly Ser Thr Ser Lys Pro Trp Lys Trp Thr Val
        675                 680                 685
Glu His Ile Ile Tyr Lys Ala Phe Arg Ser His Leu Leu Pro Pro Lys
    690                 695                 700
His Phe Thr Glu Asp Gly Asn Val Leu Gln Leu Ala Asn Leu Pro Asp
705                 710                 715                 720
Leu Tyr Lys Val Phe Glu Arg Cys
                725
```

(2) INFORMATION FOR SEQ ID NO:137:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 3065 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

```
CGGTGAAGGT CCTGAAGAAT TTCCAGATTC CTGAGTATCA TTGGAGGAGA CAGATAACCT   60
GTCGTCAGGT AACGATGGTG TATATGCAAC AGAAATGGGT GTTCCTGGAG ACGCGTCTTT  120
TCCCGAGAGC GGCACCGCAA CTCTCCCGCG GTGACTGTGA CTGGAGGAGT CCTGCATCCA  180
TGGAGCAAAC CGAAGGCGTG AGTACAGAAT GTGCTAAGGC CATCAAGCCT ATTGATGGGA  240
AGTCAGTCCA TCAAATTTGT TCTGGGCAGG TGATACTCAG TTTAAGCACC GCTGTGAAGG  300
AGTTGATAGA AAATAGTGTA GATGCTGGTG CTACTACTAT TGATCTAAGG CTTAAAGACT  360
ATGGGGTGGA CCTCATTGAA GTTTCAGACA ATGGATGTGG GGTAGAAGAA GAAAACTTTG  420
AAGGTCTAGC TCTGAAACAT CACACATCTA AGATTCAAGA GTTTGCCGAC CTCACGCAGG  480
TTGAAACTTT CGGCTTTCGG GGGGAAGCTC TGAGCTCTCT GTGTGCACTA AGTGATGTCA  540
CTATATCTAC CTGCCACGGG TCTGCAAGCG TTGGGACTCG ACTGGTGTTT GACCATAATG  600
GGAAAATCAC CCAGAAAACT CCCTACCCCC GACCTAAAGG AACCACAGTC AGTGTGCAGC  660
```

ACTTATTTTA TACACTACCC GTGCGTTACA AAGAGTTTCA GAGGAACATT AAAAAGGAGT 720
ATTCCAAAAT GGTGCAGGTC TTACAGGCGT ACTGTATCAT CTCAGCAGGC GTCCGTGTAA 780
GCTGCACTAA TCAGCTCGGA CAGGGGAAGC GGCACGCTGT GGTGTGCACA AGCGGCACGT 840
CTGGCATGAA GGAAAATATC GGGTCTGTGT TTGGCCAGAA GCAGTTGCAA AGCCTCATTC 900
CTTTTGTTCA GCTGCCCCCT AGTGACGCTG TGTGTGAAGA GTACGGCCTG AGCACTTCAG 960
GACGCCACAA AACCTTTTCT ACGTTTTCGG GCTTCATTTC ACAGTGCACG CACGGCGCCG 1020
GGAGGAGTGC AACAGACAGG CAGTTTTTCT TCATCAATCA GAGGCCCTGT GACCCAGCAA 1080
AGGTCTCTAA GCTTGTCAAT GAGGTTTATC ACATGTATAA CCGGCATCAG TACCCATTTG 1140
TCGTCCTTAA CGTTTCCGTT GACTCAGAAT GTGTGGATAT TAATGTAACT CCAGATAAAA 1200
GGCAAATTCT ACTACAAGAA GAGAAGCTAT TGCTGGCCGT TTTAAAGACC TCCTTGATAG 1260
GAATGTTTGA CAGTGATGCA AACAAGCTTA ATGTCAACCA GCAGCCACTG CTAGATGTTG 1320
AAGGTAACTT AGTAAAGTCG CATACTGCAG AACTAGAAAA GCCTGTGCCA GGAAAGCAAG 1380
ATAACTCTCC TTCACTGAAG AGCACAGCAG ACGAGAAAAG GGTAGCATCC ATCTCCAGGC 1440
TGAGAGAGGC CTTTTCTCTT CATCCTACTA AAGAGATCAA GTCTAGGGGT CCAGAGACTG 1500
CTGAACTGAC ACGGAGTTTT CCAAGTGAGA AAAGGGGCGT GTTATCCTCT TATCCTTCAG 1560
ACGTCATCTC TTACAGAGGC CTCCGTGGCT CGCAGGACAA ATTGGTGAGT CCCACGGACA 1620
GCCCTGGTGA CTGTATGGAC AGAGAGAAAA TAGAAAAAGA CTCAGGGCTC AGCAGCACCT 1680
CAGCTGGCTC TGAGGAAGAG TTCAGCACCC CAGAAGTGGC CAGTAGCTTT AGCAGTGACT 1740
ATAACGTGAG CTCCCTAGAA GACAGACCTT CTCAGGAAAC CATAAACTGT GGTGACCTGC 1800
TGCCGTCCTC CAGGTACAGG ACAGTCCTTG AAGCCAGAAG ACCATGGATA TCAATGCAAA 1860
GCTCTACCTC TAGCTCGTCT GTCACCCACA AATGCCAAGC GCTTCAAGAC AGAGGAAGAC 1920
CCTCAAATGT CAACATATCT CAAAGATTGC CTGGTCCTCA GAGCACCTCA GCAGCTGAGG 1980
TCGATGTAGC CATAAAAATG AATAAGAGAT CGTGCTCCTC GAGTTCTCTA GCTAAGCGAA 2040
TGAAGCAGTT ACAGCACCTA AAGGCGCAGA ACAAACATGA ACTGAGTTAC AGAAAATTTA 2100
GGGCCAAGAT TTGCCCTGGA GAAAACCAAG CAGCAGAAGA TGAACTCAGA AAAGAGATTA 2160
GTAAATCGAT GTTTGCAGAG ATGGAGATCT TGGGTCAGTT TAACCTGGGA TTTATAGTAA 2220
CCAAACTGAA AGAGGACCTC TTCCTGGTGG ACCAGCATGC TGCGGATGAG AAGTACAACT 2280
TTGAGATGCT GCAGCAGCAC ACGGTGCTCC AGGCGCAGAG GCTCATCACG TGGGTGCACA 2340
CAGGCTTCAG AGTTCCCAGA CCCCAGACTC TGAACTTAAC TGCTGTCAAT GAAGCTGTAC 2400
TGATAGAAAA TCTGGAAATA TTCAGAAAGA ATGGCTTTGA CTTTGTCATT GATGAGGATG 2460
CTCCAGTCAC TGAAAGGGCT AAATTGATTT CCTTACCAAC TAGTAAAAAC TGGACCTTTG 2520
GACCCCAAGA TATAGATGAA CTGATCTTTA TGTTAAGTGA CAGCCCTGGG GTCATGTGCC 2580
GGCCCTCACG AGTCAGACAG ATGTTTGCTT CCAGAGCCTG TCGGAAGTCA GTGATGATTG 2640
GAACGGCGCT CAATGCGAGC GAGATGAAGA AGCTCATCAC CCACATGGGT GAGATGGACC 2700
ACCCCTGGAA CTGCCCCCAC GGCAGGCCAA CCATGAGGCA CGTTGCCAAT CTGGATGTCA 2760
TCTCTCAGAA CTGACACACC CCTTGTAGCA TAGAGTTTAT TACAGATTGT TCGGTTCGCA 2820
AAGAGAAGGT TTTAAGTAAT CTGATTATCG TTGTACAAAA ATTAGCATGC TGCTTTAATG 2880
TACTGGATCC ATTTAAAAGC AGTGTTAAGG CAGGCATGAT GGAGTGTTCC TCTAGCTCAG 2940
CTACTTGGGT GATCCGGTGG GAGCTCATGT GAGCCCAGGA CTTTGAGACC ACTCCGAGCC 3000
ACATTCATGA GACTCAATTC AAGGACAAAA AAAAAAAGAT ATTTTTGAAG CCTTTTAAAA 3060
AAAAA 3065

(2) INFORMATION FOR SEQ ID NO:138:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 864 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

Met Glu Gln Thr Glu Gly Val Ser Thr Glu Cys Ala Lys Ala Ile Lys
1 5 10 15
Pro Ile Asp Gly Lys Ser Val His Gln Ile Cys Ser Gly Gln Val Ile
20 25 30
Leu Ser Leu Ser Thr Ala Val Lys Glu Leu Ile Glu Asn Ser Val Asp
35 40 45
Ala Gly Ala Thr Thr Ile Asp Leu Arg Leu Lys Asp Tyr Gly Val Asp
50 55 60
Leu Ile Glu Val Ser Asp Asn Gly Cys Gly Val Glu Glu Glu Asn Phe
65 70 75 80
Glu Gly Leu Ala Leu Lys His His Thr Ser Lys Ile Gln Glu Phe Ala
85 90 95
Asp Leu Thr Gln Val Glu Thr Phe Gly Phe Arg Gly Glu Ala Leu Ser
100 105 110
Ser Leu Cys Ala Leu Ser Asp Val Thr Ile Ser Thr Cys His Gly Ser
115 120 125
Ala Ser Val Gly Thr Arg Leu Val Phe Asp His Asn Gly Lys Ile Thr
130 135 140
Gln Lys Thr Pro Tyr Pro Arg Pro Lys Gly Thr Thr Val Ser Val Gln
145 150 155 160
His Leu Phe Tyr Thr Leu Pro Val Arg Tyr Lys Glu Phe Gln Arg Asn
165 170 175
Ile Lys Lys Glu Tyr Ser Lys Met Val Gln Val Leu Gln Ala Tyr Cys
180 185 190
Ile Ile Ser Ala Gly Val Arg Val Ser Cys Thr Asn Gln Leu Gly Gln
195 200 205
Gly Lys Arg His Ala Val Val Cys Thr Ser Gly Thr Ser Gly Met Lys
210 215 220
Glu Asn Ile Gly Ser Val Phe Gly Gln Lys Gln Leu Gln Ser Leu Ile
225 230 235 240
Pro Phe Val Gln Leu Pro Pro Ser Asp Ala Val Cys Glu Glu Tyr Gly
245 250 255
Leu Ser Thr Ser Gly Arg His Lys Thr Phe Ser Thr Phe Ser Gly Phe
260 265 270
Ile Ser Gln Cys Thr His Gly Ala Gly Arg Ser Ala Thr Asp Arg Gln
275 280 285

```
Phe Phe Phe Ile Asn Gln Arg Pro Cys Asp Pro Ala Lys Val Ser Lys
    290                 295                 300
Leu Val Asn Glu Val Tyr His Met Tyr Asn Arg His Gln Tyr Pro Phe
305                 310                 315                 320
Val Val Leu Asn Val Ser Val Asp Ser Glu Cys Val Asp Ile Asn Val
                325                 330                 335
Thr Pro Asp Lys Arg Gln Ile Leu Leu Gln Glu Glu Lys Leu Leu Leu
            340                 345                 350
Ala Val Leu Lys Thr Ser Leu Ile Gly Met Phe Asp Ser Asp Ala Asn
        355                 360                 365
Lys Leu Asn Val Asn Gln Gln Pro Leu Leu Asp Val Glu Gly Asn Leu
    370                 375                 380
Val Lys Ser His Thr Ala Glu Leu Glu Lys Pro Val Pro Gly Lys Gln
385                 390                 395                 400
Asp Asn Ser Pro Ser Leu Lys Ser Thr Ala Asp Glu Lys Arg Val Ala
                405                 410                 415
Ser Ile Ser Arg Leu Arg Glu Ala Phe Ser Leu His Pro Thr Lys Glu
            420                 425                 430
Ile Lys Ser Arg Gly Pro Glu Thr Ala Glu Leu Thr Arg Ser Phe Pro
        435                 440                 445
Ser Glu Lys Arg Gly Val Leu Ser Ser Tyr Pro Ser Asp Val Ile Ser
    450                 455                 460
Tyr Arg Gly Leu Arg Gly Ser Gln Asp Lys Leu Val Ser Pro Thr Asp
465                 470                 475                 480
Ser Pro Gly Asp Cys Met Asp Arg Glu Lys Ile Glu Lys Asp Ser Gly
                485                 490                 495
Leu Ser Ser Thr Ser Ala Gly Ser Glu Glu Glu Phe Ser Thr Pro Glu
            500                 505                 510
Val Ala Ser Ser Phe Ser Ser Asp Tyr Asn Val Ser Ser Leu Glu Asp
        515                 520                 525
Arg Pro Ser Gln Glu Thr Ile Asn Cys Gly Asp Leu Leu Pro Ser Ser
    530                 535                 540
Arg Tyr Arg Thr Val Leu Glu Ala Arg Arg Pro Trp Ile Ser Met Gln
545                 550                 555                 560
Ser Ser Thr Ser Ser Ser Ser Ser Val Thr His Lys Cys Gln Ala Leu Gln
                565                 570                 575
Asp Arg Gly Arg Pro Ser Asn Val Asn Ile Ser Gln Arg Leu Pro Gly
            580                 585                 590
Pro Gln Ser Thr Ser Ala Ala Glu Val Asp Val Ala Ile Lys Met Asn
        595                 600                 605
Lys Arg Ser Cys Ser Ser Ser Ser Leu Ala Lys Arg Met Lys Gln Leu
    610                 615                 620
Gln His Leu Lys Ala Gln Asn Lys His Glu Leu Ser Tyr Arg Lys Phe
625                 630                 635                 640
```

```
Arg Ala Lys Ile Cys Pro Gly Glu Asn Gln Ala Ala Glu Asp Glu Leu
                645                 650                 655
Arg Lys Glu Ile Ser Lys Ser Met Phe Ala Glu Met Glu Ile Leu Gly
            660                 665                 670
Gln Phe Asn Leu Gly Phe Ile Val Thr Lys Leu Lys Glu Asp Leu Phe
        675                 680                 685
Leu Val Asp Gln His Ala Ala Asp Glu Lys Tyr Asn Phe Glu Met Leu
    690                 695                 700
Gln Gln His Thr Val Leu Gln Ala Gln Arg Leu Ile Thr Trp Val His
705                 710                 715                 720
Thr Gly Phe Arg Val Pro Arg Pro Gln Thr Leu Asn Leu Thr Ala Val
                725                 730                 735
Asn Glu Ala Val Leu Ile Glu Asn Leu Glu Ile Phe Arg Lys Asn Gly
            740                 745                 750
Phe Asp Phe Val Ile Asp Glu Asp Ala Pro Val Thr Glu Arg Ala Lys
        755                 760                 765
Leu Ile Ser Leu Pro Thr Ser Lys Asn Trp Thr Phe Gly Pro Gln Asp
    770                 775                 780
Ile Asp Glu Leu Ile Phe Met Leu Ser Asp Ser Pro Gly Val Met Cys
785                 790                 795                 800
Arg Pro Ser Arg Val Arg Gln Met Phe Ala Ser Arg Ala Cys Arg Lys
                805                 810                 815
Ser Val Met Ile Gly Thr Ala Leu Asn Ala Ser Glu Met Lys Lys Leu
            820                 825                 830
Ile Thr His Met Gly Glu Met Asp His Pro Trp Asn Cys Pro His Gly
        835                 840                 845
Arg Pro Thr Met Arg His Val Ala Asn Leu Asp Val Ile Ser Gln Asn
    850                 855                 860
```

(2) INFORMATION FOR SEQ ID NO:139:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:

CTTGATTCTA GAGCYTCNCC NCKRAANCC 29

(2) INFORMATION FOR SEQ ID NO:140:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:
AGGTCGGAGC TCAARGARYT NGTNGANAA 29

(2) INFORMATION FOR SEQ ID NO:141:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:
ACTTGTGGAT TTTGC 15

(2) INFORMATION FOR SEQ ID NO:142:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:
ACTTGTGAAT TTTGC 15

(2) INFORMATION FOR SEQ ID NO:143:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:
TTCGGTGACA GATTTGTAAA TG 22

(2) INFORMATION FOR SEQ ID NO:144:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:
TTTACGGAGC CCTGGC 16

(2) INFORMATION FOR SEQ ID NO:145:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:
TCACCATAAA AATAGTTTCC CG 22

(2) INFORMATION FOR SEQ ID NO:146:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:
TCCTGGATCA TATTTTCTGA GC 22

(2) INFORMATION FOR SEQ ID NO:147:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:
TTTCAGGTAT GTCCTGTTAC CC 22

(2) INFORMATION FOR SEQ ID NO:148:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:
TGAGGCAGCT TTTAAGAAAC TC 22

WE CLAIM:

1. A method of diagnosing cancer susceptibility in a subject comprising detecting a mutation in a *mutL* homolog gene or gene product in a tissue of the subject, the mutation being indicative of the subject's susceptibility to cancer.

2. A method of identifying and classifying a DNA mismatch-repair-defective tumor comprising detecting in a tumor a mutation in a *mutL* homolog gene or gene product, the mutation being indicative of a defect in a mismatch repair system of the tumor.

3. The method of claim 1 or claim 2 wherein the step of detecting comprises detecting a mutation in *hMLH1* or *hPMS1*.

4. The method of claim 1 or claim 2 wherein the step of detecting mprises isolating nucleic acid from the subject;

amplifying a segment of the mismatch repair gene or gene product from the isolated nucleic acid;

comparing the amplified segment with an analogous segment of a wild-type allele of the mismatch repair gene or gene product; and

detecting a difference between the amplified segment and the analogous segment, the difference being indicative of a mutation in the mismatch repair gene or gene product.

5. The method of claim 4 wherein the step of detecting comprises determining whether the difference between the amplified segment and the analogous segment causes an affected phenotype.

6. The method of claim 4 wherein the difference in nucleotide sequence is selected from the group consisting of deletions of at least one nucleotide, insertions of at least one nucleotide, substitutions of at least one nucleotide and nucleotide rearrangements.

7. The method of claim 4 wherein the step of amplifying comprises:

reverse transcribing all or a portion of an RNA mismatch repair gene product to DNA; and

amplifying a segment of the DNA produced by reverse transcription.

8. The method of claim 4 wherein the step of amplifying comprises:

selecting a pair of oligonucleotide primers capable of hybridizing to opposite strands of the mismatch repair gene, and in opposite orientation;

performing a polymerase chain reaction utilizing the oligonucleotide primers such that nucleic acid of the mismatch repair chain intervening between the primers is amplified to become the amplified segment.

9. The method of claim 8 wherein the intervening nucleic acid comprises at least a fragment of at least one exon of the mismatch repair gene.

10. The method of claim 9 wherein the at least one exon has a nucleotide sequence selected from the group consisting of SEQ ID NOS: 25-43.

11. The method of claim 1 or claim 2 wherein the step of detecting comprises detecting a mutation in a *mutL* homolog mismatch repair protein.

12. The method of claim 4 wherein the analogous segment of a wild-type allele of the mismatch repair gene or gene product comprises a wild-type hMLH1 gene fragment having a unique portion of nucleotide sequence selected from the group consisting of: SEQ ID NOS: 6-24.

13. The method of claim 8 wherein the step of selecting comprises selecting a pair of oligonucleotide primers, each primer of the pair comprising a nucleotide sequence selected from the group consisting of: SEQ ID NOS: 44-82.

14. The method of claim 8 wherein the intervening nucleotide sequence that is amplified comprises a unique portion of at least one nucleotide sequence selected from the group consisting of: SEQ ID NOS: 6-24.

15. The method of claim 4 wherein the step of detecting a difference comprises detecting an hMLH1 mutation characterized by a C to T transition mutation which produces a non-conservative amino acid substitution at position 44 of the hMLH1 protein.

16. The method of claim 5 wherein the step of determining comprises:

deriving a yeast strain that is deleted for its *hMLH1* gene;

constructing a yeast homolog of the amplified segment including the difference;

introducing the yeast homolog of the amplified segment into the yeast strain; and

assaying the yeast strains ability to correct DNA mispairs.

17. The method of claim 5 wherein the step of determining comprises producing an hMLH1 protein including amino acids corresponding to the difference; and determining the extent of interaction between the hMLH1 protein and an hPMS1 protein compared to the degree of protein-protein interaction observed with wild-type hMLH1 and hPMS1 proteins.

18. An isolated oligonucleotide primer capable of hybridizing specifically to all or a fragment of an hMLH1 genomic sequence with a T_m of greater than about 55-degrees° C_o.

19. The isolated oligonucleotide primer of claim 18, the oligonucleotide primer being extendable by a DNA polymerase.

20. The isolated oligonucleotide primer of claim 19, the oligonucleotide primer being capable of amplifying at least a portion of an *hMLH1* gene when used in a polymerase chain reaction including another primer.

21. The isolated oligonucleotide primer of claim 20, the oligonucleotide primer being at least 13 nucleotides in length.

22. The isolated oligonucleotide primer of claim 21 comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 44-82.

23. An isolated nucleic acid including a segment having a nucleotide sequence substantially identical to a nucleotide sequence selected from the group consisting of SEQ ID NOS: 6-24.

24. An isolated nucleic acid including a segment having a nucleotide sequence substantially identical to a nucleotide sequence selected from the group consisting of SEQ ID NOS: 25-43.

25. A unique fragment of the nucleic acid of claim 23 or claim 24.

26. A method of detecting a mutation in a eukaryotic *mutL* homolog gene or fragment thereof comprising the steps of:

isolating a eukaryotic *mutL* homolog gene or fragment thereof; and

detecting a difference in activity between the isolated gene or fragment thereof and a wild-type allele of the gene or fragment thereof; the difference in activity being indicative of a mutation in the eukaryotic *mutL* homolog gene or fragment thereof.

27. A method of detecting a mutation in a eukaryotic *mutL* homolog gene or gene product comprising detecting a difference in activity between the gene or gene product and a wild-type version of the gene or gene product, the difference in activity being indicative of a mutation in the *mutL* homolog gene or gene product.

28. The method of claim 26 wherein the eukaryotic *mutL* homolog gene or fragment thereof comprises a human gene or fragment thereof.

29. The method of claim 27 wherein the *mutL* homolog gene or gene product comprises a human gene or gene product.

30. The method of claim 28 or claim 29 wherein the gene comprises an *hMLH1* and the wild-type version of the gene comprises a wild-type allele of the *hMLH1* gene.

31. The method of claim 28 or claim 29 wherein the gene comprises a *hPMS1* and the wild-type version of the gene comprises a wild-type allele of the *hPMS1* gene.

32. The method of claim 30 wherein the wild-type version of the *hMLH1* gene comprises a nucleotide sequence substantially identical to a nucleotide sequence selected from the group consisting of SEQ ID NOS: 6-24, and unique fragments thereof.

33. The method of claim 30 wherein the wild-type version of the *hMLH1* gene encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 5 and unique fragments thereof.

34. The method of claim 28 or claim 29 wherein the human mismatch repair gene product comprises a hMLH1 protein or unique fragment thereof.

35. The method of claim 34 wherein the hMLH1 protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 5 and unique fragments thereof.

36. An isolated nucleotide or protein structure including a segment sequentially corresponding to a unique portion of a human *mutL* homolog gene or gene product.

37. The nucleotide of claim 36 wherein the *mutL* homolog gene is *hMLH1* or *hPMS1*.

38. A pair of oligonucleotide primers capable of being used together in a polymerase chain reaction to amplify specifically a unique segment of a human *mutL* homolog gene.

39. The pair of oligonucleotide primers of claim 38 wherein the *mutL* homolog gene is *hMLH1* or *hPMS1*.

40. A probe comprising

a nucleotide sequence capable of binding specifically by Watson/Crick pairing to complementary bases in a portion of a human *mutL* homolog gene; and

a label-moiety attached to the sequence, wherein the label-moiety has a property selected from the group consisting of fluorescent, radioactive and chemiluminescent.

41. The probe of claim 40 wherein the human *mutL* homolog gene is *hMLH1* or *hPMS1*.

42. An amplified quantity of a nucleotide including a segment corresponding to a unique portion of a human *mutL* homolog gene.

43. The nucleotide of claim 42 wherein the human *mutL* homolog gene is *hMLH1* or *hPMS1*.

44. A pair of oligonucleotide primers capable of being employed in a polymerase chain reaction to amplify specifically a single exon from a human *mutL* homolog gene along with selected portions of flanking upstream and downstream introns.

45. The primers of claim 44 wherein the human *mutL* homolog gene is *hMLH1* or *hPMS1*.

46. The method of claim 1 wherein the detecting step comprises detecting a mutation in a portion of the individual's *hMLH1* gene, the portion being homologous to the DNA sequence including and between the two sets of underlined bases in Figure 3.

47. The nucleotide of claim 37 wherein the segment is homologous to the DNA sequence including and between the two sets of underlined bases in Figure 3.

48. An isolated nucleotide or protein structure including a segment substantially corresponding to a unique portion of a mouse *mutL* homolog gene or gene product.

49. The structure of claim 48 wherein the segment substantially corresponds to a unique portion of a mammalian *MLH1* or *PMS1* gene or protein.

50. Purified antibodies binding specifically to a MutL homolog protein.

51. The antibodies of claim 50 wherein the antibodies are monoclonal antibodies.

52. The antibodies of claim 50 wherein the MutL homolog protein is a human protein.

53. The antibodies of claim 52 wherein the protein is hMLH1 or hPMS1.

54. The antibodies of claim 50 wherein the MutL homolog protein is a mouse protein.

55. The antibodies of claim 54 wherein the protein is mMLH1 or mPMS1.

Guide for the isolation and characterization of mammalian *PMS1* and *MLH1* genes.

Step 1 Design of degenerate oligonucleotide pools for PCR.

Step 2 Reverse transcription and PCR on poly A+ selected mRNA isolated from human cells.

Step 3 Cloning and sequencing of PCR generated fragments; identification of two gene fragments representing human *PSM1* and *MLH1*.

Step 4 Isolation of complete human and mouse PMS1 and MLH1 cDNA clones using the PCR fragments as probes.

Step 5 Isolation of human and mouse, *PMS1* and *MLH1* genomic clones.

Step 6 Chromosome positional mapping of the human and mouse, *PMS1* and *MLH1* genes by fluorescence *in situ* hybridization.

Step 7 Using genomic and cDNA sequences to identify mutations in *PMS1* and *MLH1* genes from HNPCC Families.

Step 8 Design targeting vectors to disrupt mouse *PMS1* and *MLH1* genes in ES cells; study mice deficient in mismatch repair.

Figure 1



Figure 2



Human MLH1 cDNA Nucleotide and Protein Sequence

Figure 3

#1: 18442 to 19109 (-21 to 116)

TGGCTGGATGCTAAGCTACAGCTGAAGGAAGAACGTGAGCACGaggcactgaggt
gattggcTGAAGGCACTTCCGTTGAGCATCTAGACGTTTCcttggctcttctggc
gccaaaatgtcgttcgtggcaggggttattcggcggctggacgagacagtggtga
accgcatcgcggcgggggaagttatccagcggccagctaatgctatcaaagagat
gattgagaactgGTACGGAGGGAGTCGAGCCGGgctcacttaagggctacgaCTT
AACGGGCCGCGTCACTCAATGGCGCGGACACGCCTCTTTCCCCGGGCAGAGGCAT
GTACAGCGCATGCCCACAACGGCGGAGGCCGCCGGGTTCCCTACGTGCCATAAGC
CTTCTCCTTTTC

SEQ. ID NO: 25

SEQ. ID NO: 6

#2: 19689 to 19688 (117 to 207)

AAACACGTTAATGAGGCACTATTGTTTGTATTTGGAGTTTGTTATCATTGCTTGG
CTCATATTAAaatatgtacattagagtagttgCAGACTGATAAATTATTTTCTGT
TTGATTTGCCAGtttagatgcaaaatccacaagtattcaagtgattgttaaagag
ggaggcctgaagttgattcagatccaagacaatggcaccgggatcaggGTAAGTA
AAACCTCAAAGTAGCAGGATGTTTGTGCGCTTCATGGAAgagtcaggacctttct
ctgTTCTGGAAACTAGGCTTTTGCAGATGGGATTTTTTCACTGAAAAATTCAACA
CCAACAATAAATATTTATTGAGTACCTATTATTTGCGGGGCACTGTTCAGGGGAT
GTGTCAGT

SEQ. ID NO: 26

SEQ. ID NO: 7

#3: 19687 to 19786 (208 to 306)

TTTCCTGGATTAATCAAGAAATGGAATTCAAagagatttggaaaatgagtaacAT
GATTATTTACTCATCTTTTTGGTATCTAACAGaaagaagatctggatattgtatg
tgaaaggttcactactagtaaactgcagtcctttgaggatttagccagtatttct
acctatggctttcgaggtgagGTAAGCTAAAGATTCAAGAAATGTGTAAAATATc
ctcctgtgatgacattgtCTGTCATTTGTTAGTATGTATTTCTCAACATAGATAA
ATAAGGTTTGGTACCTTTTACTTGTTAAATGTATGCAAATCTGAGCAAACTTAAT
GAACTTTAACTTTCAAAGACTG

SEQ. ID NO: 27

SEQ. ID NO: 8

#4 18492 to 18421 (307 to 380)

TGGAAGCAGCAGNCAGATaacctttccctttggtgaggTGACAGTGGGTGACCCA
GCAGTGAGTTTTTCTTTCAGTCTATTTTCTTTTCTTCCTTAGgctttggccagca
taagccatgtggctcatgttactactacaacgaaaacagctgatggaaagtgtgc
atacagGTATAGTGCTGACTTCTTTTACTCATATATATTCATTCTGAAATGTATT
TTGGgcctaggtctcagagtaatcCTGTCTCAACACCAGTGTTATCTTTNNNGGC
AGAGATCTTGAGTACG

SEQ. ID NO: 28

SEQ. ID NO: 9

Figure 4A - 1

#5: 18313 to 18179 (381 to 453)

TTGATATgattttctcttttccccttgggATTAGTATCTATCTCTCTACTGGATA
TTAATTTGTTATATTTTCTCATTAGagcaagttactcagatggaaaactgaaagc
ccctcctaaaccatgtgctggcaatcaagggacccagatcacgGTAAGAATGGTA
CATGGGAGAgtaaattgttgaagctttgtttgTATAAATATTGGAATAAAAAATA
AAATTGCTTCTAAGTTTTCAGGGTAATAATAAAATGAATTTGCACTAGTTAATGG
AGGTCCCAAGATATCCTCTAAGCAAGATAAATGACTATTGGCTTTTNNTGGCATG
GCAGCCTG

SEQ. ID NO: 10

SEQ. ID NO: 29

#6: 18318 to 18317 (454 to 545)

GCTTTTGCCAGGACCATCTTgggttttatttcaagtacttctatgAATTTACAA
GAAAAATCAATCTTCTGTTCAGgtggaggacctttttacaacatagccacgagg
agaaaagctttaaaaaatccaagtgaagaatatgggaaaatttggaagttgttg
gcagGTACAGTCCAAAATCTGGGAGTGGGTCTCTGAGATTTGTCATCAAAGTAAT
GTGTTCTAGTgctcatacattgaacagttgctgagcTAGATGGTGAAAAGTAAAA

SEQ. ID NO: 11

SEQ. ID NO: 30

#7: 19009 to 19135 (546 TO 588)

CAGCAACCTATAAAAGTAGAGAGGAGTCTGTGTTTTGACGCAGCACCTTTAGCAT
TTTTATTTGGATGAAGTTTCTGCTGGTTTATTTTTCTGTGGGTAAAATATTAATA
GGCTGTATGGAGATATTTTTCTTTATATGTACCTTTGTTTAGATTACTCAACTCC
ACTAATTTATTTAACTAAAAGGGGGCTCTGACATctagtgtgtgtttttggcAAC
TCTTTTCTTACTCTTTTGTTTTTCTTTTCCAGgtattcagtacacaatgcaggca
ttagtttctcagttaaaaaaaGTAAGTTCTTGGTTTATGGGGGATGGTTTTGTTTT
ATGAAAAGAAAAAAGGGGATTTTTAATAGTTTGCTggtggagataaggttatgAT
GTTT

SEQ. ID NO: 12

SEQ. ID NO: 31

#8: 18197 to 18924 (589 TO 677)

ATGTTTCAGTctcagccatgagacaataaatccTTGTGTCTTCTGCTGTTTGTTT
ATCAGcaaggagagacagtagctgatgttaggacactacccaatgcctcaaccgt
ggacaatattcgctccatctttggaaatgctgttagtcgGTATGTCGATAACCTA
TATAAAAAAATCTTTTACATTTATTATCTTGGTTTATCATTccatcacattattt
gggaaccTTTCAAGATATTATGTGTGTTAAGAGTTTGCTTTAGTCAAATACACAG
GCTTGTTTTATGCTTCAGATTTGTTAATGGAGTTCTTATTTCACGTAATCAACAC
TTTCTAGGTGTATGTAATCTCCTAGATTCTGTGGCGTGAATCATGTGTTCT

SEQ. ID NO: 13

SEQ. ID NO: 32

Figure 4A - 2

#9: 18765 to 18198 (678 TO 790)

ACTGAGTAGGGTAGGTGGGTGAGTGGGTGGGTGGGTGGGTGGGTGGATGGATGGA
TGGGAGGATGGGTGGGTGAATGGGTGAACAGACAAATGGATGGATGAATGGACAG
GCACAGGAGGACCTCAAATGGACCAAGTCTTCGGGGCCCTCATTTCACAAAGTTA
GTTTATGGGAAGGAACCTTGTGTTTTTAAATTCTGATTCTTTTGTAATGTTTGAG
TTTTGAGTATTTTcaaaagcttcagaatctcTTTTCTAATAGagaactgatagaa
attggatgtgaggataaaaccctagccttcaaaatgaatggttacatatccaatg
caaactactcagtgaagaagtgcatcttcttactcttcatcaaccGTAAGTTAAA
AAGAACCACATGGGAAATccactcacaggaaacacccacagGGAATTTTATGGGA
CCATGGAAAAATTTCTGAGTCCATAGGTTTGATTAAACATGGAGAAACCTCATGG
CAAAGTTTGGTTTTATTGGGAAGCATGTATA

SEQ. ID NO: 14

SEQ. ID NO: 33

#10: 18305 to 18306 (791 TO 884)

ATAGTGGGCTGGAAAGTGGCCACAGGTAAAGGTGCACCTTTCTTCCTGGGGATGT
GATGTGCATATCACTACAGAAATGTCTTTCCTGAGGTGATGTcatgactttgtgt
gaatgtacaccTGTGACCTCACCCCTCAGGACAGTTTTGAACTGGTTGCTTTCTT
TTTATTGTTTAGatcgtctggtagaatcaacttccttgagaaaagccatagaaac
agtgtatgcagcctatttgcccaaaaacacacacccattcctgtacctcagGTAA
TGTAGCACCAAACTCCTCAACCAAGACTCACAAGGAAcagatgttctatcaggct
ctcctcTTTGAAAGAGATGAGCATGCTAATAGTACAATCAGAGTGAATCCCATAC
ACCACTGGCAAAAGGATGTTCTGTCCCTTCTTACAGGTACAAGGCACAG

SEQ. ID NO: 15

SEQ. ID NO: 34

#11: 18182 to 19041 (885 TO 1038)

CTTACGCAAAGCTACACAGCTCTTAAGTAGCAGTGCCAATATTTGAACACACTCA
GACTCGAGCCTGAGGTTTTGACCACTGTGTCATCTGGCCTCAAATCTTCTGGCCA
CCACATACACCATATGTgggctttttctccccctcccACTATCTAAGGTAATTGT
TCTCTCTTATTTTCCTGACAGtttagaaatcagtccccagaatgtggatgttaat
gtgcaccccacaaagcatgaagttcacttcctgcacgaggagagcatcctggagc
gggtgcagcagcacatcgagagcaagctcctgggctccaattcctccaggatgta
cttcacccagGTCAGGGCGCTTCTCATCCAGCTACTTCTCTGGGGCCTTTGAAAT
GTGCCCGGCCAGAcgtgagagcccagatttTTGCTGTTATTTAGGAACTTTTTTT
GAAGTATTACCTGGATAG

SEQ. ID NO: 16

SEQ. ID NO: 35

Figure 4A - 3

#12: 18579 to 18178 (1039 TO 1409)

GATaattatacctcatactagcTTCTTTCTTAGTACTGCTCCATTTGGGGACCTG
TATATCTATACTTCTTATTCTGAGTCTCTCCACTATATATATATATATATATATA
TTTTTTTTTTTTTTTTTTTTTAATACAGactttgctaccaggacttgctggcccc
tctggggagatggttaaatccacaacaagtctgacctcgtcttctacttctggaa
gtagtgataaggtctatgcccaccagatggttcgtacagattcccgggaacagaa
gcttgatgcatttctgcagcctctgagcaaaccccctgtccagtcagccccaggcc
attgtcacagaggataagacagatatttctagtggcagggctaggcagcaagatg
aggagatgcttgaactcccagccctgctgaagtggctgccaaaaatcagagctt
ggaggggatacaacaaaggggacttcagaaatgtcagagaagagaggacctact
tccagcaaccccagGTATGGCCTTTTGGGAAAAGTACAGCCTAcctcctttattc
tgtaataaaacTGCCTTCTAACTTTGGCTTTTCATGAATCACTTGCATCTTCTCT
CTGCCGACTTCCC

SEQ. ID NO: 17

SEQ. ID NO: 36

The splice acceptor site is believed to have 21 T's.

#13: 18420* to 18443 (1410 TO 1558)

CTGTGCTCCAGCACAGGTCATCCAGCTCTGTAGACCAGCGCAGAGAAGTTGCTTG
CTCCCAAAtgcaacccacaaaatttggcTAAGTTTAAAAACAAGAATAATAATGA
TCTGCACTTCCTTTTCTTCATTGCAGaaagagacatcgggaagattctgatgtgg
aaatggtggaagatgattcccgaaaggaaatgactgcagcttgtacccccggag
aaggatcattaacctcactagtgtttgagtctccaggaagaaattaatgagcag
ggacatgaggGTACGTAAACGCTGTGGCCTGCCTGGGATGCATAGGGCCTCAACT
GCCAAggttttggaaatggagaaagCAGTCATGTTGTCAGAGTGGCACTACAGTT
TTGATGGGCAAGCTCCTCTTCCTTTACTAACCCACAATAGCATCAGCTTAAAGAC
AATTTTTGATTGGGAGAAAAGGGAGAAAATAATCTCTG

SEQ. ID NO: 18

SEQ. ID NO: 37

#14: 19028 TO 18897 (1559 TO 1667)

CAGTTTTCACCAGGAGGCTCAAATCAGGCNNCTTTGCTTACTtggtgtctctagt
tctggTGCCTGGTGCTTTGGTCAATGAAGTGGGGTTGGTAGGATTCTATTACTTA
CCTGTTTTTTGGTTTTATTTTTTGTTTTGCAGttctccgggagatgttgcataac
cactccttcgtgggctgtgtgaatcctcagtgggccttggcacagcatcaaacca
agttataccttctcaacaccaccaagcttagGTAAATCAGCTGAGTGTGTGAACA
AgcagagctactacaacaatgGTCCAGGGAGCACAGGCACAAAAGCTAAGGAGAG
CAGCATGAAGGTAGTTGGGAAGGGCACAGGCTTTGGAGTCAGCACATGT

SEQ. ID NO: 19

SEQ. ID NO: 38

Figure 4A - 4

#15: 19025 to 18575 (1668 TO 1731)

CCCCTGGTTGAAGCGTTGGAATCCCACTCTTTGGANNNNNNNAGATTGTGTTAGA
CTGTTAACCAGATTCCACAGCCAGGCAGAACTATGTCTGTCTCATCCATGTGTCA
GGGATTACGTCTcccatttgtcccaactggTTGTATCTCAAGCATGAATTCAGCT
TTTCCTTAAAGTCACTTCATTTTTATTTTCAGtgaagaactgttctaccagatac
tcatttatgattttgccaattttggtgttctcaggttatcgGTAAGTTTAGATCC
TTTTCACTTctgacatttcaactgaccgCCCCGCAAACAGTAGCTCTCCACTAAA
TA

SEQ. ID NO: 20

SEQ. ID NO: 39

-19 of splice acceptor site is A in some people. Others are heterozygous for A and G. GTCACTTC or CTCGCTTC (Polymorphism).

#16: 18184 to 18314 (1732 TO 1896)

CATTTATGGTTTCTCACCTGCCATTCTGATAGTGGATTCTTGGGAATTCAGGCTT
catttggatgctccgttaaagcTTGCTCCTTCATGTTCTTGCTTCTTCCTAGgag
ccagcaccgctctttgaccttgccatgcttgccttagatagtccagagagtggct
ggacagaggaagatggtcccaaagaaggacttgctgaatacattgttgagtttct
gaagaagaaggctgagatgcttgcagactatttctctttggaaattgatgagGTG
TGACAGCCATTCTTATACTTCTGTTGTATTCTCcaaataaaatttccagccgggt
gCATTGGCTCA

SEQ. ID NO: 21

SEQ. ID NO: 40

#17: 18429 to 18315 (1897 TO 1989)

CAGATAGGAGGCACAAGGCCTGggaaaggcactggagaaatgggATTTGTTTAAA
CTATGACAGCATTATTTCTTGTTCCCTTGTCCTTTTTCCTGCAAGCAGgaaggga
acctgattggattacccctctgattgacaactatgtgccccctttggagggact
gcctatcttcattcttcgactagccactgaggTCAGTGATCAAGCAGATACTAAG
CATTTcggtacatgcatgtgtgctggagggAAAGGGCAAA

SEQ. ID NO: 22

SEQ. ID NO: 41

#18: 18444 to 18581 (1990 TO 2103)

CTATATCTTCCCAGCAATATTCACAGTCCGTTTACAGTTTTAACGCCTAAAGTAT
CACATTTCGTTTTTTAGCTTtaagtagtctgtgatctccgTTTAGAATGAGAATG
TTTAAATTCGTACCTATTTTGAGGTATTGAATTTCTTTGGACCAGgtgaattggg
acgaagaaaaggaatgttttgaaagcctcagtaaagaatgcgctatgttctattc
catccggaagcagtacatatctgaggagtcgaccctctcaggccagcagGTACAG
TGGTGATGCACACTGGCACCCCAGGACTAggacaggacctcatacatCTTAGGAG
ATGAAACTTG

SEQ. ID NO: 23

SEQ. ID NO: 42

Figure 4A - 5

#19: 18638 to 18637 (2104 TO 2271). 2463 is end of cDNA.

AATCCTCTTGTGTTCAGGCCTGTGGATCCCTGAGAGGCTAGCCCACAAGATCCAC
TTCAAAAGCCCTAGATAACACCAAGTCTTTCCAGACCCAGTGCACATCCCATCAG
CCAGgacaccagtgtatgttggGATGCAAACAGGGAGGCTTATGACATCTAATGT
GTTTTCCAGagtgaagtgcctggctccattccaaactcctggaagtggactgtgg
aacacattgtctataaagccttgcgctcacacattctgcctcctaaacatttcac
agaagatggaaatatcctgcagcttgctaacctgcctgatctatacaaagtcttt
gagaggtgttaaatatggttatttatgcactgtgggatgtgttcttctttctctg
tattccgatacaaagtgttgtatcaaagtgtgatatacaaagtgtaccaacataa
gtgttggtagcacttaagacttatacttgccttctgatagtattcctttatacac
agtggattgattataaataaatagatgtgtcttaacataATTTCTTATTTAATTT
TATTATGTATATA

SEQ. ID NO: 24

SEQ. ID NO: 43

Figure 4A - 6

hMLH1 EXON AMPLIFICATION PRIMERS

First Stage Amplification Primer	SEQ. ID NO:	Second Stage Amplification Primer	SEQ. ID NO:
Exon 1			
N-18442- 5'aggcactgaggtgattggc	44	N-19295- 5'tgtaaaacgacggccagtcactgaggtgattggctgaa	83
C-19109- 5'tcgtagcccttaagtgagc	45	C-19446- *5'tagcccttaagtgagcccg	84
Exon 2			
N-19689- 5'aatatgtacattagagtagttg	46	N-18685- 5'tgtaaaacgacggccagttacattagagtagttgcaga	85
C-19688- 5'cagagaaaggtcctgactc	47	C-19067- *5'aggtcctgactcttccatg	86
Exon 3			
N-19687- 5'agagatttggaaaatgagtaac	48	N-18687- 5'tgtaaaacgacggccagtttggaaaatgagtaacatgatt	87
C-19786- 5'acaatgtcatcacaggagg	49	C-19068- *5'tgtcatcacaggaggatat	88
Exon 4			
N-18492- 5'aacctttccctttggtgagg	50	N-19294- 5'tgtaaaacgacggccagtctttccctttggtgaggtga	89
C-18421- 5'gattactctgagacctaggc	51	C-19077- *5'tactctgagacctaggccca	90
Exon 5			
N-18313- 5'gattttctcttttccccttggg	52	N-19301- 5'tgtaaaacgacggccagttctctttttccccttgggattag	91
C-18179- 5'caaacaaagcttcaacaatttac	53	C-19046- *5'acaaagcttcaacaatttactct	92

Figure 4B - Page 1

First Stage Amplification Primer	SEQ. ID NO:	Second Stage Amplification Primer	SEQ. ID NO:
Exon 6			
N-18318- 5'gggttttattttcaagtacttctatg	54	N-19711- 5'tgtaaaacgacggccagtgttttattttcaagtacttctatgaatt	93
C-18317- 5'gctcagcaactgttcaatgtatgagc	55	C-19079- *5'cagcaactgttcaatgtatgagcact	94
Exon 7			
N-19009- 5'ctagtgtgtgtttttggc	56	N-19293- 5'tgtaaaacgacggccagtgtgtgtgtttttggcaac	95
C-19135- 5'cataaccttatctccacc	57	C-19435- *5'aaccttatctccaccagc	96
Exon 8			
N-18197- 5'ctcagccatgagacaataaatcc	58	N-19329- 5'tgtaaaacgacggccagtagccatgagacaataaatccttg	97
C-18924- 5'ggttcccaaataatgtgatgg	59	C-19450- *5'tcccaaataatgtgatggaatg	98
Exon 9			
N-18765- 5'caaaagcttcagaatctc	60	N-19608- 5'-tgtaaaacgacggccagtaagcttcagaatctctttt	99
C-18198- 5'ctgtgggtgtttcctgtgagtgg	61	C-19449- *5'-tgggtgtttcctgtgagtggatt	100
Exon 10			
N-18305- 5'catgactttgtgtgaatgtacacc	62	N-19297- 5'tgtaaaacgacggccagtactttgtgtgaatgtacacctgtg	101
C-18306-5'gaggagagcctgatagaacatctg	63	C-19081- *5'gagagcctgatagaacatctgttg	102

Figure 4B - Page 2

First Stage Amplification Primer	SEQ. ID NO:	Second Stage Amplification Primer	SEQ. ID NO:
Exon 11			
N-18182- 5'gggctttttctccccctccc	64	N-19486- 5'tgtaaaacgacggccagtctttttctccccctcccacta	103
C-19041- 5'aaaatctgggctctcacg	65	C-19455- *5'tctgggctctcacgtct	104
Exon 12 (See note at end)			
N-18579- 5'aattatacctcatactagc	66	N-20546- *5'cttattctgagtctctcc	105
C-18178- 5'gttttattacagaataaaggagg	67	C-20002- 5'tgtaaaacgacggccagtgtttgctcagaggctgc	106
		N-19829- *5'gatggttcgtacagattcccg	107
		C-19385- 5'tgtaaaacgacggccagtttattacagaataaaggaggtag	108
Exon 13			
N-18420- 5'tgcaacccacaaaatttggc	69	N-19300- 5'tgtaaaacgacggccagtaacccacaaaatttggctaag	109
C-18443- 5'ctttctccatttccaaaacc	70	C-19078- *5'tctccatttccaaaaccttg	110
Exon 14			
N-19028- 5'tggtgtctctagttctgg	71	N-19456- *5'tgtctctagttctggtgc	111
C-18897- 5'cattgttgtagtagctctgc	72	C-19472- 5'tgtaaaacgacggccagttgttgtagtagctctgcttg	112
Exon 15			
N-19025- 5'cccatttgtcccaactgg	73	N-19697- *5'atttgtcccaactggttgta	113
C-18575- 5'cggtcagttgaaatgtcag	74	C-19466- 5'tgtaaaacgacggccagttcagttgaaatgtcagaagtg	114

Figure 4B - Page 3

First Stage Amplification Primer	SEQ. ID NO:	Second Stage Amplification Primer	SEQ. ID NO:
Exon 16			
N-18184- 5'catttggatgctccgttaaagc	75	N-19269- 5'tgtaaaacgacggccagt	115
C-18314- 5'cacccggctggaaattttatttg	76	C-19047- *5'ccggctggaaattttatttggag	116
Exon 17			
N-18429- 5'ggaaaggcactggagaaatggg	77	N-19298- 5'tgtaaaacgacggccagtaggcactggagaaatgggatttg	117
C-18315-5'ccctccagcacacatgcatgtaccg	78	C-19080- *5'tccagcacacatgcatgtaccgaaat	118
Exon 18			
N-18444- 5'taagtagtctgtgatctccg	79	N-19436- *5'gtagtctgtgatctccgttt	119
C-18581- 5'atgtatgaggtcctgtcc	80	C-19471- 5'tgtaaaacgacggccagttatgaggtcctgtcctag	120
Exon 19			
N-18638- 5'gacaccagtgtatgttgg	81	N-19447- *5'accagtgtatgttgggatg	121
C-18637- 5'gagaaagaagaacacatccc	82	C-19330- 5'tgtaaaacgacggccagtgaaagaagaacacatcccaca	122

All sequence reads 5' to 3'. Primer identification numbers are listed before each primer sequence. N indicates the primer on the 5' side of the exon. C indicates the primer on the 3' side of the exon. * indicates that the 5' nucleotide is biotinylated.

Figure 4B - Page 4

SEQ. ID NOS:

5 and 123

Figure 5


MLH1 Human
MLH1 Mouse
MLH1 S. cerevisiae
MutL S. Typhimurium
MutL E. coli
HexB S. pneumoniae
PMS1 S. cerevisiae

Figure 6



Figure 7



Figure 8

			SEQ. ID NO
human MLH1	affected	VNRIAAGEVIQRPANAIKEMIENCLDAKFTSIQVIVKEGGLKLIQIQDNGTGIRKEDLDIVCER	124
human MLH1	normal	VNRIAAGEVIQRPANAIKEMIENCLDAKSTSIQVIVKEGGLKLIQIQDNGTGIRKEDLDIVCER	125
mouse	MLH1	.....PANAIKEMIENCLDAKSTNIQVVVKEGGLKLIQIQDNGTGIRKEDLDIVCER	126
S. cerevisiae	MLH1	VNKIAAGEIIISPVNALKEMMENSIDANATMIDILVKEGGIKVLQITDNGSGINKADLPILCER	127
S. cerevisiae	PMS1	VHRITSGQVITDLTTAVKELVDNSIDANANQIEIIFKDYGLESIECSDNGDGIDPSNYEFLALK	128
E. coli	MutL	ANQIAAGEVVERPASVVKELVENSLDAGATRIDIDIERGGAKLIRIRDNGCGIKKDELALALAR	129
S. typhimurium	MutL	ANQIAAGEVVERPASVVKELVENSLDAGATRVDIDIERGGAKLIRIRDNGCGIKKEELALALAR	130
S. pneumoniae	HexB	ANQIAAGEVIERPASVCKELVENAIDAGSSQIIIEIEEAGLKKVQITDNGHGIAHDEVELALRR	131

Figure 9

human PMS1 nucleotide sequence. The putative start (ATG) and stop (TGA) codons are underlined.

```
        |  10      |  20      |  30      |  40      |  50      |  60      |  70      |  80
   1 CCATGGAGCG AGCTGAGAGC TCGAGTACAG AACCTGCTAA GGCCATCAAA CCTATTGATC GGAAGTCAGT CCATCAGATT  80
  81 TGCTCTGGGC AGGTGGTACT GAGTCTAAGC ACTGCGGTAA AGGAGTTAGT AGAAAACAGT CTGGATGCTG GTGCCACTAA 160
 161 TATTGATCTA AAGCTTAAGG ACTATGGAGT GGATCTTATT GAAGTTTCAG ACAATGGATG TGGGGTAGAA GAAGAAACT 240
 241 TCGAAGGCTT AACTCTGAAA CATCACACAT CTAAGATTCA AGAGTTTGCC GACCTAACTC AGGTTGAAAC TTTTGGCTTT 320
 321 CGGGGGGAAG CTCTGAGCTC ACTTTGTGCA CTGAGCGATG TCACCATTTC TACCTGCCAC GCATCGGCGA AGGTTGGAAC 400
 401 TCGACTGATG TTTGATCACA ATGGGAAAAT TATCCAGAAA ACCCCCTACC CCCGCCCCAG AGGGACCACA GTCAGCGTGC 480
 481 AGCAGTTATT TTCCACACTA CCTGTGCGCC ATAAGGAATT TCAAAGGAAT ATTAAGAAGG AGTATGCCAA AATGGTCCAG 560
 561 GTCTTACATG CATACTGTAT CATTTCAGCA GGCATCCGTG TAAGTTGCAC CAATCAGCTT GGACAAGGAA AACGACAGCC 640
 641 TGTGGTATGC ACAGGTGGAA GCCCCAGCAT AAAGGAAAAT ATCGGCTCTG TGTTTGGGCA GAAGCAGTTG CAAAGCCTCA 720
 721 TTCCTTTTGT TCAGCTGCCC CCTAGTGACT CCGTGTGTGA AGAGTACGGT TTGAGCTGTT CGGATGCTCT GCATAATCTT 800
 801 TTTTACATCT CAGGTTTCAT TTCACAATGC ACGCATGGAG TTGGAAGGAG TTCAACAGAC AGACAGTTTT TCTTTATCAA 880
 881 CCGGCGGCCT TGTGACCCAG CAAAGGTCTG CAGACTCGTG AATGAGGTCT ACCACATGTA TAATCGACAC CAGTATCCAT 960
 961 TTGTTGTTCT TAACATTTCT GTTGATTCAG AATGCGTTGA TATCAATGTT ACTCCAGATA AAAGGCAAAT TTTGCTACAA 1040
1041 GAGGAAAAGC TTTTGTTGGC AGTTTTAAAG ACCTCTTTGA TAGGAATGTT TGATAGTGAT GTCAACAAGC TAAATGTCAG 1120
1121 TCAGCAGCCA CTGCTGGATG TTGAAGGTAA CTTAATAAAA ATGCATGCAG CGGATTTGGA AAAGCCCATG GTAGAAAAGC 1200
1201 AGGATCAATC CCCTTCATTA AGGACTGGAG AAGAAAAAAA AGACGTGTCC ATTTCCAGAC TGCGAGAGGC CTTTTCTCTT 1280
1281 CGTCACACAA CAGAGAACAA GCCTCACAGC CCAAAGACTC CAGAACCAAG AAGGAGCCCT CTAGGACAGA AAAGGGGTAT 1360
1361 GCTGTCTTCT AGCACTTCAG GTGCCATCTC TGACAAAGGC GTCCTGAGAT CTCAGAAAGA GGCAGTGAGT TCCAGTCACG 1440
1441 GACCCAGTGA CCCTACGGAC AGAGCGGAGG TGGAGAAGGA CTCGGGGCAC GGCAGCACTT CCGTGGATTC TGAGGGGTTC 1520
1521 AGCATCCCAG ACACGGGCAG TCACTGCAGC AGCGAGTATG CGGCCAGCTC CCCAGGGGAC AGGGGCTCGC AGGAACATGT 1600
1601 GGACTCTCAG GAGAAAGCGC CTGAAACTGA CGACTCTTTT TCAGATGTGG ACTGCCATTC AAACCAGGAA GATACCGGAT 1680
1681 GTAAATTTCG AGTTTTGCCT CAGCCAACTA ATCTCGCAAC CCCAAACACA AAGCGTTTTA AAAAAGAAGA AATTCTTTCC 1760
1761 AGTTCTGACA TTTGTCAAAA GTTAGTAAAT ACTCAGGACA TGTCAGCCTC TCAGGTTGAT GTAGCTGTGA AAATTAATAA 1840
1841 GAAAGTTGTG CCCCTGGACT TTTCTATGAG TTCTTTAGCT AAACGAATAA AGCAGTTACA TCATGAAGCA CAGCAAAGTG 1920
1921 AAGGGGAACA GAATTACAGG AAGTTTAGGG CAAAGATTTG TCCTGGAGAA AATCAAGCAG CCGAAGATGA ACTAAGAAAA 2000
2001 GAGATAAGTA AAACGATGTT TGCAGAAATG GAAATCATTG GTCAGTTTAA CCTGGGATTT ATAATAACCA AACTGAATGA 2080
2081 GGATATCTTC ATAGTGGACC AGCATGCCAC GGACGAGAAG TATAACTTCG AGATGCTGCA GCAGCACACC GTGCTCCAGG 2160
2161 GGCAGAGGCT CATAGCACCT CAGACTCTCA ACTTAACTGC TGTTAATGAA GCTGTTCTGA TAGAAAATCT GGAAATATTT 2240
2241 AGAAAGAATG GCTTTGATTT TGTTATCGAT CAAAATGCTC CAGTCACTGA AAGGGCTAAA CTGATTTCCT TGCCAACTAG 2320
2321 TAAAAACTGG ACCTTCGGAC CCCAGGACGT CGATGAACTG ATCTTCATGC TGAGCGACAG CCCTGGGGTC ATGTGCCGCC 2400
2401 CTTCCCGAGT CAAGCAGATG TTTGCCTCCA GAGCCTGCCG GAAGTCGGTG ATGATTGGGA CTGCTCTCAA CACAAGCGAA 2480
2481 TGAAGAAACT GATCACCCAC ATGGGGGAGA TGGGCCACCC CTGGAACTGT CCCCATGGAA GGCCACCATG AGACACATCG 2560
2561 CCAACCTGGG TGTCATTTCT CAGAACTGAC CGTAGTCACT GTATGGAATA ATTGGTTTTA TCGCAGATTT TTATGTTTTG 2640
2641 AAAGACAGAG TCTTCACTAA CCTTTTTTGT TTTAAAATGA AACCTGC                                    2687
        |  10      |  20      |  30      |  40      |  50      |  60      |  70      |  80
```

SEQ. ID NO: 132

Figure 10

Alignment Report of PMS1, using Clustal method with PAM250 residue weight table.
Wednesday, January 26, 1994 4:51 PM

```
PMS1_HUMAN M-ERAESSSTEPAK-------------------AIKPIDRKSVHQICSGQVVLSLSTAVKELVENSLDAGATNIDLKLKDYGVDLIEVSDNGCGVEEENF 80
PMS1_YEAST MFHHIENLLIETEKRCKQKEQRYIPVKYLFSMTQIHQINDIDVHRITSGQVITDLTTAVKELVDNSIDANANQIEIIFKDYGLESIECSDNGDGIDPSNY 100

PMS1_HUMAN EGLTLKHHTSKIQEFADLTQVETFGFRGEALSSLCALSDVTISTCHASAKVGTRLMFDHNGKIIQKTPYPRPRGTTVSVQQLFSTLPVRHKEFQRNIKKE 180
PMS1_YEAST EFLALKHYTSKIAKEQDVAKVQTLGFRGEALSSLCGIAKLSVITTTSPPKAD-KLEYDMVGHITSKTTTSRNKGTTVLVSQLFHNLPVRQKEFSKTFKRQ 199

PMS1_HUMAN YAKMVQVLHAYCIISAGIRVSCTNQLGQGKRQPVVCTGGSPSIKENIGSVFGQKQLQSL--IPFV-QLPP-SDSVCEEYGLSCSDALHNLFY---ISGFI 273
PMS1_YEAST FTKCLTVIQGYAIINAAIKFSVWNITPKGKKNLILSTMRNSSMRKNISSVFGAGGMRGLEEVDLVLDLNEFKNRMLGKYTDD--PDFLDLDYKIRVKGYI 297

PMS1_HUMAN SQCTHGVGRSSTDRQFFFINRRPCDPAKVCRLVNEVYHMYNRHQYPFVVLNISVDSECVDINVTPDKRQILLQEEKLLLAVLKTSLIGMFDSDVNKLNVS 373
PMS1_YEAST SQNSFGQGRNSKDRQFIYVNKRPVEYSTLLKCCNEVYKTFNNVQFPAVFLNLELPMSLIDVNVTPDKRVILLHNERAVIDIFKTTLSDYYNRQ--ELALP 395

PMS1_HUMAN QQPLLDVEGNLIK-MHAADLEKPMVEKQDQSPSLRTGEEKKDVSISRLREAFSLRHTTENKPHSPKTPEPRRSPLGQKRGMLSSSTSGAISDKGVLRSQK 472
PMS1_YEAST KRMCSQSEQQACKRLKTEVFDDRSTTHESDNENYHTARSESNQSN---HAHFNSTTGVIDKSNGTELTSVMDGNYTNVTDVIGSECEVSVDSSVVLDEGN 492

PMS1_HUMAN EAVSSSHGPSDPTDRAEVEKDSGHGSTSVDSEGFSIPDTGSHCSSEYAASSPGDRGSQEHVDSQEKAPETDDSFSDVDCHSNQEDTGCKFRVLPQPTNLA 572
PMS1_YEAST SSTPTKKLPSIKTDSQNLSDLNLNNFSNPEFQNITSPDKARSLEKVVEEPVYFDIDGEKFQEKAVLSQADGLVFVDNECHEHTNDCCHQERRGSTDTEQD 592

PMS1_HUMAN TPNTKRFKKEEILSSS-----DICQKLVNTQDMSASQVDVAVKINKKVVPLDFSMSS-----LAKRIKQLHHEAQQSEGEQNYRKFRAKICPGENQAAED 662
PMS1_YEAST DEADSIYAEIEPVEINVRTPLKNSRKSISKDNYRSLSDGLTHRKFEDEI-LEYNLSTKNFKEISKNGKQMSSIISKRKSEAQENIIKNKDELEDFEQGEK 691

PMS1_HUMAN ELRKEISKTMFAEMEIIGQFNLGFIIT--KLNE--DIFIVDQHATDEKYNFEMLQQHTVLQGQRLIAPQTLNLTAVNEAVLIENLEIFRKNGFDFVIDEN 758
PMS1_YEAST YLTLTVSKNDEKKMEVVGQFNLGFIIVTRKVDNKSDLFIVDQHASDEKYNFETLQAVTVFKSQKLIIPQPVELSVIDELVVLDNLPVFEKNGFKLKIDEE 791

PMS1_HUMAN APVTERAKLISLPTSKNWTFGPQDVDELIFMLSDSPGVM---CRPSRVKQMFASRACRKSVMIGTALNTSEMKKLITHMGEMGHPWNCPHGRPTMRHIAN 855
PMS1_YEAST EEFGSRVKLISLPTSKQTLFDLGDFNELIHLIKEDGGLRRDNIRCSKIRSMFAMRACRSSIMIGKPLNKKTMTRVVHNLSELDKPWNCPHGRPTMRHLME 891

PMS1_HUMAN L---GVISQN 862
PMS1_YEAST IRDWSSFSKDYEI 904
```

Decoration 'Decoration #1': Box residues that match the consensus named 'Consensus #1' exactly.

Figure 11

Partial nucleotide sequence of mouse MLH1 cDNA. The putative stop (TAA) codon is underlined

```
        |  10      |  20      |  30      |  40      |  50      |  60      |  70      |  80
   1 TTCCGGCCAA TGCTATCAAA GAGATGATAG AAAACTGTTT AGATGCAAAA TCTACAAATA TTCAAGTGGT TGTTAAGGAA  80
  81 GGTGGCCTGA AGCTAATTCA GATCCAAGAC AATGGCACTG GAATCAGGAA GGAAGATCTG GATATTGTGT GTGAGAGGTT 160
 161 CACTACGAGT AAACTGCAGA CTTTTGAGGA TTTAGCCAGT ATTTCTACCT ATGGCTTTCG TGGTGAGCAT TTGGCAAGCA 240
 241 TAAGTCATGT GGCCCATGTC ACTATTACAA CCAAAACAGC TGATGGGAAA TGTGCGTACA GAGCAAGTTA CTCAGATGGA 320
 321 AAGCTGCAAG CCCCTCCTAA ACCCTGTGCA GGCAACCAGG GCACCCTGAT CACGGTGGAA GACCTTTTTT ACAACATAAT 400
 401 CACAAGGAGG AAAGCTTTAA AAAATCCAAG TGAAGAGTAC GGAAAAATTT TGGAAGTTGT TGGCAGGTAT TCAATACACA 480
 481 ATTCAGGCAT TAGTATCTCA GTTAAAAAAC AAGGTGAGAC AGTATCTGAT GTCAGAACAC TGCCCAATGC CACAACCGTG 560
 561 GACAACATTC GCTCCATCTT TGGAAATGCG GTTAGTCGAG AACTGATAGA AGTTGGGTGT GAGGATAAAA CCCTAGCTTT 640
 641 CAAAATGAAT GGCTATATAT CGAATGCAAA GTATTCAGTG AAGAAGTGCA TTTTCCTACT CTTCATCAAC CACCGTCTGG 720
 721 TAGAATCAGC TGCCTTGAGA AAAGCCATTG AAACTGTATA TGCAGCATAC TTGCCAAAAA CACACACCCA TTCCTGTACC 800
 801 TCAGTTTGAA ATCAGCCCTC AGAACGTGAC GTCAATGTAC ACCCCACCAA GACAGAAGTT CATTTTCTGC ACGAGGAGAG 880
 881 CATTCTGCAG CGTGTGCAGC AGCACATTGA GAGCAAGCTG CTGGGCTCCA ATTCCTCCAG GATGTATTTC ACCCAGACCT 960
 961 TGCTTCCAGG ACTTGCTGGG CCTCTGGGGA GGCAGCTAGA CCCACGACAG GGGTGGCTTC CTCATCCACT AGTGGAAGTG 1040
1041 GCGACAAGGT CTACGCTTAC CAGATGTCGC GTACGGACTC CCGGGATCAG AAGCTTGACG CCTTTCTGCA GCCTGTAAGC 1120
1121 AGCCTTGTGC CCAGCCAGCC CCAGGACCCT CGCCCTGTCC GAGGGGCCAG GACAGAGGGC TCTCCTGAAA GGGCCACGCG 1200
1201 GGAGGATGAG GAGATGCTTG CTCTCCCAGC CCCCGCTGAA GCAGCTGCTG AGAGTGAGAA CTTGGAGAGG GAATCACTAA 1280
1281 TGGAGACTTC AGACGCAGCC CAGAAAGCGG CACCCACTTC CAGTCCAGGA AGCTCCAGAA AGAGTCATCG GGAGGACTCT 1360
1361 GATGTGGAAA TGGTGGAAAA TGCTTCCGGG AAGGAAATGA CAGCTGCTTG CTACCCCAGG AGGAGGATCA TTAACCTCAC 1440
1441 CAGCGTCTTG AGTCTCCAGG AAGAGATTAG TGAGCGGTGC CATGAGACTC TCCGGGAGAT ACTCCGTAAC CATTCCTTTG 1520
1521 TGGGCTGTGT GAATCCTCAG TGGGCCTTGG CACAGCACCA GACCAAGCTA TACCTCCTCA ACACTACCAA GCTCAGTGAA 1600
1601 GAGCTGTTCT ACCAGATACT CATTTATGAT TTTGCCAACT TTGGTGTTCT GAGGTTATCG GAACCAGCGC CACTCTTCGA 1680
1681 CCTGGCCATG CTGGCTTAGA CAGTCCTGAA AGTGGCTGGA CAGAGGACGA CGGCCCGAAG AAGGGCTTGC AGAGTACATT 1760
1761 GTCGAGTTTC TGAAGAGAAG CGAGATGCTT GCAGACTATT CTCTGTGAGA TCGATGAGAA GGGAACCTGA TTGATTACTC 1840
1841 TTCTGATGAC AGCTATGTGC CACCTTTGGA GGGACTGCCT ATCTTCATTC TTCGACTGGC CACTGAGGTG AATTGGGTGA 1920
1921 AGAAAAGGAG TGTTTTGAAA GTCTCAGTAA AGAATGTGCT ATGTTTTACT CCATTCGGAA GCAGTATATA CTGGAGGAGT 2000
2001 CGACCCTCTC AGGCCAGCAG AGTGACATGC CTGGCTCCAC GTCAAAGCCC TGGAAGTGGA CTGTGGAGCA CATTATCTAT 2080
2081 AAAGCCTTCC GCTCACACCT CCTACCTCCG AAGCATTTCA CAGAAGATGG CAATGTCCTG CAGCTTGCCA ACCTGCCAGA 2160
2161 TCTATACAAA GTCTTTGAGC GGTGTTAAAT ACAATCATAG CCACCGTAGA GACTGCATGA CCATCCAAGG CGAAGTGTAT 2240
2241 GGTACTAATC TGGAAGCCAC AGAATAGGAC ACTTGGTTTC AGCTCCAGGG TTTTCAGTGC TCACTATTCT TGTTCTGTAT 2320
2321 CCCAGTATTG GTGCTGCAAC TTAATGTACT TCACCTGTGG ATTGGCTGCA AATAAACTCA CGTGTATTGG AAAAAAGGAA 2400
2401 TTCCTGCAGC CCGGGGGATC CACTAGTTCT AGAGCGGCCG CCACCGGTGG AGCTCCAGCT TTTGTTCCCT TTAGTGAGGG 2480
2481 TTAATTTCGA GCTTGGCGTA ATCATGGTCA TAGCTGTTTC CTGTGTGAAA TTGTTATCCG CTCACAATTC CACACAACAT 2560
2561 ACGAGCCGGA AGCATAA                                                                    2577
        |  10      |  20      |  30      |  40      |  50      |  60      |  70      |  80
```

SEQ. ID NO: 135

Figure 12

WO 95/16793

Comparison of the predicted amino acid sequences for mMLH1 and hMLH1 proteins. Vertical lines indicate amino acid identities. (Note: reading frames of both are pieced together to include those with strong similarity to yeast MLH1, not based on similarity with each other)

SEQ. ID NO:

```
mouse 1 ...........................PANAIKEMIENCLDAKSTNIQVVVKEGGLKLIQIQDNGTGIRKEDLDIVCERFTTSKLQTFEDLASISTYGFR 73  136
human 1 MSFVAGVIRRLDETVVNRIAAGEVIQRPANAIKEMIENCLDAKSTSIQVIVKEGGLKLIQIQDNGTGIRKEDLDIVCERFTTSKLQSFEDLASISTYGFR 100

 74 GEHLASISHVAHVTITTKTADGKCAYRASYSDGKLQAPPKPCAGNQGTLITVEDLFYNIITRRKALKNPSEEYGKILEVVGRYSIHNSGISISVKKQGET 173
101 GEALASISHVAHVTITTKTADGKCAYRASYSDGKLKAPPKPCAGNQGTQITVEDLFYNIATRRKALKNPSEEYGKILEVVGRYSVHNAGISFSVKKQGET 200

174 VSDVRTLPNATTVDNIRSIFGNAVSRELIEVGCEDKTLAFKMNGYISNAKYSVKKCIFLLFINHRLVESAALRKAIETVYAAYLPK-THTHSCTSVZNQP 272
201 VADVRTLPNASTVDNIRSIFGNAVSRELIEIGCEDKTLAFKMNGYISNANYSVKKCIFLLFINHRLVESTSLRKAIETVYAAYLPKNTHPFLYLSLEISP 300

273 SERDVNVHPTKTEVHFLHEESILQRVQQHIESKLLGSNSSRMVFHPDLASRTCWASGEAARPTTGVASSSTSGSGDKVYAYQMSRTDSRDQKLDAFLQPV 372
301 QNVDVNVHPTKHEVHFLHEESILERVQQHIESKLLGSNSSRMYFTQTLLPGLAGPSGEMVKSTTSLTSSSTSGSSDKVYAHQMVRTDSREQKLDAFLQPL 400

373 SSLVPSQPQDPRPVRGARTEGSPERATREDEEMLALPAPAEAAAESENLERESLMETSDAAQKAAPTSSPGSSRKSHREDSDVEMVENASGKEMTAACYP 472
401 SKPLSSQPQA--IVTEDKTDISSGRARQQDEEMLELPAPAEVAAKNQSLEGDTTKGTSEMSEKRGPTSS--NPRKRHREDSDVEMVEDDSRKEMTAACTP 496

473 RRRIINLTSVLSLQEEISERCHETLREILRNHSFVGCVNPQWALAQHQTKLYLLNTTKLSEELFYQILIYDFANFGVLRLSEPAPLFDLAMLAZTVLKVA 572
497 RRRIINLTSVLSLQEEINEQGHEVLREMLHNHSFVGCVNPQWALAQHQTKLYLLNTTKLSEELFYQILIYDFANFGVLRLSEPAPLFDLAMLA--LDSPE 594

573 GQRTTAR-RRACRVHCRVSEEKRDACRLFSVRSMRREPDZ-----LLFZZQLCATFGGTAYLHSSTGHZGELGEEKECFESLSKECAMFYSIRKQYILEE 666
595 SGWTEEDGPKEGLAEYIVEFLKKKAEMLADYFSLEIDEEGNLIGLPLLIDNYVPPLEGLPIFILRLATEVNWDEEKECFESLSKECAMFYSIRKQYISEE 694

667 STLSGQQSDMPGSTSKPWKWTVEHIIYKAFRSHLLPPKHFTEDGNVLQLANLPDLYKVFERC 728
695 STLSGQQSEVPGSIPNSWKWTVEHIVYKALRSHILPPKHFTEDGNILQLANLPDLYKVFERC 756
```

Figure 13

mouse PMS1 nucleotide sequence. The putative start (ATG) and stop (TGA) codons are underlined.

```
          |   10        |   20        |   30        |   40        |   50        |   60        |   70        |   80
    1 CGGTGAAGGT CCTGAAGAAT TTCCAGATTC CTGAGTATCA TTGGAGGAGA CAGATAACCT GTCGTCAGGT AACGATGGTG 80
   81 TATATGCAAC AGAAATGGGT GTTCCTGGAG ACGCGTCTTT TCCCGAGAGC GGCACCGCAA CTCTCCCGCG GTGACTGTGA 160
  161 CTGGAGGAGT CCTGCATCCA TGGAGCAAAC CGAAGGCGTG AGTACAGAAT GTGCTAAGGC CATCAAGCCT ATTGATGGGA 240
  241 AGTCAGTCCA TCAAATTTGT TCTGGGCAGG TGATACTCAG TTTAAGCACC GCTGTGAAGG AGTTGATAGA AAATAGTGTA 320
  321 GATGCTGGTG CTACTACTAT TGATCTAAGG CTTAAAGACT ATGGGGTGGA CCTCATTGAA GTTTCAGACA ATGGATGTGG 400
  401 GGTAGAAGAA GAAAACTTTG AAGGTCTAGC TCTGAAACAT CACACATCTA AGATTCAAGA GTTTGCCGAC CTCACGCAGG 480
  481 TTGAAACTTT CGGCTTTCGG GGGGAAGCTC TGAGCTCTCT GTGTGCACTA AGTGATGTCA CTATATCTAC CTGCCACGGG 560
  561 TCTGCAAGCG TTGGGACTCG ACTGGTGTTT GACCATAATG GGAAAATCAC CCAGAAAACT CCCTACCCCC GACCTAAAGG 640
  641 AACCACAGTC AGTGTGCAGC ACTTATTTTA TACACTACCC GTGCGTTACA AAGAGTTTCA GAGGAACATT AAAAAGGAGT 720
  721 ATTCCAAAAT GGTGCAGGTC TTACAGGCGT ACTGTATCAT CTCAGCAGGC GTCCGTGTAA GCTGCACTAA TCAGCTCGGA 800
  801 CAGGGGAAGC GGCACGCTGT GGTGTGCACA AGCGGCACGT CTGGCATGAA GGAAAATATC GGGTCTGTGT TTGGCCAGAA 880
  881 GCAGTTGCAA AGCCTCATTC CTTTGTTCA GCTGCCCCCT AGTGACGCTG TGTGTGAAGA GTACGGCCTG AGCACTTCAG 960
  961 GACGCCACAA AACCTTTTCT ACGTTTCGG GCTTCATTTC ACAGTGCACG CACGGCGCCG GGAGGAGTGC AACAGACAGG 1040
 1041 CAGTTTTTCT TCATCAATCA GAGGCCCTGT GACCCAGCAA AGGTCTCTAA GCTTGTCAAT GAGGTTTATC ACATGTATAA 1120
 1121 CCGGCATCAG TACCCATTTG TCGTCCTTAA CGTTTCCGTT GACTCAGAAT GTGTGGATAT TAATGTAACT CCAGATAAAA 1200
 1201 GGCAAATTCT ACTACAAGAA GAGAAGCTAT TGCTGGCCGT TTTAAAGACC TCCTTGATAG GAATGTTTGA CAGTGATGCA 1280
 1281 AACAAGCTTA ATGTCAACCA GCAGCCACTG CTAGATGTTG AAGGTAACTT AGTAAAGTCG CATACTGCAG AACTAGAAAA 1360
 1361 GCCTGTGCCA GGAAAGCAAG ATAACTCTCC TTCACTGAAG AGCACAGCAG ACGAGAAAAG GGTAGCATCC ATCTCCAGGC 1440
 1441 TGAGAGAGGC CTTTTCTCTT CATCCTACTA AAGAGATCAA GTCTAGGGGT CCAGAGACTG CTGAACTGAC ACGGAGTTTT 1520
 1521 GCAAGTGAGA AAAGGGGCGT GTTATCCTCT TATCCTTCAG ACGTCATCTC TTACAGAGGC CTCCGTGGCT CGCAGGACAA 1600
 1601 ATTGGTGAGT CCCACGGACA GCCCTGGTGA CTGTATGGAC AGAGAGAAAA TAGAAAAAGA CTCAGGGCTC AGCAGCACCT 1680
 1681 CAGCTGGCTC TGAGGAAGAG TTCAGCACCC CAGAAGTGGC CAGTAGCTTT AGCAGTGACT ATAACGTGAG CTCCCTAGAA 1760
 1761 GACAGACCTT CTCAGGAAAC CATAAACTGT GGTGACCTGC TGCCGTCCTC CAGGTACAGG ACAGTCCTTG AAGCCAGAAG 1840
 1841 ACCATGGATA TCAATGCAAA GCTCTACCTC TAGCTCGTCT GTCACCCACA AATGCCAAGC GCTTCAAGAC AGAGGAAGAC 1920
 1921 CCTCAAATGT CAACATATCT CAAAGATTGC CTGGTCCTCA GAGCACCTCA GCAGCTGAGG TCGATGTAGC CATAAAAATG 2000
 2001 AATAAGAGAT CGTGCTCCTC GAGTTCTCTA GCTAAGCGAA TGAAGCAGTT ACAGCACCTA AAGGCGCAGA ACAAACATGA 2080
 2081 ACTGAGTTAC AGAAATTTA GGGCCAAGAT TTGCCCTGGA GAAAACCAAG CAGCAGAAGA TGAACTCAGA AAAGAGATTA 2160
 2161 GTAAATCGAT GTTTGCAGAG ATGGAGATCT TGGGTCAGTT TAACCTGGGA TTTATAGTAA CCAAACTGAA AGAGGACCTC 2240
 2241 TTCCTGGTGG ACCAGCATGC TGCGGATGAG AAGTACAACT TTGAGATGCT GCAGCAGCAC ACGGTGCTCC AGGCGCAGAG 2320
 2321 GCTCATCACG TGGGTGCACA CAGGCTTCAG AGTTCCCAGA CCCCAGACTC TGAACTTAAC TGCTGTCAAT GAAGCTGTAC 2400
 2401 TGATAGAAAA TCTGGAAATA TTCAGAAAGA ATGGCTTTGA CTTTGTCATT GATGAGGATG CTCCAGTCAC TGAAAGGGCT 2480
 2481 AAATTGATTT CCTTACCAAC TAGTAAAAAC TGGACCTTTG GACCCCAAGA TATAGATGAA CTGATCTTTA TGTTAAGTGA 2560
 2561 CAGCCCTGGG GTCATGTGCC GGCCCTCACG AGTCAGACAG ATGTTTGCTT CCAGAGCCTG TCGGAAGTCA GTGATGATTG 2640
 2641 GAACGGCGCT CAATGCGAGC GAGATGAAGA AGCTCATCAC CCACATGGGT GAGATGGACC ACCCCTGGAA CTGCCCCCAC 2720
 2721 GGCAGGCCAA CCATGAGGCA CGTTGCCAAT CTGGATGTCA TCTCTCAGAA CTGACACACC CCTTGTAGCA TAGAGTTTAT 2800
 2801 TACAGATTGT TCGGTTCGCA AAGAGAAGGT TTTAAGTAAT CTGATTATCG TTGTACAAAA ATTAGCATGC TGCTTTAATG 2880
 2881 TACTGGATCC ATTTAAAAGC AGTGTTAAGG CAGGCATGAT GGAGTGTTCC TCTAGCTCAG CTACTTGGGT GATCCGGTGG 2960
 2961 GAGCTCATGT GAGCCCAGGA CTTTGAGACC ACTCCGAGCC ACATTCATGA GACTCAATTC AAGGACAAAA AAAAAAGAT 3040
 3041 ATTTTTGAAG CCTTTTAAAA AAAAA                                                          3065
```

Figure 14

SEQ. ID NO: 137

Comparison of the predicted amino acid sequences for mPMS1 and hPMS1 proteins. Vertical lines indicate amino acid identities

SEQ. ID NO: 138

```
mouse 1   MEQTEGVSTECAKAIKPIDGKSVHQICSGQVILSLSTAVKELIENSVDAGATTIDLRLKDYGVDLIEVSDNGCGVEEENFEGLALKHHTSKIQEFADLTQ 100
          ||  |  ||| ||||||||| |||||||||| |||||||||| ||| ||||| ||| |||||||||||||||||||||||||| ||||||||||||||||
human 1   MERAESSSTEPAKAIKPIDRKSVHQICSGQVVLSLSTAVKELVENSLDAGATNIDLKLKDYGVDLIEVSDNGCGVEEENFEGLTLKHHTSKIQEFADLTQ 100

    101   VETFGFRGEALSSLCALSDVTISTCHGSASVGTRLVFDHNGKITQKTPYPRPKGTTVSVQHLFYTLPVRYKEFQRNIKKEYSKMVQVLQAYCIISAGVRV 200
          |||||||||||||||||||||||||| || ||||| |||||||| |||||||| ||||||| || ||||| |||||||||||| ||||||| |||||||| ||
    101   VETFGFRGEALSSLCALSDVTISTCHASAKVGTRLMFDHNGKIIQKTPYPRPRGTTVSVQQLFSTLPVRHKEFQRNIKKEYAKMVQVLHAYCIISAGIRV 200

    201   SCTNQLGQGKRHAVVCTSGTSGMKENIGSVFGQKQLQSLIPFVQLPPSDAVCEEYGLSTSGRHKTFSTFSGFISQCTHGAGRSATDRQFFFINQRPCDPA 300
          ||||||||||| |||| |    |||||||||||||||||||||||||| |||||||| |          |||||||||| ||| ||||||||| ||||||
    201   SCTNQLGQGKRQPVVCTGGSPSIKENIGSVFGQKQLQSLIPFVQLPPSDSVCEEYGLSCSDALHNLFYISGFISQCTHGVGRSSTDRQFFFINRRPCDPA 300

    301   KVSKLVNEVYHMYNRHQYPFVVLNVSVDSECVDINVTPDKRQILLQEEKLLLAVLKTSLIGMFDSDANKLNVNQQPLLDVEGNLVKSHTAELEKPVPGKQ 400
          ||  |||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||| ||||| |||||||||| | | | ||||   ||
    301   KVCRLVNEVYHMYNRHQYPFVVLNISVDSECVDINVTPDKRQILLQEEKLLLAVLKTSLIGMFDSDVNKLNVSQQPLLDVEGNLIKMHAADLEKPMVEKQ 400

    401   DNSPSLKSTADEKRVASISRLREAFSLHPTKEIKSRGPETAELTRSFPSEKRGVLSSYPSDVISYRGLRGSQDKLVSPTDSPGDCMDREKIEKDSGLSST 500
          | ||||  | ||  ||||||||||  | | |  | | |  ||   ||| |||  |  ||  |  ||   ||   | |  ||  |||||  ||
    401   DQSPSLR-TGEEKKDVSISRLREAFSLRHTTENKPHSPKTPEPRRSPLGQKRGMLSSSTSGAISDKGVLRSQKEAVSSSHGPSDPTDRAEVEKDSGHGST 499

    501   SAGSEEEFSTPEVASSFSSDYNVSSLEDRPSQETINC-------GDLLPSSRYRTVLEARRPWISMQSSTSSSSVTHKCQALQDRGRPSNVNISQRLPGP 593
          |  | | ||| |  | || |  ||  || |||          |          |                |  | | |
    500   SVDS-EGFSIPDTGSHCSSEYAASSPGDRGSQEHVDSQEKAPETDDSFSDVDCHSNQEDTGCKFRVLPQPTNLA-TPNTKRFKKEEILSSSDICQKLVNT 597

    594   QSTSAAEVDVAIKMNKR----SCSSSSLAKRMKQLQHLKAQNKHELSYRKFRAKICPGENQAAEDELRKEISKSMFAEMEILGQFNLGFIVTKLKEDLFL 689
          |  ||  |||| | ||       | |||||| ||| |  ·|.  | |||||||||||||||||||||||| ||||||| |||||||| ||| || |
    598   QDMSASQVDVAVKINKKVVPLDFSMSSLAKRIKQLHHEAQQSEGEQNYRKFRAKICPGENQAAEDELRKEISKTMFAEMEIIGQFNLGFIITKLNEDIFI 697

    690   VDQHAADEKYNFEMLQQHTVLQAQRLITWVHTGFRVPRPQTLNLTAVNEAVLIENLEIFRKNGFDFVIDEDAPVTERAKLISLPTSKNWTFGPQDIDELI 789
          ||||| ||||||||||||||| ||||           |||||||||||||||||||||||||||||||| |||||||||||||||||||| ||||
    698   VDQHATDEKYNFEMLQQHTVLQGQRLIA----------PQTLNLTAVNEAVLIENLEIFRKNGFDFVIDENAPVTERAKLISLPTSKNWTFGPQDVDELI 787

    790   FMLSDSPGVMCRPSRVRQMFASRACRKSVMIGTALNASEMKKLITHMGEMDHPWNCPHGRPTMRHVANLDVISQN 864
          |||||||||||||||| |||||||||||||||||| |||||||||||| |||||||||||||| ||| |||||
    788   FMLSDSPGVMCRPSRVKQMFASRACRKSVMIGTALNTSEMKKLITHMGEMGHPWNCPHGRPTMRHIANLGVISQN 862
```

Figure 15

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/14746

A. CLASSIFICATION OF SUBJECT MATTER
IPC(6) :Please See Extra Sheet.
US CL :Please See Extra Sheet.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF MOLECULAR BIOLOGY, VOLUME 190, ISSUED 1986, GRANGER-SCHNARR ET AL., "SPECIFICITY OF N-ACETOXY-N-2-ACETYLAMINOFLUORENE-INDUCED FRAMESHIFT MUTATION SPECTRUM IN MISMATCH REPAIR DEFICIENT ESCHERICHIA COLI STRAINS MUTH, L, S AND U", PAGES 499-507, SEE ENTIRE DISCLOSURE.	1-55
Y	JOURNAL OF BACTERIOLOGY, VOLUME 171, NUMBER 10, ISSUED OCTOBER 1989, PRUDHOMME ET AL., "NUCLEOTIDE SEQUENCE OF THE STREPTOCOCCUS PNEUMONIAE HEXB MISMATCH REPAIR GENE: HOMOLOGY OF HEXB TO MUTL OF SALMONELLA TYPHIMURIUM AND TO PMS1 OF SACCHAROMYCES CEREVISIAE", PAGES 5332-5338, SEE ESPECIALLY THE ABSTRACT AND THE DISCUSSION AT PAGE 5336, SECOND COLUMN, SECOND PARAGRAPH.	26,27, 36-45, 47-55

[X] Further documents are listed in the continuation of Box C. [ ] See patent family annex.

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 29 MARCH 1995	Date of mailing of the international search report 10APR1995
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer Deborah Frieze for ARDIN MARSCHEL Telephone No. (703)308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

ernational application No.
PCT/US94/14746

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JOURNAL OF BACTERIOLOGY, VOLUME 171, NUMBER 10, ISSUED OCTOBER 1989, MANKOVICH ET AL., "NUCLEOTIDE SEQUENCE OF THE SALMONELLA TYPHIMURIUM MUTL GENE REQUIRED FOR MISMATCH REPAIR: HOMOLOGY OF MUTL TO HEXB OF STREPTOCOCCUS PNEUMONIAE AND TO PMS1 OF THE YEAST SACCHAROMYCES CEREVISIAE", PAGES 5325-5331, SEE ESPECIALLY THE ABSTRACT AND THE DISCUSSION SECTIONS.	26, 27, 36-45, 47-55
Y	GENETICS, VOLUME 110, ISSUED AUGUST 1985, WILLIAMSON ET AL, "MEIOTIC GENE CONVERSION MUTANTS IN SACCHAROMYCES CEREVISIAE: I. ISOLATION AND CHARACTERIZATION OF PMS1-1 AND PMS1-2", PAGES 609-646, SEE THE ENTIRE DISCLOSURE.	1-55
Y	NATURE, VOLUME 365, ISSUED 16 SEPTEMBER 1993, STRAND ET AL., "DESTABILIZATION OF TRACTS OF SIMPLE REPETITIVE DNA IN YEAST BY MUTATIONS AFFECTING DNA MISMATCH REPAIR", PAGES 274-276, SEE ENTIRE DISCLOSURE.	26, 27, 36-45, 47-55
Y	JOURNAL OF BACTERIOLOGY, VOLUME 171, NUMBER 10, ISSUED OCTOBER 1989, KRAMER ET AL., "CLONING AND NUCLEOTIDE SEQUENCE OF DNA MISMATCH REPAIR GENE PMS1 FROM SACCHAROMYCES CEREVISIAE: HOMOLOGY OF PMS1 TO PROCARYOTIC MUTL AND HEXB", PAGES 5339-5346, SEE ESPECIALLY THE ABSTRACT AND DISCUSSION SECTIONS.	26,27, 36-45, 47-55

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/14746

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

C12Q 1/68; C07H 21/00,21/02,21/04; C12P 19/34; C07K 13/00

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

435/6,91.2; 530/350,387.1; 536/23.1,24.3,24.31,24.33

B. FIELDS SEARCHED
Minimum documentation searched
Classification System: U.S.

435/6,69.3,91.1,91.2,810; 530/350,387.1,388.1; 536/23.1,24.3,24.31,24.33; 935/77,78

B. FIELDS SEARCHED
Electronic data bases consulted (Name of data base and where practicable terms used):

APS, CAS ONLINE, MEDLINE, BIOTECH ABS, WPI, BIOSIS
search terms: cancer,mlh1,mlh2,pms1,mutl,pmlh1,pmlh2,pmutl,ppms1,mismatch,repair